PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
38939496,Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors: Insights From the SPARCL Trial.,2023,"Swietek, Michael J","Pfizer Inc, Groton, Connecticut, USA.",None
38939381,Sex Differences in Coronary Artery Disease Characteristics Among Patients With Type 2 Myocardial Infarction.,2024,"Rogers, Campbell","HeartFlow Inc, Mountain View, California, USA.",None
38938723,The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia.,2023,"Ali, Shazia; Banerjee, Poulabi; Chan, Kuo-Chen; Khilla, Nagwa; McGinniss, Jennifer; Pordy, Robert; Zhang, Yi","Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.",None
38938482,Longitudinal Control of Lipid Levels in Patients With Premature Coronary Artery Disease.,2023,"Rojas-Fernandez, Carlos; Leblond, Francois","Novartis Pharmaceuticals Canada, Dorval, Quebec, Canada.; Novartis Pharmaceuticals Canada, Dorval, Quebec, Canada.",None
38817323,Whole-genome sequencing uncovers two loci for coronary artery calcification and identifies ARSE as a regulator of vascular calcification.,2023,"Tcheandjieu, Catherine; Hilliard, Austin T; Musharoff, Shaila; Clarke, Shoa L; Viaud-Martinez, Karine A; Kim, Ryan W; Damrauer, Scott M; O'Donnell, Christopher J; Assimes, Themistocles L","VA Palo Alto Healthcare System, Palo Alto, CA, USA.; VA Palo Alto Healthcare System, Palo Alto, CA, USA.; VA Palo Alto Healthcare System, Palo Alto, CA, USA.; VA Palo Alto Healthcare System, Palo Alto, CA, USA.; Illumina Laboratory Services, Illumina Inc., San Diego, CA, USA.; Psomagen Inc., Rockville, MD, USA.; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Palo Alto Healthcare System, Palo Alto, CA, USA.",None
38752575,Description of a Nonhuman Primate Model of Retinal Ischemia/Reperfusion Injury.,2023/Jun/01,"Gong, Li; Pan, Lingzhen; Yang, Zhenyan; Wu, Mingling; Zeng, Zirui; Yang, Zunyuan; Shen, Yubo; Zeng, Wen","PriMed Non-human Primate Research Center of Sichuan PriMed Shines Bio-tech Co., Ltd., Ya'an, Sichuan Province, China.; PriMed Non-human Primate Research Center of Sichuan PriMed Shines Bio-tech Co., Ltd., Ya'an, Sichuan Province, China.; PriMed Non-human Primate Research Center of Sichuan PriMed Shines Bio-tech Co., Ltd., Ya'an, Sichuan Province, China.; PriMed Non-human Primate Research Center of Sichuan PriMed Shines Bio-tech Co., Ltd., Ya'an, Sichuan Province, China.; PriMed Non-human Primate Research Center of Sichuan PriMed Shines Bio-tech Co., Ltd., Ya'an, Sichuan Province, China.; PriMed Non-human Primate Research Center of Sichuan PriMed Shines Bio-tech Co., Ltd., Ya'an, Sichuan Province, China.; PriMed Non-human Primate Research Center of Sichuan PriMed Shines Bio-tech Co., Ltd., Ya'an, Sichuan Province, China.; PriMed Non-human Primate Research Center of Sichuan PriMed Shines Bio-tech Co., Ltd., Ya'an, Sichuan Province, China.",None
38736057,Role of Bisoprolol in Heart Failure Management: A Consensus Statement from India.,2023,"Swami, Onkar C; Shah, Priyank; Jain, Sanjay","Sr. Vice President, Medical Services, Alembic Pharmaceuticals Ltd, Mumbai, Maharashtra, India.; Assistant General Manager, Medical Services, Alembic Pharmaceuticals Ltd., Mumbai, Maharashtra, India.; Associate Vice President, Medical Services, Alembic Pharmaceuticals Ltd., Mumbai, Maharashtra, India.",None
38700308,β-blockers as the First Line of Treatment for Hypertension Management.,2023,"Kumar, Kamal; Baishali, Nath","General Manager-Medical Affairs, Ajanta Pharma Ltd., Mumbai, Maharashtra, India.; Medical Advisor-Medical Affairs, Ajanta Pharma Ltd., Mumbai, Maharashtra, India.",None
38419787,Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial.,2024,"Petrini, Michaela; Hantel, Stefan; Mattheus, Michaela","Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut.; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.",None
38406910,The Interplay Of The Angiotensin Receptor Blockers And Haematological Abnormalities: Insights And Implications.,2023,"Ahmed, Ghada Muthana","Nineveh health directorate, Mosul, Nineveh province, Iraq.",None
38371292,Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial.,2024,"Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
38362263,Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis increasing the risk of cerebrovascular complications.,2023/Jun/26,"Schmidt, Steffen; Lindholm, Marie W","Roche Pharma Research and Early Development, RNA Therapeutics Research, Roche Innovation Center Copenhagen, Hørsholm, Denmark.; Roche Pharma Research and Early Development, RNA Therapeutics Research, Roche Innovation Center Copenhagen, Hørsholm, Denmark.",None
38251601,"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.",2023,"App, Christine; Pournara, Effie; Mendelson, Meryl H; Sieder, Christian; Maricos, Meron","Novartis Pharma, Nuremberg, Germany.; Novartis Pharma, Basel, Switzerland.; Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharma, Nuremberg, Germany.; Novartis Pharma, Nuremberg, Germany.",jens.thiel@uniklinik-freiburg.de.
38251498,"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.",2023,"Johnson, Lynne; Arora, Vipin; Osuntokun, Olawale","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",kapapp@probitymedical.com.
38212206,Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study.,2024,"Diels, Joris; Haddad, Imène; Pacaud, Lida","Janssen Pharmaceutica NV, Beerse, Belgium.; Janssen Pharmaceutica NV, Beerse, Belgium.; Legend Biotech USA Inc., Somerset, NJ.",mvmateos@usal.es.
38205351,Junctional Ectopic Tachycardia Caused by Junctophilin-2 Expression Silencing Is Selectively Sensitive to Ryanodine Receptor Blockade.,2023,"Ludwig, Andreas","Institut für Experimentelle und Klinische Pharmakologie, und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.",None
38205345,Development of a Mechanism-Based Next-Generation Therapeutic for Heart Failure Derived From the Dark Genome.,2023,"Viereck, Janika; Thum, Thomas","Cardior Pharmaceuticals GmbH, Hannover, Germany.; Cardior Pharmaceuticals GmbH, Hannover, Germany.",None
38190104,Genome-wide study investigating effector genes and polygenic prediction for kidney function in persons with ancestry from Africa and the Americas.,2024/Jan/10,"Best, Lyle G","Missouri Breaks Industries Research Inc., Eagle Butte, SD, USA.",noraf@unc.edu.
38188599,Recombinant Human Bone Morphogenetic Protein-2 Priming of Mesenchymal Stem Cells Ameliorate Acute Lung Injury by Inducing Regulatory T Cells.,2023,"Bae, Han-Sol; Lee, Young Jin","Cellular Therapeutics Team, Daewoong Pharmaceutical, Yongin 17028, Korea.; Cellular Therapeutics Team, Daewoong Pharmaceutical, Yongin 17028, Korea.",None
38186847,Characterization of orthopedic manifestations in patients with mucopolysaccharidosis II using data from 15 years of the Hunter Outcome Survey.,2024,"Botha, Jaco",Takeda Pharmaceuticals International AG Zürich Switzerland.,None
38169574,"Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Coronary Heart Disease Complicating Chronic Heart Failure (Syndrome of Qi Deficiency with Blood Stasis): Study Protocol for a Randomized, Placebo-Controlled, Double-Blind and Multi-Centre Phase II Clinical Trial.",2023,"Wang, Xiaojing","Clinical Medical Center, Tasly Pharmaceutical Group Co. Ltd., Tianjin, People's Republic of China.",None
38162658,IL-17A-driven psoriasis is critically dependent on IL-36 signaling.,2023,"Kölsch, Stephan Marcus","Boehringer Ingelheim Pharma GmbH & Co. KG, Medical Affairs, Ingelheim am Rhein, Germany.",None
38162437,Lipid-lowering therapy and LDL-C control for primary prevention in persons with diabetes across 90 health systems in the United States.,2023,"Khalaf Gillard, Kristin; Sarnes, Evelyn","Esperion Therapeutics, Inc., Ann Arbor, MI, USA.; Esperion Therapeutics, Inc., Ann Arbor, MI, USA.",None
38159829,Network pharmacology and experimental verification to explore the anti-superficial thrombophlebitis mechanism of Mailuo shutong pill.,2024/Mar/25,"Xiao, He; Sun, Chenghong; Yao, Jingchun; Zhang, Guimin","State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co. LTD., Linyi, 276005, China. Electronic address: baochifeixiang@163.com.; State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co. LTD., Linyi, 276005, China. Electronic address: sch658@163.com.; State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co. LTD., Linyi, 276005, China. Electronic address: yaojingchun@yeah.net.; State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co. LTD., Linyi, 276005, China. Electronic address: lunanzhangguimin@yeah.net.",kai1219@163.com.
38159295,Conquering cholesterol: a report from the front lines.,2023/Dec/30,"Pinkosky, Stephen L","Esperion Therapeutics, Inc., Ann Arbor, MI 48108, USA.",None
38158636,Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.,2024,"Iwata, Tomoko; Nitta, Daisuke","Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.; Medicine Division, Nippon Boehringer Ingelheim Co. Ltd, Tokyo, Japan.",Centre-UnIC@RISE
38156550,Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States.,2024/Jan/02,"Philip, Sephy","Amarin Pharma, Inc Bridgewater NJ USA.",None
38155446,Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease.,2024,"Mattheus, Michaela","Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.",None
38150937,"Synthesis and biological evaluations of 8-biaryl-2,2-dimethylbenzopyranamide derivatives against Alzheimer's disease and ischemic stroke.",2024,"Xiao, Wei","Jiangsu Kanion Pharmaceutical Co., Ltd., Jiangning Industrial City, Economic and Technological Development Zone, Lianyungang, Jiangsu 222001, China. Electronic address: xw_kanion@163.com.",chenguoliang@syphu.edu.cn.
38150256,Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.,2023/Dec/01,"Khan, Nader; Snabes, Michael C; Li, Xue","AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.",None
38149752,Molecular characterization of chronic cutaneous wounds reveals subregion- and wound type-specific differential gene expression.,2024,"Richards, Shola Michelle; Gubser Keller, Caroline; Kreutzer, Robert; Greiner, Géraldine; Ley, Svenja; Doelemeyer, Arno; Dubost, Valerie; Flandre, Thierry; Kirkland, Susan; Carbone, Walter; Pandya, Rishika; Knehr, Judith; Roma, Guglielmo; Schuierer, Sven; Bouchez, Laure; Seuwen, Klaus; Aebi, Alexandra; Hintzen, Gabriele; Jurisic, Giorgia; Hossain, Imtiaz; Neri, Marilisa; Manevski, Nenad; Balavenkatraman, Kamal Kumar; Moulin, Pierre; Begrich, Annette; Bertschi, Barbara; Huber, Roland; Bouwmeester, Tewis; Driver, Vickie R; Ruffner, Heinz","Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.",None
38145819,Cost-effectiveness analysis of intralesional and perilesional recombinant human epidermal growth factor vs hydrocolloid therapy in venous ulcer treatment in the Colombian context.,2024,"Moreno-Mattar, Ornella","Praxis Pharmaceutical, Bogotá, CO. Electronic address: ornellamorenomattar@gmail.com.",ornellamorenomattar@gmail.com.
38144948,"Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group.",2023,"Morland, Kellie",Global Medical Affairs United Therapeutics Corporation Research Triangle Park North Carolina USA.,None
38143082,Timing of Worsening Renal Function in Patients Hospitalized for Heart Failure Exacerbation Who Were Being Treated With Intravenous Diuretic Therapy.,2024/Apr/25,"Kurita, Yuka; Mori, Hiromasa; Oishi, Kazuyuki; Matsukawa, Miyuki","Medical Affairs, Otsuka Pharmaceutical Co., Ltd.; Medical Affairs, Otsuka Pharmaceutical Co., Ltd.; Medical Affairs, Otsuka Pharmaceutical Co., Ltd.; Medical Affairs, Otsuka Pharmaceutical Co., Ltd.",None
38142864,Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema.,2024,"Bordone, Laura; Revenko, Alexey; Newman, Kenneth B","Ionis Pharmaceuticals, Carlsbad, Calif.; Ionis Pharmaceuticals, Carlsbad, Calif.; Ionis Pharmaceuticals, Carlsbad, Calif.",mriedl@health.ucsd.edu.
38140315,"Totum-070, a Polyphenol-Rich Plant Extract, Prevents Hypercholesterolemia in High-Fat Diet-Fed Hamsters by Inhibiting Intestinal Cholesterol Absorption.",2023/Dec/09,"Groult, Hugo; Achour, Oussama; Maugard, Thierry; Bard, Jean-Marie","Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), UMR (Unité Mixte de Recherche) CNRS (Centre National de la Recherche Scientifique) 7266 LIENSs (LIttoral ENvironnement Et Sociétés), La Rochelle Université, 17042 La Rochelle, France.; BioAqtiv, Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), LIENSs (LIttoral ENvironnement Et Sociétés), UMR (Unité Mixte de Recherche) 7266 CNRS (Centre National de la Recherche Scientifique), La Rochelle Université, 17042 La Rochelle, France.; Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), UMR (Unité Mixte de Recherche) CNRS (Centre National de la Recherche Scientifique) 7266 LIENSs (LIttoral ENvironnement Et Sociétés), La Rochelle Université, 17042 La Rochelle, France.; Laboratoire de Biochimie Générale et Appliquée, UFR (Unité de Formation et de Recherche) de Pharmacie, ISOMer-UE 2160, IUML-Institut Universitaire Mer et Littoral-FR3473 CNRS, Université de Nantes, 44035 Nantes, France.",None
38140087,Unknown,2023/Dec/08,"Xing, Yueyang; Wang, Dandan","SPH XingLing Sci. & Tech. Pharmaceutical Co., Ltd., Shanghai 201203, China.; SPH XingLing Sci. & Tech. Pharmaceutical Co., Ltd., Shanghai 201203, China.",None
38133847,Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.,2024,"Kastelein, John J P; Hsieh, Andrew; Ditmarsch, Marc; Davidson, Michael H","NewAmsterdam Pharma B.V., Naarden, Netherlands.; NewAmsterdam Pharma B.V., Naarden, Netherlands. Andrew.Hsieh@NewAmsterdamPharma.com.; NewAmsterdam Pharma B.V., Naarden, Netherlands.; NewAmsterdam Pharma B.V., Naarden, Netherlands.",Andrew.Hsieh@NewAmsterdamPharma.com.
38128748,Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.,2024,"Felten, Renaud","Centre d'Investigation Clinique, INSERM CIC-1434, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Département Universitaire de Pharmacologie-Addictologie, Toxicologie et Thérapeutique, Université de Strasbourg, Strasbourg, France.",sdanese@hotmail.com.
38126776,Injectable Biodegradable Silica Depot for Controlled Subcutaneous Delivery of Antisense Oligonucleotides with beyond Monthly Administration.,2024/Jan/01,"McGowan, Asmaa; Gennemark, Peter; Akieh-Pirkanniemi, Marceline; Wirman, Linda; Davies, Nigel; Elebring, Marie; Tivesten, Anna; Strimfors, Marie; Hölttä, Mikko; Söderberg, Magnus; Berntsson, Veronica; Balas, Daniela; Koskinen, Mika; Leino, Lasse; Abrahmsén-Alami, Susanna","DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland.; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.; DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland.; DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland.; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.; CVRM CMC Projects, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.; Bioscience metabolism, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.; Pathology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.; DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland.; DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland.; Sustainable Innovation & Transformational Excellence, Pharmaceutical Technology & Development, Operations, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.",None
38122865,Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.,2024,"Collis, Phil; Johnston, Douglas T; Desai, Bhavisha; Tomita, Dianne; McNeil, Donald","BioCryst Pharmaceuticals, Inc., Durham, NC.; BioCryst Pharmaceuticals, Inc., Durham, NC.; BioCryst Pharmaceuticals, Inc., Durham, NC.; BioCryst Pharmaceuticals, Inc., Durham, NC.; Optimed Research, Ltd., Columbus, Ohio.",lumrymd@aararesearch.com.
38118067,A non-inferiority study to compare the effect of silica gel fiber dressing with alginate dressing on healing of venous leg ulcers.,2023,"Dong, Ruiping; Liu, Dongyang","Jiangsu Synecoun Medical Technology Co., Ltd, West Side of Chengkou Road, Taizhou City, Jiangsu Province, China.; Jiangsu Synecoun Medical Technology Co., Ltd, West Side of Chengkou Road, Taizhou City, Jiangsu Province, China.",None
38114956,Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.,2023/Dec/19,"Jeong, Seonjeong","AbbVie Ltd, Seoul, Republic of Korea.",geniushee@yuhs.ac.
38114111,[Chemical constituents and mechanism of Chuanzhi Tongluo Capsules based on UPLC-Q-Exactive Orbitrap-MS and network pharmacology].,2023,"Guan, Yong-Xia; Fan, Jian-Wei; Yuan, Xiao-Mei","State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co., Ltd. Linyi 276005, China.; State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co., Ltd. Linyi 276005, China.; State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co., Ltd. Linyi 276005, China.",None
38112795,"Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.",2024,"Liu, Bo; Zhu, Yanan; Yang, Xinai; Kang, Xiaoyan","Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.",13910107759@163.com.
38111701,Association of long-term aspirin use with kidney disease progression.,2023,"Streja, Elani","VA Connecticut Healthcare System, West Haven VA Medical Center, West Haven, CT, United States.",None
38110653,Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.,2024,"Diels, Joris; Strulev, Vadim","Janssen Pharmaceutica NV, Beerse, Belgium.; Janssen Pharmaceutica NV, Beerse, Belgium.",k.weisel@uke.de.
38107636,Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation.,2023,"Livingston, Terrie","Patient Solutions and Center of Excellence Strategic Engagement, EMD Serono, Inc., Rockland, MA, United States.",None
38104937,"Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER.",2024,"Langkilde, Anna Maria; Bengtsson, Olof; Petersson, Magnus; Sjöstrand, Mikaela; Wilderäng, Ulrica","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",john.mcmurray@glasgow.ac.uk.
38104755,Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials.,2024/Mar/01,"Amazonas, Roberto","EMS Pharmaceuticals, Hortolȃndia, São Paulo, Brazil.",rhmfurtado@gmail.com.
38103591,Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms.,2024,"Ho, Caleb; Huang, Ying; Miller, Jeffrey","Loxo Oncology, Inc., Stamford, Connecticut.; Invivoscribe, Inc., San Diego, California.; Invivoscribe, Inc., San Diego, California.",arcilam@mskcc.org.
38102588,Artichoke (Cynara scolymus L.) water extract alleviates palmitate-induced insulin resistance in HepG2 hepatocytes via the activation of IRS1/PI3K/AKT/FoxO1 and GSK-3β signaling pathway.,2023/Dec/15,"Chen, Jun; Chen, Kaiyi","Sanjin Group Hunan Sanjin Pharmaceutical Co., Ltd, Changde, 415000, China.; Sanjin Group Hunan Sanjin Pharmaceutical Co., Ltd, Changde, 415000, China.",xiaobing01@xinhuamed.com.cn.
38100106,Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.,2023/Dec/01,"Nishimura, Kunihiro; Hiraoka, Manabu","Xcoo Inc, Tokyo, Japan.; Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan.",None
38099327,Role of platelet count in a murine stasis model of deep vein thrombosis.,2024,"Lorentz, Christina U; Revenko, Alexey","Aronora, Inc, Portland, OR, USA.; Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.",None
38098210,Treatment patterns and trajectories in patients after acute heart failure hospitalization.,2024,"Motoya, Yuki; Fukui, Masato","Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Ono Pharmaceutical Co., Ltd., Osaka, Japan.",None
38097862,Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.,2024,"Langkilde, Anna Maria","BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",gchertow@stanford.edu.
38097108,"Reporting standard for describing first responder systems, smartphone alerting systems, and AED networks.",2024,"Elschenbroich, D","Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.",michael.mueller@grc-org.de.
38092897,Inhibition of the K,2024,"Holst, Anders G; Vestbjerg, Birgitte; Grunnet, Morten; Sørensen, Ulrik S; Diness, Jonas G; Bentzen, Bo H; Edvardsson, Nils","Acesion Pharma, Copenhagen, Denmark. agh@acesionpharma.com.; Acesion Pharma, Copenhagen, Denmark.; Acesion Pharma, Copenhagen, Denmark.; Acesion Pharma, Copenhagen, Denmark.; Acesion Pharma, Copenhagen, Denmark.; Acesion Pharma, Copenhagen, Denmark.; Acesion Pharma, Copenhagen, Denmark.",agh@acesionpharma.com.
38084911,Shenxiang Suhe pill improves cardiac function through modulating gut microbiota and serum metabolites in rats after acute myocardial infarction.,2024,"Chen, Wei; Zhu, Jiaming","Hangzhou Hu Qing Yu Tang Pharmaceutical Co., Ltd, Hangzhou, China.; Hangzhou Hu Qing Yu Tang Pharmaceutical Co., Ltd, Hangzhou, China.",None
38082237,"The effects of curcumin-piperine supplementation on inflammatory, oxidative stress and metabolic indices in patients with ischemic stroke in the rehabilitation phase: a randomized controlled trial.",2023/Dec/11,"Majeed, Muhammed","Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ, 08520, USA.",bagherniya@yahoo.com.
38081956,Latent inter-organ mechanism of idiopathic pulmonary fibrosis unveiled by a generative computational approach.,2023/Dec/11,"Kozawa, Satoshi; Tejima, Kengo; Takagi, Shunki; Sato, Thomas N","Karydo TherapeutiX, Inc., 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto, 619-0288, Japan.; Karydo TherapeutiX, Inc., 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto, 619-0288, Japan.; Karydo TherapeutiX, Inc., 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto, 619-0288, Japan.; Karydo TherapeutiX, Inc., 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto, 619-0288, Japan. island1005@gmail.com.",island1005@gmail.com.
38077040,Exploring the genetics of lithium response in bipolar disorders.,2023/Dec/02,"Leckband, Susan G",VA San Diego Healthcare System.,None
38065584,BNP level predicts bleeding event in patients with heart failure after percutaneous coronary intervention.,2023/Dec/07,"Sato, Hisahiko","Precision Inc, Tokyo, Japan.",masa2006starmind@gmail.com.
38065307,Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.,2024,"Rush, Stephen; Chen, Jersey; Zhou, Wunan; Kwoh, Jesse; Duran, Jason M","BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.; Ionis Pharmaceuticals, Inc., Carlsbad, California.; Ionis Pharmaceuticals, Inc., Carlsbad, California.",ssolomon@bwh.harvard.edu.
38063433,Viral infection and host immune response in diabetes.,2024,"Joshi, Garima; Das, Anushka; Verma, Garima; Guchhait, Prasenjit","Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India.; Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India.; Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India.; Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India.",None
38062874,Treatment with Cerebrolysin Prolongs Lifespan in a Mouse Model of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy.,2024,"Kastberger, Birgit; Winter, Stefan; Brandstätter, Hemma","Ever Pharma, Oberburgau 3, Unterach am Attersee, 4866, Austria.; Ever Pharma, Oberburgau 3, Unterach am Attersee, 4866, Austria.; Ever Pharma, Oberburgau 3, Unterach am Attersee, 4866, Austria.",None
38062078,Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.,2023/Dec/08,"Fan, Xiao-Hu","Legend Biotech China, Nanjing, 211112, China. frankfanwondercel@gmail.com.",shuochen@sjtu.edu.cn.
38061370,Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.,2024,"Li, Na; Louie, Michael J","Esperion Therapeutics, Ann Arbor, MI, USA.; Esperion Therapeutics, Ann Arbor, MI, USA.",k.ray@imperial.ac.uk.
38060531,"Trends in cost and consumption of essential medicines for non-communicable diseases in Azerbaijan, Georgia, and Uzbekistan, from 2019 to 2021.",2023,"Aghayev, Elsever","Pharmacological and Pharmacopoeial Expert Council, Ministry of Health of the Republic of Azerbaijan, Baku, Azerbaijan.",None
38059368,Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.,2024/Mar/12,"Hammarstedt, Ann; Maria Langkilde, Anna; Reicher, Barry; Wilderäng, Ulrica","Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research & Development, AstraZeneca, Gothenburg, Sweden (A.H., A.M.L., U.W.).; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research & Development, AstraZeneca, Gothenburg, Sweden (A.H., A.M.L., U.W.).; AstraZeneca BioPharmaceuticals Research & Development, Late-Stage Development, Cardiovascular, Renal and Metabolic, Gaithersburg, MD (B.R.).; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research & Development, AstraZeneca, Gothenburg, Sweden (A.H., A.M.L., U.W.).",None
38057072,Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease.,2023/Dec/12,"Dyme, Joshua L; Reedy, Alison M; Ajavon-Hartmann, Toni; Jarugula, Praneeth; Carlson-Taneja, Lauren E; Mills, Donna","Bristol Myers Squibb, Inc, Lawrence Township, New Jersey, USA.; Bristol Myers Squibb, Inc, Lawrence Township, New Jersey, USA.; Bristol Myers Squibb, Inc, Lawrence Township, New Jersey, USA.; Bristol Myers Squibb, Inc, Lawrence Township, New Jersey, USA.; Bristol Myers Squibb, Inc, Lawrence Township, New Jersey, USA.; Bristol Myers Squibb, Inc, Lawrence Township, New Jersey, USA.",rpayne@iu.edu.
38057066,Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials.,2023/Dec/12,"Lesogor, Anastasia; Maheux, Pierre; Stratz, Christian; Zang, Xiao","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA.",wright.scott@mayo.edu.
38056780,"A first-in-human study of Brozopentyl Sodium, following single and multiple ascending intravenous infusion in Chinese healthy volunteers.",2024/Jan/01,"Li, Yun-Feng; Zheng, Zhi-Guo","Zhejiang Ausun Pharmaceutical Co., Ltd., Zhejiang, China.; Zhejiang Ausun Pharmaceutical Co., Ltd., Zhejiang, China.",cui.pharm@pkufh.com.
38048880,Diagnostic value of papillary muscle hypertrophy and mitral valve thickness to discriminate cardiac amyloidosis and Fabry disease.,2024/Feb/15,"Canaan-Kühl, Sima","Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany; Amyloidosis Center Charité Berlin (ACCB), Charité - Universitätsmedizin Berlin, Germany; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin, Fabry Zentrum, Zentrum für seltene Nierenerkrankungen (CeRKiD), Campus Charité Mitte, Berlin, Germany.",anna.brand@dhzc-charite.de.
38042151,"Selective and brain-penetrant HCN1 inhibitors reveal links between synaptic integration, cortical function, and working memory.",2024/Mar/21,"Harde, Eva; Hierl, Markus; Weber, Michael; Waiz, David; Wyler, Roger; Wach, Jean-Yves; Haab, Rachel; Gundlfinger, Anja; He, Weiping; Schnider, Patrick; Greiter-Wilke, Andrea; Gasser, Rodolfo; Reutlinger, Michael; Dupont, Amanda; Roberts, Sonia; O'Connor, Eoin C; Bartels, Björn; Hall, Benjamin J","Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: eva.harde@roche.com.; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; WuXi AppTec (Wuhan) Co., Ltd, 666 Gaoxin Road, Wuhan East Lake High-Tech Development Zone, Wuhan, Huibei, China.; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: eoin.oconnor@roche.com.; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: bjoern.bartels@roche.com.; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",bjoern.bartels@roche.com.
38039752,Protective effect of novel angiotensin receptor neprilysin inhibitor S086 on target organ injury in spontaneously hypertensive rats.,2024,"Xiao, Ying; Sun, Jing-Chao; Xing, Wei; Yan, Jie; Xu, Wen-Jie; Lu, Yin-Suo","Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China.; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China. Electronic address: sunjingchao@salubris.com.; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China.; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China.; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China.; Shenzhen Salubris Pharmaceutical Co., Ltd., Shenzhen, Guangdong, China.",dingxiangshu2020@163.com.
38037709,Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials.,2024,"Panova-Noeva, Marina","Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.",UnIC@RISE
38035037,"Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.",2023,"Pineda, Armando Lira; Ketchum, Steven B; Doyle, Ralph T","Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA.; Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA.; Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA.",None
38032573,Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design.,2024,"Heitner, Stephen B; Jacoby, Daniel L; Kupfer, Stuart; Malik, Fady I; Meng, Lisa; Wohltman, Amy","Cytokinetics Incorporated, South San Francisco, California, USA.; Cytokinetics Incorporated, South San Francisco, California, USA.; Cytokinetics Incorporated, South San Francisco, California, USA.; Cytokinetics Incorporated, South San Francisco, California, USA.; Cytokinetics Incorporated, South San Francisco, California, USA.; Cytokinetics Incorporated, South San Francisco, California, USA.",caroline.coats@glasgow.ac.uk.
38030645,Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro.,2023/Nov/29,"Fortin, Marie C; Tan, Lei; Wang, Qi; Manca, Dino","Jazz Pharmaceuticals, 2005 Market Street, 21St Floor, Philadelphia, PA, 19103, USA. marie.fortin@jazzpharma.com.; Jazz Pharmaceuticals, 2005 Market Street, 21St Floor, Philadelphia, PA, 19103, USA.; Jazz Pharmaceuticals, 2005 Market Street, 21St Floor, Philadelphia, PA, 19103, USA.; Jazz Pharmaceuticals, 2005 Market Street, 21St Floor, Philadelphia, PA, 19103, USA.",marie.fortin@jazzpharma.com.
38030465,Event rates and risk factors for venous thromboembolism and major bleeding in a population of hospitalized adult patients with acute medical illness receiving enoxaparin thromboprophylaxis.,2024,"Ponomareva, Ekaterina","Axtria Inc, Berkeley Heights, NJ, USA.",glegal@toh.ca.
38030254,Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink.,2023/Nov/29,"Durand, Adeline; Lahoz, Raquel","Novartis Pharmaceuticals, London, UK.; Novartis Pharma AG, Basel, Switzerland.",chris.morgan@humandatasciences.com.
38029107,Evaluation of cholesterol transformation abilities and probiotic properties of ,2023,"He, Zhili; Wang, Tinghui; Zhang, Shichang; Shi, Kuojiang; Wang, Fan; Li, Yanzhao; Lin, Chanqing; Chen, Jianguo","Beijing YuGen Pharmaceutical Co., Ltd., Beijing, China.; Beijing YuGen Pharmaceutical Co., Ltd., Beijing, China.; Beijing YuGen Pharmaceutical Co., Ltd., Beijing, China.; Beijing YuGen Pharmaceutical Co., Ltd., Beijing, China.; Beijing YuGen Pharmaceutical Co., Ltd., Beijing, China.; Beijing Hotgen Biotechnology Inc., Beijing, China.; Beijing Hotgen Biotechnology Inc., Beijing, China.; Beijing YuGen Pharmaceutical Co., Ltd., Beijing, China.",None
38019499,An Evaluation of the Repeatability of Visual Function Following Surgical Repair of Macula-Off Rhegmatogenous Retinal Detachment.,2023/Nov/01,"Kocab, Andrew J; van de Goor, Jana; Wagner, Brandie D","ONL Therapeutics, Inc., Ann Arbor, MI, USA.; ONL Therapeutics, Inc., Ann Arbor, MI, USA.; ONL Therapeutics, Inc., Ann Arbor, MI, USA.",None
38016401,Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials.,2023,"Han, Jackie; Conde, Lorena Garcia","Novartis Pharmaceuticals Corp, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.",ulf.landmesser@dhzc-charite.de.
38015167,Report From the 2022 Mary Tyler Moore Vision Initiative Diabetic Retinal Disease Clinical Endpoints Workshop.,2023/Nov/01,"Sherman, Steve; Luhmann, Ulrich F O; Pallinat, Martin","Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Roche Pharmaceutical Research and Early Development, Translational Medicine Ophthalmology, Roche Innovation Center, Basel, Switzerland.; Visiontree Software, Inc., San Diego, CA, USA.",None
38009241,A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.,2024,"Bordone, Laura; Deng, Yiwen; Newman, Kenneth B; Alexander, Veronica J; Lui, Cindy; Schneider, Eugene","Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.; Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.; Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.; Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.; Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.; Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.",None
38006972,Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat.,2024,"Desai, Bhavisha; Tomita, Dianne; Collis, Phil","BioCryst Pharmaceuticals, Inc, Durham, North Carolina.; BioCryst Pharmaceuticals, Inc, Durham, North Carolina.; BioCryst Pharmaceuticals, Inc, Durham, North Carolina.",bernstja@ucmail.uc.edu.
38005332,Bioactive Peptides from ,2023/Nov/15,"Wang, Weixia; Liu, Jinli; Zou, Shengcan; Yin, Dongli; Lyu, Chenghan","Qingdao Chenlan Pharmaceutical Co., Ltd., Qingdao 266061, China.; Qingdao Chenlan Pharmaceutical Co., Ltd., Qingdao 266061, China.; Qingdao Chenlan Pharmaceutical Co., Ltd., Qingdao 266061, China.; Qingdao Chenlan Pharmaceutical Co., Ltd., Qingdao 266061, China.; Qingdao Chenlan Pharmaceutical Co., Ltd., Qingdao 266061, China.",None
37999870,A multicenter prospective randomized controlled trial investigating the effects of combustion-free nicotine alternatives on cardiovascular risk factors and metabolic parameters in individuals with type 2 diabetes who smoke: the DiaSmokeFree study protocol.,2024,"Belsey, Jonathan","JB Medical Ltd, Sudbury, UK.",arkadiuszkrysinski@gmail.com.
37998401,Oral Administration of Rhamnan Sulfate from ,2023/Nov/20,"Terasawa, Masahiro; Uchida, Ryota; Nishiura, Kaoru; Matsuda, Koichi","Konan Chemical Manufacturing Co., Ltd., Kitagomizuka, Kusu-cho, Yokkaichi 510-0103, Japan.; Konan Chemical Manufacturing Co., Ltd., Kitagomizuka, Kusu-cho, Yokkaichi 510-0103, Japan.; Konan Chemical Manufacturing Co., Ltd., Kitagomizuka, Kusu-cho, Yokkaichi 510-0103, Japan.; Konan Chemical Manufacturing Co., Ltd., Kitagomizuka, Kusu-cho, Yokkaichi 510-0103, Japan.",None
37996265,Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.,2024,"Bent-Ennakhil, Nawal; Stull, Dawn Marie; Gavini, François","Takeda Pharmaceuticals International AG, Zurich, Switzerland.; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA.; Takeda Pharmaceuticals International AG, Zurich, Switzerland.",heinz.ludwig@extern.gesundheitsverbund.at.
37993548,"Thrombocytopenia and venous thromboembolic events after BNT162b2, CoronaVac, ChAdOx1 vaccines and SARS-CoV-2 infection: a self-controlled case series study.",2023/Nov/22,"Wo, Wee Kee; Yeoh, Hee Sheong","National Pharmaceutical Regulatory Agency, Ministry of Health, Shah Alam, Selangor, Malaysia.; National Pharmaceutical Regulatory Agency, Ministry of Health, Shah Alam, Selangor, Malaysia.",norazida@crc.gov.my.
37993116,Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks.,2024/Jan/22,"Frade, Joao P; Fasehun, Marie; Audhya, Paul K","KalVista Pharmaceuticals, Cambridge, Massachusetts.; KalVista Pharmaceuticals, Cambridge, Massachusetts.; KalVista Pharmaceuticals, Cambridge, Massachusetts.",None
37992916,The Annexin-A1 mimetic RTP-026 promotes acute cardioprotection through modulation of immune cell activation.,2023,"Sanni, Samra; Jonassen, Thomas En","ResoTher Pharma A/S, Holte, Denmark.; ResoTher Pharma A/S, Holte, Denmark.",m.perretti@qmul.ac.uk.
37992168,ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.,2023/Nov/24,"Valentine, Henkel; Abbosh, Philip","Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.",None
37991694,A Patient Charter for Chronic Urticaria.,2024,"McCarthy, Jessica","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",twinders@gaapp.org.
37989299,Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Heart Failure According to Baseline Systolic Blood Pressure　- Results From a Subgroup Analysis of the PARALLEL-HF Study.,2023/Dec/25,"Ohishi, Tomomi; Iimori, Takayuki; Kitamura, Toshihito",Novartis Pharma K.K.; Novartis Pharma K.K.; Novartis Pharma K.K.,None
37987918,"Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study.",2024,"Zhu, Ke-Wei","Office of Pharmacovigilance, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, No. 88 Yunxiang Road Tonghe Street, Baiyun District, Guangzhou, 510515, Guangdong Province, China. zhukew2018@outlook.com.",hxg7807@sina.com.
37985002,Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: the VITALITY-HFpEF trial.,2024,"Blaustein, Robert O","Merck & Co., Inc., Rahway, NJ, USA.",None
37984714,Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.,2024,"Joshi, Prashant; Yu, Edward; Liu, Liang","Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.",Leslie.Ballas@cshs.org.
37981439,Systolic heart failure induced by butylparaben in zebrafish is caused through oxidative stress and immunosuppression.,2023,"Zheng, Jia","Wuliangye Group Co., Ltd., Yibin 644007, China.",wangningzhuhui@hotmail.com.
37980402,Inhibition of PDGFRβ alleviates endothelial cell apoptotic injury caused by DRP-1 overexpression and mitochondria fusion failure after mitophagy.,2023/Nov/18,"Ma, Xiao","Yunnan Characteristic Plant Extraction Laboratory, Yunnan Yunke Characteristic Plant Extraction Laboratory Co., Ltd, Kunming, 650106, China.",zjcpu2016@163.com.
37978379,WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis.,2023/Nov/17,"Li, Chaopeng; Ouyang, Dongsheng","Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd, Changsha, China.; Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd, Changsha, China.",csucaoke@163.com.
37977177,Inclusion of functional measures and frailty in the development and evaluation of medicines for older adults.,2023,"Cupelli, Amelia; Laslop, Andrea; Trauffler, Martine","Pharmacovigilance Risk Assessment Committee, European Medicines Agency, Amsterdam, Netherlands; Pharmacovigilance Office, Italian Medicines Agency, Rome, Italy.; Pharmacovigilance Risk Assessment Committee, European Medicines Agency, Amsterdam, Netherlands; Scientific Office, Austrian Medicines and Medical Devices Agency, Federal Office for Safety in Health Care, Vienna, Austria.; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, Netherlands; Division of Pharmacy and Medicines, Directorate of Health, Ministry of Health, Luxembourg.",michael.denkinger@agaplesion.de.
37976820,Prompt-enhanced hierarchical transformer elevating cardiopulmonary resuscitation instruction via temporal action segmentation.,2023,"Gao, Zhenyuan; Huang, Qiming","Miragestars Inc., Tianjin, 300392, China.; Shenzhen ZNV Technology Co., Ltd, Shenzhen, 518057, China.",pwqin@sz.tsinghua.edu.cn.
37973338,"Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study.",2023,"Schweizer, Anja; Obergfell, Achim","Novartis Pharma, Basel, Switzerland.; Novartis Pharma, Basel, Switzerland.",angermann_c@ukw.de.
37972922,Anaphylaxis in Clinical Trials of Sublingual Immunotherapy Tablets.,2024,"Azuma, Ryuji","Torii Pharmaceutical Co, Ltd, Tokyo, Japan.",Hendrik.nolte@alk.net.
37971723,Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.,2023/Dec/01,"Kim, Yong Soo; He, Fanyin; Cho, Ga Eun; Wang, Yuhua","Novartis Pharma AG, Basel, Switzerland.; Beijing Novartis Pharma, Beijing, China.; Novartis Pharmaceuticals, East Hanover, New Jersey.; Novartis Pharma AG, Basel, Switzerland.",None
37969852,Coronary Artery Calcium Scoring in Asymptomatic Patients.,2023,"Mahmood, Ahmed; Flynn, Michael G; Alexander, Thomas","Corpus Christi Medical Center, Corpus Christi, TX.; HCA Healthcare Graduate Medical Education, Brentwood, TN.; Corpus Christi Medical Center, Corpus Christi, TX.",None
37969049,Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.,2024,"Kotobuki, Yutaro; Nitta, Daisuke","Medicine Division, Nippon Boehringer Ingelheim Co., Ltd., Shinagawa, Tokyo, Japan.; Medicine Division, Nippon Boehringer Ingelheim Co., Ltd., Shinagawa, Tokyo, Japan.",None
37969032,The 8th International RASopathies Symposium: Expanding research and care practice through global collaboration and advocacy.,2024,"Kieran, Mark W","Research and Development, Day One Biopharmaceuticals, Brisbane, California, USA.",None
37968424,Therapeutic efficacies of mitochondria-targeted esculetin and metformin in the improvement of age-associated atherosclerosis via regulating AMPK activation.,2024,"Thennati, Rajamannar","High Impact Innovations-Sustainable Health Solutions (HISHS), Sun Pharmaceutical Industries Ltd, Vadodara-390012, India.",giridhar@iict.res.in.
37967762,Tyvaso DPI: Drug-device characteristics and patient clinical considerations.,2023,"Smutney, Chad; Dillon, Chris; Winkler, Thomas; Davis, Brittany N; Broderick, Meredith","MannKind Corporation, Danbury, CT, USA.; United Therapeutics Corporation, Research Triangle Park, NC, USA.; United Therapeutics Corporation, Research Triangle Park, NC, USA.; United Therapeutics Corporation, Research Triangle Park, NC, USA.; United Therapeutics Corporation, Research Triangle Park, NC, USA.",burger.charles@mayo.edu.
37967390,Acute heart failure: mechanisms and pre-clinical models-a Scientific Statement of the ESC Working Group on Myocardial Function.,2023/Nov/15,"Zacchigna, Serena","Laboratory of Cardiovascular Biology, The International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.",UnIC@RISE
37964408,Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program.,2024,"Maldonado, Sandra González; Panova-Noeva, Marina; Masson, Serge","Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.; Roche Diagnostics International Ltd, Rotkreuz, Switzerland.",None
37963901,Evaluation of recombinant human IGF-1/IGFBP-3 on intraventricular hemorrhage prevention and survival in the preterm rabbit pup model.,2023/Nov/13,"Barton, Norman","Scientific Advisory Board, Oak Hill Bio Ltd, WA14 2DT, UK.",magnus.gram@med.lu.se.
37962898,Enhancing identification and treatment of patients with concomitant chronic venous insufficiency and diabetes mellitus. A modified Delphi study from the CODAC (ChrOnic venous disease and Diabetes Advisory Council) group.,2023,"Zingg, Daniel; Calabrese, Alessandra","OM Pharma, Geneva, Switzerland.; OM Pharma, Geneva, Switzerland.",m.vanrijn@erasmusmc.nl.
37961920,Intranasal G5-BGG/pDNA Vaccine Elicits Protective Systemic and Mucosal Immunity against SARS-CoV-2 by Transfecting Mucosal Dendritic Cells.,2024,"Xie, Cao","Shanghai Tayzen Pharmlab Co., Ltd., Shanghai, 201203, China.",None
37961802,Sortilin-induced lipid accumulation and atherogenesis are suppressed by HNF1b SUMOylation promoted by flavone of ,2023/Nov/15,"Zeng, Zhaoming","Hunan Mingshun Pharmaceutical Co., Ltd., Shaodong 422800, China. anthony0723@163.com, zzhg88@163.com.",anthony0723@163.com.
37959269,Reduction in Arterial Stiffness Index (SI) in Response to Combination Antioxidant Therapy.,2023/Oct/27,"Howes, Jan B","Phoenix Pharmaceuticals Australia Pty Ltd., Sanctuary Cove, Gold Coast 4212, Australia.",None
37956920,Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021.,2024,"Hebbe, Annika; Daus, Marguerite; Waldo, Stephen W; Ho, P Michael; Simons, Carol","VA Puget Sound Health Care System, Seattle, WA; Seattle-Denver Center of Innovation for Veteran-Centered and Value Driven Care, Veterans Health Administration Eastern Colorado Healthcare System, Aurora, CO; Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO; CART Program, Office of Quality and Patient Safety, Veterans Health Administration, Washington, DC.; VA Puget Sound Health Care System, Seattle, WA; Seattle-Denver Center of Innovation for Veteran-Centered and Value Driven Care, Veterans Health Administration Eastern Colorado Healthcare System, Aurora, CO; Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO.; VA Puget Sound Health Care System, Seattle, WA; Seattle-Denver Center of Innovation for Veteran-Centered and Value Driven Care, Veterans Health Administration Eastern Colorado Healthcare System, Aurora, CO; Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO; CART Program, Office of Quality and Patient Safety, Veterans Health Administration, Washington, DC.; VA Puget Sound Health Care System, Seattle, WA; Seattle-Denver Center of Innovation for Veteran-Centered and Value Driven Care, Veterans Health Administration Eastern Colorado Healthcare System, Aurora, CO.; VA Puget Sound Health Care System, Seattle, WA; Seattle-Denver Center of Innovation for Veteran-Centered and Value Driven Care, Veterans Health Administration Eastern Colorado Healthcare System, Aurora, CO.",jdoll@uw.edu.
37954898,Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis.,2023,"Manvelian, Garen; Coppi, Alida; Jorgensen, Susan; Attre, Richa; Kyratsous, Christos A; Sleeman, Mark W; DelGizzi, Richard; Pordy, Robert; Baras, Aris","Regeneron Pharmaceuticals, Inc., Tarrytown, NY.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY.",None
37952254,"Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.",2023/Dec/05,"Linnebjerg, Helle; Shen, Xi; Ma, Xiaosu; Lim, Shufen; Michael, Laura F; Ruotolo, Giacomo","Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.",None
37951374,Jingfang Granule mitigates Coxsackievirus B3-induced myocardial damage by modulating mucolipin 1 expression.,2024/Feb/10,"Yao, Jingchun; Zhang, Guimin","State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co., Ltd., Linyi, 276006, China.; State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co., Ltd., Linyi, 276006, China.",lichao71795@hotmail.com.
37950726,"Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201).",2023,"Thermil, Nathalie; Shardonofsky, Silvia; Bharucha, David B","Milestone Pharmaceuticals, Montreal, Canada (N.T., S.S.).; Milestone Pharmaceuticals, Montreal, Canada (N.T., S.S.).; Milestone Pharmaceuticals, Charlotte, NC (D.B.B.).",None
37950392,Cerebral microbleeds and asundexian in non-cardioembolic ischemic stroke: Secondary analyses of the PACIFIC-STROKE randomized trial.,2024,"Colorado, Pablo","Pharmaceuticals, Bayer US, Whippany, NJ, USA.",None
37949472,Ethnic disparities in progression rates for sight-threatening diabetic retinopathy in diabetic eye screening: a population-based retrospective cohort study.,2023,"Anderson, John; Chambers, Ryan; Bolter, Louis","Diabetes, Homerton Healthcare NHS Foundation Trust, London, UK.; Diabetes, Homerton Healthcare NHS Foundation Trust, London, UK.; Diabetes, Homerton Healthcare NHS Foundation Trust, London, UK.",arudnick@sgul.ac.uk
37947105,Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy.,2023/Nov/21,"Melbourne, Kathleen","HIV Medical Affairs, Gilead Sciences, Inc. Foster CA USA.",None
37945286,"MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.",2023,"Khan, Nasser; Shmagel, Anna K; Palac, Hannah; Suboticki, Jessica","AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.",ccharles@mednet.ucla.edu.
37944136,4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification.,2023/Nov/21,"Yang, Wenjin","Foresee Pharmaceuticals, Co., Ltd, Taipei, Taiwan.",None
37943443,Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.,2024,"Greasley, Peter J","Early Discovery and Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",Subodh.Verma@unityhealth.to.
37943324,Real-world experience with ultrasound renal denervation utilizing home blood pressure monitoring: the Global Paradise System registry study design.,2024,"Scicli, Andrea","Recor Medical, Inc., Palo Alto, CA, USA.",Felix.Mahfoud@uks.eu.
37943200,DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis.,2023/Nov/27,"Allocco, Dominic J","Boston Scientific Corp, Marlborough, Massachusetts, USA.",Megan.Coylewright@erlanger.org.
37942912,The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development.,2023,"Zannikos, Peter N; Masters, Joanna C; Willmann, Stefan; Shen, Jinshan; Frost, Charles","Johnson & Johnson Innovative Medicine, Clinical Pharmacology and Pharmacometrics, Titusville, NJ, USA.; Pfizer Worldwide Research, Development and Medical, Clinical Pharmacology and Bioanalytics, San Diego, CA, USA.; Bayer AG, Pharmaceuticals, Research & Development, Pharmacometrics/Modeling & Simulation, Wuppertal, Germany.; Relay Therapeutics, Clinical Pharmacology, Cambridge, MA, USA.; Bristol-Myers Squibb, Global Scientific and Regulatory Documentation, Princeton, NJ, USA.",None
37942277,Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a ,2023,"Wang, Cunshan; Sawyerr, Gosford A; Menon, Sujatha; Connell, Carol A; Mortezavi, Mahta","Inflammation and Immunology, Pfizer Inc, Groton, CT, USA.; Inflammation and Immunology, Pfizer Inc, New York, NY, USA.; Inflammation and Immunology, Pfizer Inc, Groton, CT, USA.; Inflammation and Immunology, Pfizer Inc, Groton, CT, USA.; Inflammation and Immunology, Pfizer Inc, 66 Hudson Boulevard, New York, NY 10001, USA.",None
37937463,Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease.,2024/Jan/30,"Natarajan, Pradeep","Boston VA Healthcare System, MA (A.M.S., P.N., C.J.O.).",None
37936360,[Health economic evaluation of telemedicine diabetic retinopathy examination using a non-mydriatic fundus camera in China].,2023/Nov/11,"Zhao, W Y; Hu, W T","Shanghai Phoebus Medical Technology Co., Ltd, Shanghai 200070, China.; Shanghai Phoebus Medical Technology Co., Ltd, Shanghai 200070, China.",None
37933184,Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.,2024,"Mody, Freny Vaghaiwalla; Zhou, Yinong","Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.",None
37931634,"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.",2023/Dec/02,"Bieler, Stewart; Diva, Ulysses A; Inrig, Jula K; Komers, Radko; Mercer, Alex; Preciado, Priscila; Rote, William E","Travere Therapeutics, San Diego, CA, USA.; Travere Therapeutics, San Diego, CA, USA.; Travere Therapeutics, San Diego, CA, USA.; Travere Therapeutics, San Diego, CA, USA.; JAMCO Pharma Consulting, Stockholm, Sweden.; Travere Therapeutics, San Diego, CA, USA.; Travere Therapeutics, San Diego, CA, USA.",brad.rovin@osumc.edu.
37931629,"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.",2023/Nov/25,"Lin, Min; Wijkmark, Emma; Mercier, Anne-Kristina; Åstrand, Magnus; Ueckert, Sebastian; Greasley, Peter J; Ambery, Phil","Biometrics Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Biometrics Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",h.j.lambers.heerspink@umcg.nl.
37930588,Pharmacodynamic Drug-Drug Interactions and Bleeding Outcomes in Patients with Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study.,2025,"Steurbaut, Stephane","Centre for Pharmaceutical Research, Research Group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Jette, Belgium.",Lies.lahousse@ugent.be.
37929602,Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.,2024/Jan/02,"Lei, Lei; Louie, Michael J","Esperion Therapeutics, Ann Arbor, MI (L.L., M.J.L.).; Esperion Therapeutics, Ann Arbor, MI (L.L., M.J.L.).",None
37927298,Wound management across Australian and New Zealand pediatric cardiac services: a cross-sectional survey.,2024,"Tallon, Mary","HeartKids Ltd, Parramatta, Australia.",None
37923653,Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial Disparities.,2024,"Mearns, Elizabeth S; Yellow-Duke, Archibong","Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.",allie.cichewicz@evidera.com.
37922883,The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care.,2023/Nov/02,"MacIsaac, Katharine; Yi, Thomas; Danowski, Morgan E; Cardellino, Mark P; Harris, Elizabeth; Kulkarni, Preetika; Antwi, Ashley A","VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.",jvassy@bwh.harvard.edu.
37920127,Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction.,2023,"Lagerström Fermer, Maria; Gan, Li-Ming","Early Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Sweden.; Ribocure Pharmaceuticals AB, Sweden, Suzhou Ribo Life Science Co. Ltd., China.",None
37918818,The Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation.,2024/Jan/01,"Wagner, Jonathan","Ward Family Heart Center, Children's Mercy Kansas City, Kansas City, Missouri; Division of Clinical Pharmacology, Children's Mercy Kansas City, Kansas City, Missouri.",edelsonj@email.chop.edu.
37918129,The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trial.,2024,"Cadogan, Kathy-Ann; Sullivan, Adam; Zhang, Barbara","Takeda Pharmaceuticals, Cambridge, MA, USA.; Takeda Pharmaceuticals, Cambridge, MA, USA.; Takeda Pharmaceuticals, Cambridge, MA, USA.",bruno.francois@chu-limoges.fr.
37915263,Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.,2024,"Schöder, Stefan","Pharma Division, Bayer AG, Berlin, Germany.",None
37914514,Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.,2023/Nov/07,"Davies, Michael J; Banks, Phillip","Lexicon Pharmaceuticals, Inc, the Woodlands, Texas, USA.; Lexicon Pharmaceuticals, Inc, the Woodlands, Texas, USA.",DLBhattMD@post.Harvard.edu.
37914282,Initiation and Up-Titration of Guideline-Based Medications in Hospitalized Acute Heart Failure Patients　- A Report From the West Tokyo Heart Failure Registry.,2023/Dec/25,"Nakatsu, Fumiko; Umemura, Ichiro","Medical Affairs Division, Novartis Pharma K.K.; Medical Affairs Division, Novartis Pharma K.K.",None
37914225,Incidence of Cardiovascular Events in Patients With Prostate Cancer and Treated With Androgen Deprivation Therapy.,2024,"Fallick, Mark; Pruett, Janis; Brown, Bruce; Dufour, Robert","Myovant Sciences, Inc, Brisbane, California.; Now with Sumitomo Pharma America, Inc, Marlborough, Massachusetts.; Aura Biosciences, Inc, Boston, Massachusetts.; Myovant Sciences, Inc, Brisbane, California.",None
37909222,"Detailed Assessment of the ""I Need Help"" Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry.",2023,"Davison, Beth A","Momentum Research Inc, Durham, NC (B.A.D.).",None
37906417,Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.,2024,"Yang, Ya-Wen","Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA.",brucestrober30@me.com.
37905772,1-Year Outcomes of Transcatheter Edge-to-Edge Repair in Anatomically Complex Degenerative Mitral Regurgitation Patients.,2023/Dec/11,"Hermiller, James","St. Vincent Heart Center of Indiana, Indianapolis, Indiana, USA.",Robert.Smith1@BSWHealth.org.
37902443,Healthcare resource utilization and costs among patients with post-stroke spasticity before and after spasticity management including onabotulinumtoxina.,2023/Oct/30,"Bloudek, Lisa; Migliaccio-Walle, Kristen; Tung, Amy; Gillard, Patrick","Curta, Inc., Seattle, WA, USA.; Curta, Inc., Seattle, WA, USA.; Allergan, an AbbVie Company, Chicago, IL, USA.; Allergan, an AbbVie Company, Chicago, IL, USA.",aesquena@einstein.edu.
37898670,"CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1.",2024,"Asnagli, Hélène; Parker, Andrew E; Beer, Philip A","Step Pharma, Saint-Genis-Pouilly, France.; Step Pharma, Saint-Genis-Pouilly, France.; Step Pharma, Saint-Genis-Pouilly, France. pb@step-ph.com.",heinz.ludwig@extern.gesundheitsverbund.at.
37898443,The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease.,2023,"Mehta, Nehal; Ditmarsch, Marc","Mobius Scientific, Inc., JLABS @ Washington, DC, Washington, DC, USA.; NewAmsterdam Pharma, Naarden, the Netherlands.",j.j.kastelein@amsterdamumc.nl.
37897797,"Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA), updates in 2022-2023. Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy.",2024,"Aldea, Roxana; Ethell, Douglas W; Rich, Steven A","Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Leucadia Therapeutics Inc, Riverside, California, USA.; QAAM Pharmaceuticals. LLC, Canandaigua, New York, USA.",None
37895858,Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population?,2023/Sep/30,"Abutaily, Sarah A","Ambulatory Care Clinical, Prince Sultan Military Medical City, Riyadh 12233, Saudi Arabia.",None
37894622,Radiosynthesis and Early Evaluation of a Positron Emission Tomography Imaging Probe [,2023/Oct/18,"Lohith, Talakad G; Kaittanis, Charalambos; Sandoval, Phil; Cohen, Lawrence; Rajarshi, Girija; Ruangsiriluk, Wanida; Islam, Rizwana; Winkelmann, Christopher T; McQuade, Paul","Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA.; Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA.; Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA.; Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA.; Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA.; Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA.; Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA.; Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA.; Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA.",None
37890646,"Molecular complexes of drug combinations: A review of cocrystals, salts, coamorphous systems and amorphous solid dispersions.",2023/Dec/15,"Yu, Dongyue","Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08540, United States.",kunlinwang88@gmail.com.
37890443,Study on the underlying mechanism of Poria in intervention of arrhythmia zebrafish by integrating metabolomics and network pharmacology.,2024,"Wang, Ming-Geng","Shandong Buchang Pharmaceutical Co., Ltd, Shandong 274000, PR China.",cczyyjal@163.com.
37889486,Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial.,2023/Oct/02,"Flevaris, Panagiotis; Chan, Anna; Li, Xue","AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.; AbbVie Inc, North Chicago, Illinois.",None
37888984,"A multifunctional bio-patch crosslinked with glutaraldehyde for enhanced mechanical performance, anti-coagulation properties, and anti-calcification properties.",2023/Nov/08,"Yu, Liyin","Jiangsu Biosurf Biotech Company Ltd., Building 26, Dongjing Industrial Square, No. 1, Jintian Road, Suzhou Industrial Park, Suzhou 215123, P. R. China. lyyu@suda.edu.cn.",liuxiaoli@suda.edu.cn.
37886880,Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.,2023,"Bachus, Erasmus","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (E.B.).",None
37885110,The (Pro)renin Receptor - A Regulatory Nodal Point in Disease Networks.,2023,"Funke-Kaiser, Heiko","CCR Pharma (CCRP) Therapeutics, Berlin, Germany.",None
37884189,"Li, P HY-021068 alleviates cerebral ischemia-reperfusion injury by inhibiting NLRP1 inflammasome and restoring autophagy function in mice.",2024,"Mo, Jiajia; Chu, Zhaoxing","Hefei Industrial and Pharmaceutical Co., Ltd, Hefei 230200, Anhui, China.; Hefei Industrial and Pharmaceutical Co., Ltd, Hefei 230200, Anhui, China. Electronic address: zhuzhaoxing@163.com.",weizu_li@ahmu.edu.cn.
37884126,Prevalence of cardiac abnormalities and heart failure in unselected out-patients with type 2 diabetes mellitus and associated clinical factors: Real-world evidence from an Indian registry.,2023,"Vasnawala, Hardik; Kumar, Amit; Hs, Bharath; Sarda, Shital","Medical Affairs, AstraZeneca Pharma India Ltd, India.; Medical Affairs, AstraZeneca Pharma India Ltd, India.; Medical Affairs, AstraZeneca Pharma India Ltd, India.; Medical Affairs, AstraZeneca Pharma India Ltd, India.",a51hauzkhas@gmail.com.
37883784,Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.,2024/Mar/05,"Claude, Lisa; Augustin, Dimitri A","Recor Medical, Inc., Palo Alto, CA (L.C., D.A.A.).; Recor Medical, Inc., Palo Alto, CA (L.C., D.A.A.).",None
37881891,"Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review.",2024,"Garcia, Michael Cristian; Tsang, Kai La; Lohit, Simran; Deng, Jiawen; Schneider, Tyler; Matos Silva, Jessyca; Holbrook, Anne","Clinical Pharmacology & Toxicology Research Group, St. Joseph's Healthcare, Hamilton, ON, Canada.; Clinical Pharmacology & Toxicology Research Group, St. Joseph's Healthcare, Hamilton, ON, Canada.; Clinical Pharmacology & Toxicology Research Group, St. Joseph's Healthcare, Hamilton, ON, Canada.; Clinical Pharmacology & Toxicology Research Group, St. Joseph's Healthcare, Hamilton, ON, Canada.; Clinical Pharmacology & Toxicology Research Group, St. Joseph's Healthcare, Hamilton, ON, Canada.; Clinical Pharmacology & Toxicology Research Group, St. Joseph's Healthcare, Hamilton, ON, Canada.; Clinical Pharmacology & Toxicology Research Group, St. Joseph's Healthcare, Hamilton, ON, Canada.",None
37881406,Effects of Two Soluble ACE2-Fc Variants on Blood Pressure and Albuminuria in Hypertensive Mice: Research Letter.,2023,"Gillard, John W; Yoganathan, Nathan; Sulea, Traian","JN Nova Pharma Inc., Montreal, QC, Canada.; JN Nova Pharma Inc., Montreal, QC, Canada.; Human Health Therapeutics Research Centre, National Research Council Canada, Montreal, QC, Canada.",None
37879802,"Artificial Intelligence, Computational Simulations, and Extended Reality in Cardiovascular Interventions.",2023/Oct/23,"Mickley, Timothy; Bicek, Andrew; Fontana, Jason","Boston Scientific Inc, Marlborough, Massachusetts, USA.; Boston Scientific Inc, Marlborough, Massachusetts, USA.; Medtronic, Inc, Minneapolis, Minnesota, USA.",ychatzizisis@icloud.com.
37875993,Sex-specific role of galectin-3 in aortic stenosis.,2023/Oct/24,"Muntendam, Pieter","G3 Pharmaceuticals, Burlington, MA, USA.",natalia.lopez.andres@navarra.es.
37875374,Two-year recall for people with no diabetic retinopathy: a multi-ethnic population-based retrospective cohort study using real-world data to quantify the effect.,2023/Nov/22,"Anderson, John; Bolter, Louis; Chambers, Ryan","Homerton Healthcare NHS Foundation Trust, London, UK cowen@sgul.ac.uk john.anderson@nhs.net.; Homerton Healthcare NHS Foundation Trust, London, UK.; Homerton Healthcare NHS Foundation Trust, London, UK.",cowen@sgul.ac.uk
37874253,Management of diabetic macular oedema in France from 2012 to 2018: The nationwide LANDSCAPE study.,2024,"Ponthieux, Anne","Novartis Pharma SAS, Rueil-Malmaison, France.",None
37873628,Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea.,2023/Oct/23,"Hyun, BokJin; Nam, HyunSun; Kim, Eunhye; Kwak, Min Joo; Won, Yong Kyun","Clinical Research, Handok Inc., Seoul, Korea.; Clinical Research, Handok Inc., Seoul, Korea.; Clinical Research, Handok Inc., Seoul, Korea.; Medical Affairs, Handok Inc., Seoul, Korea.; Medical Affairs, Handok Inc., Seoul, Korea.",jwlee@catholic.ac.kr.
37872654,Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.,2023/Dec/01,"Schloemer, Patrick; Little, Dustin J; Brinker, Meike; Tasto, Christoph; Karpefors, Martin; Nkulikiyinka, Richard; Rossert, Jerome; Gasparyan, Samvel B","Pharmaceuticals, Research and Development, Bayer AG, Berlin, Germany.; Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.; Pharmaceuticals, Research and Development, Bayer AG, Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Wuppertal, Germany.; Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Pharmaceuticals, Research and Development, Bayer AG, Berlin, Germany.; Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.; Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
37872160,"Genome-wide association study of thyroid-stimulating hormone highlights new genes, pathways and associations with thyroid disease.",2023/Oct/23,"Hennah, William; Rao, Balasubramanya S","Orion Pharma, Espoo, Finland.; Orion Pharma, Nottingham, UK.",cj153@leicester.ac.uk.
37865771,"Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.",2023/Oct/21,"Brill-Almon, Einat; Alon, Sari; Chertkoff, Raul","Protalix Biotherapeutics, Carmiel, Israel.; Protalix Biotherapeutics, Carmiel, Israel.; Protalix Biotherapeutics, Carmiel, Israel.",ales.linhart@vfn.cz.
37865311,Drug discovery for heart failure targeting myosin-binding protein C.,2023,"Thomas, Jennifer J","Photonic Pharma LLC, Minneapolis, Minnesota, USA.",bcolson@arizona.edu.
37863204,Integration of 16S rRNA gene sequencing and LC/MS-based metabolomic analysis of early biomarkers of acute ischaemic stroke in Tibetan miniature pigs.,2023,"Xu, Fei; Xie, Shuilin","Guangdong Mingzhu Biotechnology Co., Ltd., Foshan 510168, China.; Guangdong Mingzhu Biotechnology Co., Ltd., Foshan 510168, China. Electronic address: xsl@scut.edu.cn.",bieyanan0624@outlook.com.
37861443,Synthesis and Bioevaluation of 3-(Arylmethylene)indole Derivatives: Discovery of a Novel ALK Modulator with Antiglioblastoma Activities.,2023/Nov/09,"Kiboku, Takayuki; Kawasaki, Atsushi; Horimoto, Katsuhisa","Socium Inc., Tokyo 1350064, Japan.; Socium Inc., Tokyo 1350064, Japan.; Socium Inc., Tokyo 1350064, Japan.",None
37857609,Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456.,2023/Oct/19,"Yang, Yili; Zhan, Xuelin","China Regional Research Centre, International Centre of Genetic Engineering & Biotechnology, Taizhou, PR China.; China Regional Research Centre, International Centre of Genetic Engineering & Biotechnology, Taizhou, PR China.",wdzhangy@hotmail.com.
37855126,Targeting Angiotensinogen With ,2023,"Tu, Ho-Chou; Zlatev, Ivan","Alnylam Pharmaceuticals, Cambridge, MA (H.-C.T., I.Z.).; Alnylam Pharmaceuticals, Cambridge, MA (H.-C.T., I.Z.).",None
37852468,Azithromycin reduces hemoglobin-induced innate neuroimmune activation.,2024,"Ritzel, Rodney M; Guzman, Gary U","Lexington Veterans' Affairs Healthcare System, Lexington, KY 40502, United States of America.; Lexington Veterans' Affairs Healthcare System, Lexington, KY 40502, United States of America.",brandon.a.miller@uth.tmc.edu.
37852254,Hema-seq reveals genomic aberrations in a rare simultaneous occurrence of hematological malignancies.,2023/Oct/23,"Ryu, Taehoon; Kim, Okju; Jung, Yushin","ATG Lifetech, Inc., Seoul 08507, Republic of Korea.; ATG Lifetech, Inc., Seoul 08507, Republic of Korea.; ATG Lifetech, Inc., Seoul 08507, Republic of Korea.",soonlee@snu.ac.kr.
37851562,"Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials.",,"Fujita, Tachie; Kawano, Mika; Ohsawa, Shino; Abreu, Francis; Haskova, Zdenka; Ives, Jane; Silverman, David","Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Roche Products Ltd, Welwyn Garden City, Hertfordshire.; Roche Products Ltd, Welwyn Garden City, Hertfordshire.",None
37851297,Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).,2024,"Alsumali, Adnan; Klok, Rogier; Martinez, Eliana C; Chevure, Jestinah; De Oliveira Pena, Janethe; Lautsch, Dominik","Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck Sharp & Dohme (UK) Ltd., London, UK.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",vmclaugh@umich.edu.
37850379,"Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.",2024/Jan/30,"Bi, Ran; Talloczy, Zsolt; Maheux, Pierre; Lesogor, Anastasia","Novartis Pharmaceuticals Corporation, East Hannover, NJ (R.B., Z.T.).; Novartis Pharmaceuticals Corporation, East Hannover, NJ (R.B., Z.T.).; Novartis Pharmaceuticals Corporation, Basel, Switzerland (P.M., A.L.).; Novartis Pharmaceuticals Corporation, Basel, Switzerland (P.M., A.L.).",None
37847442,Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study.,2023,"Ibuki, Tatsuki","Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.",morimoto@kuhp.kyoto-u.ac.jp.
37845584,Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model.,2024,"Ghaith Al-Kuwari, Mohammed; Abdulmajeed, Jazeel","Strategy Planning & Health Intelligence, Primary Healthcare Corporation, Doha, Qatar.; Strategy Planning & Health Intelligence, Primary Healthcare Corporation, Doha, Qatar.",None
37845353,Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target.,2023,"Spin, Joshua M; Rhee, Yae Hyun; Deng, Alicia; Headley, Colwyn A; Einarsson, Gudmundur; Thorleifsson, Gudmar; Gudbjartsson, Daniel; Gretarsdottir, Solveig; Thorsteinsdottir, Unnur; Holm, Hilma; Stefansson, Kari; Tsao, Philip S","VA Palo Alto Healthcare System, Palo Alto, CA, USA.; VA Palo Alto Healthcare System, Palo Alto, CA, USA.; VA Palo Alto Healthcare System, Palo Alto, CA, USA.; VA Palo Alto Healthcare System, Palo Alto, CA, USA.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; VA Palo Alto Healthcare System, Palo Alto, CA, USA.",damrauer@upenn.edu.
37844263,A Sequential Dual Functional Supramolecular Hydrogel with Promoted Drug Release to Scavenge ROS and Stabilize HIF-1α for Myocardial Infarction Treatment.,2024,"Yang, Xiayan; Yu, Qifeng","Shanghai NewMed Medical Technology Co., Ltd, Pudong New Area, Shanghai, 201318, China.; Shanghai NewMed Medical Technology Co., Ltd, Pudong New Area, Shanghai, 201318, China.",None
37842953,Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.,2024,"Davis-Karim, Anne","VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico.",None
37842912,Modulating microbiome-immune axis in the deployment-related chronic diseases of Veterans: report of an expert meeting.,2023,"Kim, Tae Kon","Tennessee Valley Healthcare System-Nashville VA, Nashville, TN, USA.",None
37840134,"A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.",2023/Oct/16,"Giannelou, Angeliki; Nivens, Michael C; Akinlade, Bolanle","Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.",wolfgang.schmidt@immanuelalbertinen.de.
37839304,Association between switching prescribed drugs for lower urinary tract symptoms and independence of urination in post-stroke patients: A retrospective cohort study.,2023,"Hashimoto, Masako; Masuda, Akio; Nagamoto, Takehito","Temari Pharmacy, Ishikawa, Japan.; Komeya Pharmacy, Ishikawa, Japan.; Komeya Pharmacy, Ishikawa, Japan.",t-shimada@staff.kanazawa-u.ac.jp.
37838670,"Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.",2023/Oct/14,"Yang, Shifang; Zheng, Xiangjun; Wei, Peng; Pang, Hongyan; Yu, Wei","Beijing Sunbio Biotech Co., Ltd., Beijing, China.; Beijing Sunbio Biotech Co., Ltd., Beijing, China.; Beijing Sunbio Biotech Co., Ltd., Beijing, China.; Beijing Sunbio Biotech Co., Ltd., Beijing, China.; Beijing Sunbio Biotech Co., Ltd., Beijing, China.",cwm13910107759@163.com.
37837886,Effect of TAVR commissural alignment on coronary flow: A fluid-structure interaction analysis.,2023,"Oks, David; Vázquez, Mariano","Barcelona Supercomputing Center, Computer Applications in Science and Engineering, Plaça d'Eusebi Güell, 1-3, 08034, Barcelona, Spain; ELEM Biotech SL, Plaça Pau Vila, 1, Bloc A, Planta 3, Porta 3A1, 08003, Barcelona, Spain. Electronic address: david.oks@bsc.es.; Barcelona Supercomputing Center, Computer Applications in Science and Engineering, Plaça d'Eusebi Güell, 1-3, 08034, Barcelona, Spain; ELEM Biotech SL, Plaça Pau Vila, 1, Bloc A, Planta 3, Porta 3A1, 08003, Barcelona, Spain.",david.oks@bsc.es.
37832822,Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19.,2024,"Yamatake, Takahiro; Sakurai, Tsutomu","Development Division, FUJIFILM Toyama Chemical Co., Ltd., Tokyo, Japan.; Development Division, FUJIFILM Toyama Chemical Co., Ltd., Tokyo, Japan. Electronic address: tsutomu.sakurai@fujifilm.com.",tsutomu.sakurai@fujifilm.com.
37832406,Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors.,2023,"Kolkhof, P","Cardiovascular Precision Medicines, Research & Early Development, Pharmaceuticals, Bayer AG, Wuppertal, Germany.",marisolf@ucm.es.
37831962,Signaling Pathways Triggering Therapeutic Hydrogels in Promoting Chronic Wound Healing.,2024,"Sun, Guoming","Sunogel Biotechnologies Inc., Lutherville Timonium, 9 W Ridgely Road Ste 270, Maryland, 21093, USA.",None
37831045,Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial.,2023,"Malik, Fady I","Cytokinetics Inc, South San Francisco, California, USA.",ssolomon@rics.bwh.harvard.edu.
37831030,Intracardiac vs Transesophageal Echocardiography for Left Atrial Appendage Occlusion With Watchman FLX in the U.S.,2023,"Roy, Kristine; Allocco, Dominic J","Boston Scientific Corporation, Marlborough, Massachusetts, USA.; Boston Scientific Corporation, Marlborough, Massachusetts, USA.",jonathan.piccini@duke.edu.
37830208,Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.,2023/Dec/12,"Petersson, Magnus; Maria Langkilde, Anna","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.P., A.M.L.).; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.P., A.M.L.).",None
37827219,Structural and clinical characterization of CYP11B2 inhibition by dexfadrostat phosphate.,2023,"Steele, Ronald E; Schumacher, Christoph","DAMIAN Pharma AG, Haltli 6, 6318 Walchwil, Switzerland.; DAMIAN Pharma AG, Haltli 6, 6318 Walchwil, Switzerland.",emanuele.pignatti@unibe.ch.
37824793,Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.,2023/Dec/01,"Levine, Joshua A; Bergman, Brandon K; Wang, Hui; Lee, Clare J","Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; TechData Service Company, King of Prussia, PA.; Eli Lilly and Company, Indianapolis, IN.",None
37823674,Targeting phospholipid remodeling pathway improves insulin resistance in diabetic mouse models.,2023,"Lee, Richard","Ionis Pharmaceuticals, Carlsbad, California, USA.",None
37822270,"Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.",2024,"Hu, P; Liu, W; Shen, Z; Sorli, C","Novo Nordisk (Shanghai) Pharma Trading Co., Ltd, Beijing, China.; Novo Nordisk (Shanghai) Pharma Trading Co., Ltd, Beijing, China.; Novo Nordisk (Shanghai) Pharma Trading Co., Ltd, Beijing, China.; Acerus Pharma, Toronto, Ontario, Canada.",None
37821442,Single-cell multi-omics analysis identifies two distinct phenotypes of newly-onset microscopic polyangiitis.,2023/Oct/11,"Inukai, Sachi","Research Division, Chugai Pharmaceutical Co. Ltd, Yokohama, Kanagawa, Japan.",kumanogo@imed3.med.osaka-u.ac.jp.
37821130,Implementation status and consideration for the globalisation of decentralised clinical trials: a cross-sectional analysis of clinical trial databases.,2023/Oct/11,"Sato, Takahiro","Astellas Pharma Inc, Tokyo, Japan 3b20704@ed.tus.ac.jp.",3b20704@ed.tus.ac.jp.
37816446,Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study.,2024,"Ward, Jonathan H; Williamson, Kristin M","Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.",jjanuzzi@partners.org.
37814929,Pharmacokinetics and Drug-Drug Interaction of Allisartan Isoproxil and Indapamide Sustained-Release Formulation.,2023,"Huang, Hua; Deng, Chongyang; Sun, Jingchao","Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, China.; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, China.; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, China.",None
37814896,Cardiovascular Disease Knowledge Portal: A Community Resource for Cardiovascular Disease Research.,2023,"Khera, Amit V",Verve Therapeutics (A.V.K.).,None
37813587,"Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan.",2024,"Lefkowitz, Martin P","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",None
37812476,Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial.,2023/Dec/15,"Coffey, Matt; Fields, Paul","Oncolytics Biotech, Inc, Calgary, Alberta, Canada.; Formerly, Adaptive Biotechnologies, Seattle, Washington; currently, Tempus Labs, Seattle, Washington.",None
37807952,Unknown,2024,"Ren, Kaili; Stull, Dawn Marie; Cherepanov, Dasha; Bogard, Kimberly; Noga, Stephen J","Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA.; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA.; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA.; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA.",None
37807165,Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review.,2023/Dec/01,"Little, Dustin J; Gasparyan, Samvel B; Schloemer, Patrick; Brinker, Meike; Karpefors, Martin; Tasto, Christoph; Rethemeier, Nicole; Frison, Lars; Nkulikiyinka, Richard; Rossert, Jerome","Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.; Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Pharmaceuticals, Research and Development, Bayer AG, Berlin, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Wuppertal, Germany.; Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Pharmaceuticals, Research and Development, Bayer AG, Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Wuppertal, Germany.; Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Pharmaceuticals, Research and Development, Bayer AG, Berlin, Germany.; Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.",None
37805100,"Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval.",2024,"Donaldson, Kirsteen; Custodio, Joseph M; Hand, Austin L; Moraitis, Andreas G","Jade Consultants (Cambridge) Ltd, Cambridge, United Kingdom.; Corcept Therapeutics Incorporated, Menlo Park, California.; Corcept Therapeutics Incorporated, Menlo Park, California.; Corcept Therapeutics Incorporated, Menlo Park, California. Electronic address: amoraitis@corcept.com.",amoraitis@corcept.com.
37805000,Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.,2023,"Lawatscheck, Robert; Scott, Charlie; Edfors, Robert; Scheerer, Markus F; Kolkhof, Peter","Cardiology and Nephrology Clinical Research, Bayer AG, Research & Development, Pharmaceuticals, Clinical Development, Building S101, 13342 Berlin, Germany.; Data Science and Analytics, Bayer PLC, Research & Development, Pharmaceuticals, 400 South Oak Way, Reading RG2 6AD, UK.; Cardiovascular Studies & Pipeline, Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Building S102, 13342 Berlin, Germany.; Medical Affairs & Pharmacovigilance, Pharmaceuticals, TA CardioRenal & Heart Disease, Bayer AG, Building S102, 04/160, 13353 Berlin, Germany.; Research and Development, Pharmaceuticals, Cardiovascular Precision Medicines, Bayer AG, 42113 Wuppertal, Germany.",h.j.lambers.heerspink@umcg.nl.
37804438,Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study.,2023,"Wani, Rajvi J; Philip, Kiran; Wu, Johnny; Mackinnon, Erin S","Amgen Canada Inc., 6775 Financial Dr., Suite 300, Mississauga, ON, L5N 0A4, Canada.; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.; Amgen Canada Inc., 6775 Financial Dr., Suite 300, Mississauga, ON, L5N 0A4, Canada. emackinn@amgen.com.",emackinn@amgen.com.
37804290,1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI.,2023/Oct/23,"Hermiller, James","Ascension St. Vincent Heart Center, Carmel, Indiana, USA.",roxana.mehran@mountsinai.org.
37802619,Can we collect health-related quality of life information from anticoagulated atrial fibrillation participants who have recently experienced a bleed? An observational feasibility study in primary and secondary care in Wales and through a UK online forum.,2023/Oct/06,"Pollock, Kevin; Lister, Steven","Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK.; Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK.",h.a.hutchings@swansea.ac.uk.
37802221,Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol.,2023,"Shumbayawonda, Elizabeth; Banerjee, Rajarshi; Pepin, Kay; Kalutkiewicz, Mike; Trylesinksi, Aldo; Coxson, Harvey O; Yunis, Carla; Tuthill, Theresa","Perspectum Ltd, Oxford, UK.; Perspectum Ltd, Oxford, UK.; Resoundant Inc, Rochester, MN, USA.; Resoundant Inc, Rochester, MN, USA.; ADVANZPHARMA, Capital House, 1st Floor, 85 King William Street, London EC4N 7BL, United Kingdom.; Boehringer Ingelheim Pharma GmbH & Co., KG, Germany.; Clinical Development and Operations, Pfizer Inc., Lake Mary, FL, USA.; Clinical Development and Operations, Pfizer Inc., Lake Mary, FL, USA.",Michael.pavlides@cardiov.ox.ac.uk.
37802074,ERRγ agonist under mechanical stretching manifests hypertrophic cardiomyopathy phenotypes of engineered cardiac tissue through maturation.,2023/Nov/14,"Deguchi, Kohei; Sakoda, Ayaka; Imaichi, Sachiko; Sugo, Tsukasa; Nishimoto, Tomoyuki; Imahashi, Kenichi","Takeda-CiRA Joint Program, Fujisawa, Japan; T-CiRA Discovery, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.; Takeda-CiRA Joint Program, Fujisawa, Japan; T-CiRA Discovery, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.; Pharmaceutical Science, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.; GenAhead Bio Inc., Fujisawa, Japan.; Orizuru therapeutic Inc., Fujisawa, Japan.; Takeda-CiRA Joint Program, Fujisawa, Japan; T-CiRA Discovery, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.",yoshinor@cira.kyoto-u.ac.jp.
37802043,Rare variants in long non-coding RNAs are associated with blood lipid levels in the TOPMed whole-genome sequencing study.,2023/Oct/05,"Kim, Ryan; Viaud-Martinez, Karine A","Psomagen, Inc. (formerly Macrogen USA), Rockville, MD, USA.; Illumina Laboratory Services, Illumina Inc., San Diego, CA, USA.",gpeloso@bu.edu.
37799702,Potential application of PS-OCT in the safety assessment of non-steroidal topical creams for atopic dermatitis treatment.,2023/Aug/01,"Cha, Amy; Zang, Chuanbo; Werth, John; Adiri, Roni","Pfizer, Inc, New York, NY, USA.; Pfizer, Inc, New York, NY, USA.; Pfizer, Inc, New York, NY, USA.; Pfizer Pharmaceutical Israel LTD, Israel.",None
37794518,Resveratrol: a potential medication for the prevention and treatment of varicella zoster virus-induced ischemic stroke.,2023/Oct/05,"Song, Feiyu","Jilin Connell Pharmaceutical Co., Ltd, JilinJilin, 132013, China.",jinhua1@jlu.edu.cn.
37793771,"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.",2023,"Bright, Shelley","Pharmacovigilance, GSK, Upper Providence, PA, USA.",mdimop@med.uoa.gr.
37791408,Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.,2023/Dec/14,"Steurbaut, Stephane","Centre for Pharmaceutical Research, Research group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Jette, Belgium.",None
37788412,"Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.",2024/Jan/10,"Khanna, Sadhvi; Bossen, Claudia; Carbini, Mariana; Turri, Sabine; Myers, Andrea","Novartis Pharma S.A.S, Rueil-Malmaison, France.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma S.A.S, Rueil-Malmaison, France.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.",None
37787877,"Profile, Healthcare Resource Consumption and Related Costs in ANCA-Associated Vasculitis Patients: A Real-World Analysis in Italy.",2023,"Ramirez de Arellano, Antonio","Vifor Pharma Group, Glattbrugg, Switzerland.",luca.degliesposti@clicon.it.
37783983,Factors Affecting Prescribing of Type 2 Diabetes Medications in Older Adults within an Integrated Healthcare System.,2024,"Lussier, Mia E; Graham, Jove H; Wright, Eric A","Center for Pharmacy Innovation and Outcomes, Geisinger Health System, Danville, PA, USA. mlussier@binghamton.edu.; Center for Pharmacy Innovation and Outcomes, Geisinger Health System, Danville, PA, USA.; Center for Pharmacy Innovation and Outcomes, Geisinger Health System, Danville, PA, USA.",mlussier@binghamton.edu.
37783970,Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.,2023,"Damore, Michael A; Jiang, Sibo; Basu, Cynthia; Chan, Edward M","Oncology Research and Development, Pfizer Inc., San Diego, CA, USA.; Early Clinical Development, Pfizer Inc., San Diego, CA, USA.; Early Clinical Development, Pfizer Inc., San Diego, CA, USA.; Oncology Research and Development, Pfizer Inc., South San Francisco, CA, USA.",nbahlis@ucalgary.ca.
37782143,"Stasis Dermatitis: The Burden of Disease, Diagnosis, and Treatment.",2024,"Adiri, Roni; Cha, Amy; Canosa, Juliana M","Pfizer Pharmaceuticals Ltd., Herzliya Pituah, Israel.; Pfizer Inc., New York, New York, USA.; Pfizer Brasil Ltda., São Paulo, Brazil.",None
37781463,Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study.,2023,"Eguchi, Kosei; Nishijima, Keiji; Sato, Toshihiro","Novo Nordisk Pharma Ltd., Tokyo, Japan.; Novo Nordisk Pharma Ltd., Tokyo, Japan.; Novo Nordisk Pharma Ltd., Tokyo, Japan.",None
37778526,"Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry).",2024,"Han, Michelle; Cho, Michelle; Tobore, Tobore; Rahman, Mohammad","Actelion Pharmaceuticals US, Inc., Titusville, New Jersey.; Actelion Pharmaceuticals US, Inc., Titusville, New Jersey.; Actelion Pharmaceuticals US, Inc., Titusville, New Jersey.; Actelion Pharmaceuticals US, Inc., Titusville, New Jersey.",vmclaugh@med.umich.edu.
37777947,Coronary Computed Tomographic Angiography With Fractional Flow Reserve in Patients With Type 2 Myocardial Infarction.,2023/Oct/24,"Rogers, Campbell","HeartFlow Inc, Mountain View, California, USA.",jjanuzzi@mgh.harvard.edu.
37777298,Chapter 2: Rate Versus Rhythm Control.,2023,"Deering, Thomas F","Piedmont Healthcare, Atlanta, GA, USA.",jar2@columbia.edu.
37777297,Chapter 1: The Evolving Atrial Fibrillation Landscape: Importance of Early Diagnosis and Treatment.,2023,"Deering, Thomas F","Piedmont Healthcare, Atlanta, GA, USA.",jar2@columbia.edu.
37777296,"Chapter 6: AAD Use in Different Patient Populations, and a Patient-Centric Approach to Optimal Patient Management.",2023,"Deering, Thomas F","Piedmont Healthcare, Atlanta, GA, USA.",jar2@columbia.edu.
37777295,Chapter 5: Guideline Recommendations: Which AAD and for Whom?,2023,"Deering, Thomas F","Piedmont Healthcare, Atlanta, GA, USA.",jar2@columbia.edu.
37777294,Chapter 4: Evidence for the Early Use of Ablation and AADs Post-Ablation.,2023,"Deering, Thomas F","Piedmont Healthcare, Atlanta, GA, USA.",jar2@columbia.edu.
37777293,Chapter 3: Evidence for the Use of Early Rhythm Control to Prevent Atrial Fibrillation Progression.,2023,"Deering, Thomas F","Piedmont Healthcare, Atlanta, GA, USA.",jar2@columbia.edu.
37777292,Introduction: Early Diagnosis and Appropriate Treatment of Atrial Fibrillation.,2023,"Deering, Thomas F","Piedmont Healthcare, Atlanta, GA, USA.",jar2@columbia.edu.
37776209,Developing Clinical Risk Prediction Models for Worsening Heart Failure Events and Death by Left Ventricular Ejection Fraction.,2023/Oct/03,"Shen, Xian; Cristino, Joaquim",Novartis Pharmaceuticals Corporation East Hanover NJ USA.; Novartis Pharmaceuticals Corporation East Hanover NJ USA.,None
37776124,Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.,2023,"Cheng, Mu; DerSarkissian, Maral; Pi, Selina; Zhang, Melody; Banatwala, Azeem; Duh, Mei Sheng","Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.",None
37775650,New drug discovery of cardiac anti-arrhythmic drugs: insights in animal models.,2023/Sep/29,"Sahu, Sanjay Kumar","Medley Pharmaceuticals Ltd., Formulation R&D, Mumbai, 400059, India.",ashishksharma2003@yahoo.com.
37770635,Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification.,2023,"Hilliard, Austin T; Assimes, Themistocles L","VA Palo Alto Healthcare System, Palo Alto, CA, USA.; VA Palo Alto Healthcare System, Palo Alto, CA, USA.",clintm@virginia.edu.
37770367,Preservation Efficacy of a Quercetin and Sucrose Solution for Warm Ischemically Damaged Porcine Liver Grafts.,2023,"Imamura, Masashi","Business Planning Division, Healthcare Business Headquarters, Ishihara Sangyo Kaisha, Ltd., 3-15, Edobori 1-chome, Nishi-ku, Osaka 550-0002, Japan.",m-otani@asahikawa-med.ac.jp.
37768671,Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.,2023/Oct/17,"Jung, Shiangtung W; Buchele, Gustavo; Brambatti, Michela; Chen, Jersey; Hughes, Steven G; Schneider, Eugene; Viney, Nicholas J","Ionis Pharmaceuticals Inc, Carlsbad, California.; Ionis Pharmaceuticals Inc, Carlsbad, California.; Ionis Pharmaceuticals Inc, Carlsbad, California.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.; Ionis Pharmaceuticals Inc, Carlsbad, California.; Ionis Pharmaceuticals Inc, Carlsbad, California.; Ionis Pharmaceuticals Inc, Carlsbad, California.",None
37767674,Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial.,2024,"Petersson, Magnus; Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",ssolomon@bwh.harvard.edu.
37766492,The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A.,2023,"Harada, Suguru; Tashiro, Yoshihito; Soeda, Tetsuhiro","Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.; Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.; Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.",None
37765106,Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study.,2023/Sep/14,"Andújar, Iván","Proteomic Laboratory, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.",None
37764856,Alleviating Effects of Ovatodiolide and Antcin K Supplements on High-Fat Diet-Induced Cardiovascular Dysfunction in ApoE-Knockout Mice by Attenuating Oxidative Stress.,2023/Sep/20,"Wu, Yeh-B; Liang, Hui-Ju","ARJIL Pharmaceuticals LLC, Hsinchu City 30013, Taiwan.; ARJIL Pharmaceuticals LLC, Hsinchu City 30013, Taiwan.",None
37760723,Analysis of Clinical Phenotypes through Machine Learning of First-Line ,2023/Sep/10,"Spínola, Miguel A; Ortega, Guillermo J","Unidad de Análisis de Datos del Instituto de Investigación Sanitaria Princesa (IIS-Princesa), 28006 Madrid, Spain.; Unidad de Análisis de Datos del Instituto de Investigación Sanitaria Princesa (IIS-Princesa), 28006 Madrid, Spain.",None
37759755,The Potential Mechanisms behind Loperamide-Induced Cardiac Arrhythmias Associated with Human Abuse and Extreme Overdose.,2023/Sep/06,"Lu, Hua Rong; Damiano, Bruce P; Kreir, Mohamed; Rohrbacher, Jutta; van der Linde, Henk; Saidov, Tamerlan; Teisman, Ard; Gallacher, David J","Global Safety Pharmacology, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.; Global Safety Pharmacology, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.; Global Safety Pharmacology, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.; Global Safety Pharmacology, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.; Global Safety Pharmacology, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.; Global Safety Pharmacology, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.; Global Safety Pharmacology, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.; Global Safety Pharmacology, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.",None
37758440,Recurrent Events in Cardiovascular Trials: JACC State-of-the-Art Review.,2023/Oct/03,"Zeller, Cordula","Boehringer Ingelheim Pharma, Biberach, Germany.",john.gregson@lshtm.ac.uk.
37758044,Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.,2024,"Bartee, Amy; Miller, Debra; Nishiyama, Hiroshi; Pavo, Imre; Weerakkody, Govinda; Wiese, Russell J","Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.",stephen.nicholls@monash.edu.
37757694,Aptamer-thrombin loaded magnetic microspheres for bio-specific extraction and precise detection of hirudin.,2024/Jan/15,"Shang, Chunqing","Enriching Biotechnology (Shanghai) Co. Ltd, 1688 North Guoquan Road, Shanghai, 200438, PR China.",chdeng@fudan.edu.cn.
37755956,Intramuscular Bleeding and Formation of Microthrombi during Skeletal Muscle Damage Caused by a Snake Venom Metalloprotease and a Cardiotoxin.,2023/Aug/28,"Williams, Harry F; Mitchell, Robert D","Toxiven Biotech Private Limited, Coimbatore 641042, Tamil Nadu, India.; Micregen Ltd., Thames Valley Science Park, Reading RG2 9LH, UK.",None
37755814,Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.,2023/Nov/01,"Shen, Xian; Cristino, Joaquim","Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.",None
37755728,"Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020.",2023/Nov/01,"Palli, Swetha R; Donato, Bonnie M K","Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut.; Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut.",None
37755492,Clinical comprehensive evaluation of direct oral anticoagulants for patients with atrial fibrillation in China.,2023,"Ma, Er-Li; Liu, Bing-Long","Shanghai Pharmaceutical Association, 200040, Shanghai, China.; Shanghai Pharmaceutical Association, 200040, Shanghai, China.",linhouwenrenji@163.com.
37753718,Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study.,2023/Oct/03,"Chen, Michael; Shardonofsky, Silvia; Plat, Francis","TCM Groups, Inc Berkeley Heights NJ USA.; Milestone Pharmaceuticals Montreal Quebec Canada.; Milestone Pharmaceuticals Montreal Quebec Canada.",None
37752030,Nursing Care Throughout the Chimeric Antigen Receptor T-Cell Therapy Process for Multiple Myeloma.,2023,"Florendo, Erika; Lee, Erin; Riccobono, Carrie","Legend Biotech USA, Inc, Somerset, NJ.; Janssen Pharmaceuticals, Inc, Titusville, NJ.; Legend Biotech USA, Inc, Somerset, NJ.",Elizabeth.Aronson@mountsinai.org.
37750995,Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.,2023,"Saadoun, Carine; Chang, Chia-Ling; Yang, Ya-Wen","Regional Medical Affairs Janssen Asia Pacific, Janssen, a division of Johnson & Johnson Pte Ltd., 2 Science Park Drive, #07-13, Ascent, Singapore Science Park 1, Singapore, 118222, Singapore.; Regional Medical Affairs Janssen Asia Pacific, Janssen, a division of Johnson & Johnson Pte Ltd., 2 Science Park Drive, #07-13, Ascent, Singapore Science Park 1, Singapore, 118222, Singapore.; Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, LLC, Horsham, PA, USA.",tftsai@yahoo.com.
37750935,Impact of calcium channel blockers and angiotensin receptor blockers on hematological parameters in type 2 diabetic patients.,2024,"Ahmed, Ghada M","Nineveh Health Directorate, Mosul, Nineveh Province, Iraq.",m.n.abed@uomosul.edu.iq.
37747911,"2-iminobiotin, a selective inhibitor of nitric oxide synthase, improves memory and learning in a rat model after four vessel occlusion, mimicking cardiac arrest.",2023,"Meilin, Sigal; Berckovich, Yafit","Neurology Service, MD Biosciences Ltd, Nes-Ziona, Israel.; Neurology Service, MD Biosciences Ltd, Nes-Ziona, Israel.",None
37747626,Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis.,2023,"Orzechowski, Hans-Dieter; Lendl, Udo; Watson, Chris","Medical Affairs, Galapagos Biopharma Deutschland GmbH, Munich, Germany.; Medical Affairs, Galapagos Biopharma Deutschland GmbH, Munich, Germany.; Medical Affairs, Galapagos Biotech Ltd, Cambridge, UK.",alejandro.balsa@salud.madrid.org.
37745104,Virtual healthcare solutions in heart failure: a literature review.,2023,"Breznen, Boris","Evidence Synthesis, Evidinno Outcomes Research Inc., Vancouver, BC, Canada.",None
37741105,Predictors of All-Cause Mortality After Successful Transcatheter Aortic Valve Implantation in Patients With Atrial Fibrillation.,2023/Nov/15,"Jin, James; Chen, Cathy; Unverdorben, Martin","Global Specialty Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Global Specialty Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.; Global Specialty Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.",George.Dangas@mountsinai.org.
37739038,Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry.,2023,"Applegate, Darrin","Intermountain Healthcare, Murray, Utah, USA.",jdouket@mcmaster.ca.
37738020,The importance of assessing the safe and effective use of oral anticoagulants in older adults.,2023,"Creixell, Mar; Harxhi, Ante","Medical Affairs-Cardiovascular & Metabolism, Janssen Pharmaceuticals, Inc., Titusville, New Jersey, USA.; Medical Affairs-Cardiovascular & Metabolism, Janssen Pharmaceuticals, Inc., Titusville, New Jersey, USA.",None
37737773,Atrioesophageal Fistula Rates Before and After Adoption of Active Esophageal Cooling During Atrial Fibrillation Ablation.,2023,"Cogan, John; Timilsina, Saroj; Castillo, Demetrio; Kutayli, W Michael; Percell, Robert; Lanes, Daniel Benhayon; Kawasaki, Raymond; Henry, Christopher","Memorial Healthcare System, Hollywood, Florida, USA.; Memorial Healthcare System, Hollywood, Florida, USA.; Memorial Healthcare System, Hollywood, Florida, USA.; Bryan Heart, Lincoln, Nebraska, USA.; Bryan Heart, Lincoln, Nebraska, USA.; Memorial Healthcare System, Hollywood, Florida, USA.; Northwest Community Healthcare, Arlington Heights, Illinois, USA.; Northwest Community Healthcare, Arlington Heights, Illinois, USA.",Erik.Kulstad@UTSouthwestern.edu.
37730949,"Comparing Cardiovascular Outcomes and Costs of Perindopril-, Enalapril- or Losartan-Based Antihypertensive Regimens in South Africa: Real-World Medical Claims Database Analysis.",2023,"Snyman, Jacques R","Clinical Pharmacologist, Pretoria, South Africa.",Ntobeko.Ntusi@uct.ac.za.
37728093,A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/amlodipine single-pill vs. multiple-pill combination in Italy.,2024/Jan/01,"Snyman, Jacques R","Forte Research (Pty ltd) and Private Practice South Africa, Pretoria, South Africa.",None
37727649,Premature morbidity and mortality associated with potentially undiagnosed familial hypercholesterolemia in the general population.,2023,"Pillas, Demetris; Neasham, David; Addison, Janet","Amgen Ltd, Uxbridge, United Kingdom.; Amgen Ltd, Uxbridge, United Kingdom.; Biogen Idec Ltd, Maidenhead, United Kingdom.",None
37726298,In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.,2023/Sep/19,"Noga, Stephen J; Cherepanov, Dasha; Lloyd, Eric; Whidden, Presley","Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Pharmaceuticals U.S.A., Inc., Bannockburn, IL, USA.; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA.",robert.rifkin@usoncology.com.
37725271,The Role of p90 Ribosomal S6 Kinase (RSK) in Tyrosine Kinase Inhibitor (TKI)-Induced Cardiotoxicity.,2024,"Al Najjar, Afnan; Korashy, Hesham M; Mraiche, Fatima","National Center for Cancer Care and Research, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar. mraiche1@ualberta.ca.",mraiche1@ualberta.ca.
37719133,Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis.,2023,"Finkel, Muriel; Quock, Tiffany","Amyloidosis Support Groups Inc, Wood Dale, IL, USA.; Health Economics and Outcomes Research, Prothena Biosciences Ltd., South San Francisco, CA, USA.",None
37716872,Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.,2023,"Pacaud, Lida; Akram, Muhammad","Legend Biotech USA Inc., Somerset, NJ.; Legend Biotech USA Inc., Somerset, NJ.",sundar.jagannath@mountsinai.org.
37714283,Topographic Correlation of Microperimetry With Structural Characteristics in Diabetic Macular Ischemia.,2024,"Pearce, Elizabeth","Boehringer Ingelheim Pharmaceuticals Inc.(E.P.), Ridgefield, CT, USA.",sobha.sivaprasad@nhs.net.
37713090,Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.,2023,"Iwaki, Yuki","Janssen Pharmaceutical KK, Tokyo, Japan.",xmiao0831@gmail.com.
37713058,Real-world safety and effectiveness of inhaled nitric oxide therapy for pulmonary hypertension during the perioperative period of cardiac surgery: a post-marketing study of 2817 patients in Japan.,2024,"Matsugi, Emi; Takashima, Shigeki; Doteguchi, Shuhei; Kobayashi, Tomomi; Okayasu, Motohiro","Medical Affairs, Mallinckrodt Pharmaceuticals, 1-12-32 Akasaka, Minato-ku, Tokyo, 107-6030, Japan. emi.matsugi@mnk.com.; Pharmacovigilance, Mallinckrodt Pharmaceuticals, Tokyo, Japan.; Medical Affairs, Mallinckrodt Pharmaceuticals, 1-12-32 Akasaka, Minato-ku, Tokyo, 107-6030, Japan.; Medical Affairs, Mallinckrodt Pharmaceuticals, 1-12-32 Akasaka, Minato-ku, Tokyo, 107-6030, Japan.; Medical Affairs, Mallinckrodt Pharmaceuticals, 1-12-32 Akasaka, Minato-ku, Tokyo, 107-6030, Japan.",emi.matsugi@mnk.com.
37712845,Smart Liposomal Nanocarrier Enhanced the Treatment of Ischemic Stroke through Neutrophil Extracellular Traps and Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase-Stimulator of Interferon Genes (cGAS-STING) Pathway Inhibition of Ischemic Penumbra.,2023/Sep/26,"Zhu, Baoli; Xu, Ming","Jiangsu Engineering Research Center of Health Emergency, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.; Jiangsu Engineering Research Center of Health Emergency, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.",None
37709021,Buffalo yogurt fermented with commercial starter and Lactobacillus plantarum originating from breast milk lowered blood pressure in pregnant hypertensive rats.,2024,"Jun, Chen Li; Ying, Zhao Jun","National Engineering Center of Dairy for Maternal and Child Health, Beijing Sanyuan Foods Co. Ltd., Beijing 100163, China.; National Engineering Center of Dairy for Maternal and Child Health, Beijing Sanyuan Foods Co. Ltd., Beijing 100163, China.",jtm@glut.edu.cn.
37708857,Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.,2023,"Lawatscheck, Robert; Wang, Lili","Medical Affairs and Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany.; Bayer Pte Ltd, South East Asia, Singapore, Singapore.",koya@seikoukai-sc.or.jp.
37708596,Plasma protein signatures for high on-treatment platelet reactivity to aspirin and clopidogrel in peripheral artery disease.,2023,"Heitmeier, S","Division Pharmaceuticals, Bayer AG, Wuppertal, Germany.",kerstin.jurk@unimedizin-mainz.de.
37707648,Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death: A Nationwide Cohort Study.,2025,"Steurbaut, Stephane","Centre for Pharmaceutical Research, Research group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, Jette, 1090, Belgium.",Lies.lahousse@ugent.be.
37704939,Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction.,2023/Sep/13,"Alexander, Joe","Medical and Health Informatics, NTT Research, Inc, Sunnyvale, CA, 94085, USA.",torukawa@ncvc.go.jp.
37703055,Infected wound repair with an ultrasound-enhanced nanozyme hydrogel scaffold.,2023/Nov/27,"Feng, Liwen","Boji Pharmaceutical Research Center, Boji Medical Biotechnological Co. Ltd, Guangzhou 510630, P. R. China.",jixiaoyuan@tju.edu.cn.
37703006,Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.,2023/Nov/01,"Ali, Shazia; Khilla, Nagwa; McGinniss, Jennifer; Pordy, Robert","Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.",None
37702849,Optimized solubility and bioavailability of genistein based on cocrystal engineering.,2023/Sep/13,"Su, Bin","Shandong Soteria Pharmaceutical Co., Ltd., Laiwu, 271100, China.",luy@imm.ac.cn.
37702048,"Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative.",2023,"Bauer, Brenton","COR Healthcare Associates/Torrance Memorial Medical Center, CA (B.B.).",None
37696565,Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.,2023,"Lin, Jianxin; Johnson-Levonas, Amy O; de Oliveira Pena, Janethe","Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",hoeper.marius@mh-hannover.de.
37695543,Timing of prescription of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients hospitalized for acute heart failure with reduced/mildly reduced ejection fraction: a retrospective analysis.,2024,"Ishii, Tsuyoshi; Matsunaga, Yuki; Iekushi, Kazuma; Homma, Yuji; Morita, Yohei","Novartis Pharma K.K., Tokyo, Japan.; Novartis Pharma K.K., Tokyo, Japan.; Novartis Pharma K.K., Tokyo, Japan.; JMDC Inc., Tokyo, Japan.; Novartis Pharma K.K., Tokyo, Japan.",yuya8950@gmail.com.
37695378,"A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.",2024,"Yoshida, Takahiro; Mori, Ikuo","Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Co. Ltd, Tokyo, Japan.; Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Co. Ltd, Tokyo, Japan.",iida@med.nagoya-cu.ac.jp.
37694403,Enhancing Enrollment in Acute Stroke Trials: Current State and Consensus Recommendations.,2023,"Smith, Elaine M","Neuroscience Development, AbbVie, Inc (E.M.S.).",None
37690286,Metabolism configures immune response across multi-systems: Lessons from COVID-19.,2023,"Rajendran, Dhanya","Rajiv Gandhi Centre for Biotechnology, Trivandrum, Kerala, 695014, India.",vikaskumar.science@gmail.com.
37690061,Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.,2023/Sep/26,"Rodman, David; Slingsby, B T","Mineralys Therapeutics, Radnor, Pennsylvania.; Mineralys Therapeutics, Radnor, Pennsylvania.",None
37689641,Gut microbiome profile of Chinese hypertension patients with and without type 2 diabetes mellitus.,2023/Sep/09,"Xu, Yue; Dong, Shiye","Shanghai Biotecan Pharmaceuticals Co., Ltd, Shanghai, China.; Shanghai Biotecan Pharmaceuticals Co., Ltd, Shanghai, China.",tangoush@usx.edu.cn.
37686723,"Antihypertensive Effects of an Optimized Aged Garlic Extract in Subjects with Grade I Hypertension and Antihypertensive Drug Therapy: A Randomized, Triple-Blind Controlled Trial.",2023/Aug/23,"Morán-Valero, María Inés; González-Hedström, Daniel; Espinel, Alberto E","Pharmactive Biotech S.L.U., 28049 Madrid, Spain.; Pharmactive Biotech S.L.U., 28049 Madrid, Spain.; Pharmactive Biotech S.L.U., 28049 Madrid, Spain.",None
37684184,A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure.,2023,"Vogel, Prisca; Dhanasiri, Sujith","Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.",Faith.Davies@nyulangone.org.
37683911,The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF.,2024,"Abbasi, Siddique A; Divanji, Punag; Heitner, Stephen B; Kupfer, Stuart; Malik, Fady I","Amgen, Inc, Thousand Oaks, California.; Cytokinetics, Inc., South San Francisco, California.; Cytokinetics, Inc., South San Francisco, California.; Cytokinetics, Inc., South San Francisco, California.; Cytokinetics, Inc., South San Francisco, California.",john.mcmurray@glasgow.ac.uk.
37682090,[Social and economic burden of stroke in Russian Federation].,2023,"Reznik, A V; Vinitskiy, A A","Novartis Pharma LCC, Moscow, Russia.; Novartis Pharma LCC, Moscow, Russia.",None
37680892,Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.,2023,"Paul, Michaela","Novartis Pharma AG, Basel, Switzerland.",None
37679680,"Patient satisfaction survey of the ""Healthy Heart"" pharmaceutical care service - evaluation of pharmacy labelling with pharmaceutical pictograms.",2023/Sep/07,"Šola, Katarina Fehir","European Association of Employed Community Pharmacist (EPhEU), Vienna, Austria.",Urszula.religioni@gmail.com.
37679419,"GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification.",2023,"Thorleifsson, Gudmar; Steinthorsdottir, Valgerdur; Thorsteinsdottir, Unnur; Stefansson, Kari","deCODE genetics/Amgen, Inc., Reykjavik, Iceland.; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.",i.prokopenko@surrey.ac.uk.
37678961,Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry.,2023,"Schweizer, Anja; Obergfell, Achim","Novartis Pharma, Basel, Switzerland.; Novartis Pharma, Basel, Switzerland.",carolyn.lam@duke-nus.edu.sg.
37678704,Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study.,2024,"Butylin, D; Noe, A; Schwende, H; Lawrence, D; Suryawanshi, B","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; IQVIA India Ltd, Mumbai, India.",ewa.straburzynska-migaj@skpp.edu.pl.
37676213,Short-Term Changes in Peak VO,2023,"Núñez, Eduardo; Soler, Maria José","INCLIVA, Valencia, Spain.; INCLIVA, Valencia, Spain.",yulnunez@gmail.com.
37675095,"Comparison between a dedicated stent positioning system and conventional stenting of aorto-ostial lesions: a prospective, multi-center, randomized controlled study.",2023/Aug/31,"Liu, Qing","Beijing Advanced Medical Technologies, Ltd. Inc., Beijing, China.",None
37669844,Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals.,2023/Sep/05,"Lane, Thirusha","Patient Advocacy and Engagement, Alnylam Pharmaceuticals, Maidenhead, UK.",l.obici@smatteo.pv.it.
37669257,Exploring the relationship between patient-relevant outcomes and Alzheimer's disease progression assessed using the clinical dementia rating scale: a systematic literature review.,2023,"Eichinger, Christian Stefan; Freeman, Caroline","Oxford PharmaGenesis, Oxford, United Kingdom.; Oxford PharmaGenesis, Oxford, United Kingdom.",None
37667412,Identifying individuals with non-Alzheimer's disease co-pathologies: A precision medicine approach to clinical trials in sporadic Alzheimer's disease.,2024,"Yardibi, Ozlem; Simen, Arthur; Schwarz, Adam J","Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA.; Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA.; Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA.",None
37667044,The (pro)renin receptor as a pharmacological target in cardiorenal diseaes.,2023,"Funke-Kaiser, Heiko","CCR Pharma (CCRP) Therapeutics, Berlin, Germany. heiko@funke-kaiser.com.",heiko@funke-kaiser.com.
37665792,Pericardial Delivery of SDF-1α Puerarin Hydrogel Promotes Heart Repair and Electrical Coupling.,2024,"Chen, Yanmei; Liao, Yulin","Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou, 510515, China.; Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou, 510515, China.",None
37665595,"A protocol for an international, multicenter, prospective, non-interventional observational registry for patients with hypertriglyceridemia.",2023,"Jandhyala, Ravi","Medialis Ltd, Milton Keynes, UK.",None
37661008,Beyond the Global Brain Differences: Intraindividual Variability Differences in 1q21.1 Distal and 15q11.2 BP1-BP2 Deletion Carriers.,2024/Jan/15,"Hehir-Kwa, Jayne Y","Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.",boenrune@gmail.com.
37659912,Current approach to Waldenström macroglobulinemia.,2023,"Rajkumar, S Vincent","Mayo Clinic, Rochester, MN, USA. Electronic address: rajkumar.vincent@mayo.edu.",rajkumar.vincent@mayo.edu.
37659761,Quantitative proteomics based bioactive proteins discovery and quality control of medicinal leeches.,2024/Jan/30,"Qi, Yan","Yangshengtang Pharmaceutical Co., Ltd, Hangzhou, 310000, China.",gw_cpu@126.com.
37659430,"Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study.",2023,"Sanchez-Gonzalez, Javier","Philips Healthcare Iberia, Madrid, Spain.",marta.cortes@cnic.es.
37658280,Sodium Glucose Transporter-2 Inhibitors (SGLT2Is)-TLRs Axis Modulates Diabetes.,2023,"Momtaz, Saeideh","GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. momtaz@imp.ac.ir.",ah.abdolghaffari@iautmu.ac.ir.
37653496,Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.,2023/Aug/31,"Carrasco, Marc; Shay, Christina","Boehringer Ingelheim Pharmaceuticals, Inc., Barcelona, Spain.; Boehringer Ingelheim Pharmaceuticals USA, 00 Ridgebury Road, Ridgefield, CT, 06877, USA. christina.shay@boehringer-ingelheim.com.",christina.shay@boehringer-ingelheim.com.
37650213,Assessment of women's treatment preferences for vasomotor symptoms due to menopause.,2023,"Shiozawa, Aki; Cook, Erin; Yang, Hongbo; King, Deanna D; Kristy, Rita M; Mancuso, Shayna","Medical Affairs US, Astellas Pharma, Inc, Northbrook, IL, USA.; Analysis Group, Inc, Boston, MA, USA.; Analysis Group, Inc, Boston, MA, USA.; Medical Affairs US, Astellas Pharma, Inc, Northbrook, IL, USA.; Medical Affairs US, Astellas Pharma, Inc, Northbrook, IL, USA.; Medical Affairs US, Astellas Pharma, Inc, Northbrook, IL, USA.",None
37650117,Improved tropoelastin synthesis in the skin by codon optimization and nucleotide modification of tropoelastin-encoding synthetic mRNA.,2023/Sep/12,"Hoffmann, Thomas; Mandler, Markus; Schmidhuber, Sabine; Schneeberger, Achim","Accanis Biotech, Karl-Farkas-Gasse 22, Vienna 1030, Austria.; Accanis Biotech, Karl-Farkas-Gasse 22, Vienna 1030, Austria.; Accanis Biotech, Karl-Farkas-Gasse 22, Vienna 1030, Austria.; Accanis Biotech, Karl-Farkas-Gasse 22, Vienna 1030, Austria.",None
37649316,Hospitalization for acute heart failure during non-working hours impacts on long-term mortality: the REPORT-HF registry.,2023,"Obergfell, Achim","Novartis Pharma AG, Basel, Switzerland.",None
37648637,Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.,2023,"Hanselman, Jeffrey C; Lei, Lei","Esperion Therapeutics Inc., Ann Arbor, MI, USA.; Esperion Therapeutics Inc., Ann Arbor, MI, USA.",agoldber@wustl.edu.
37641968,Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study.,2024,"Fanter, Lena; Müller, Gerrit; Hirche, Christoph","Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.",None
37641688,Recombinant Neorudin for the Prevention of Deep-Vein Thrombosis After Spinal-Cord Injury.,2023,"Xia, Xia","Beijing SH Biotechnology Co., Ltd., Beijing, People's Republic of China.",None
37641636,Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population.,2023,"Booth, John N; López, J Antonio G; Kent, Shia T","Center for Observational Research, Amgen Inc., Thousand Oaks, CA 91320, USA.; Global Development, Amgen Inc., Thousand Oaks, CA 91320, USA.; Center for Observational Research, Amgen Inc., Thousand Oaks, CA 91320, USA.",None
37639574,External Application of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Hyaluronic Acid Gel Repairs Foot Wounds of Types I and II Diabetic Rats Through Paracrine Action Mode.,2023/Oct/05,"Zhang, Jingwen","Cell Resource Bank and Integrated Cell Preparation Center of Xiaoshan District, Hangzhou Regional Cell Preparation Center (Shangyu Biotechnology Co., Ltd), Hangzhou, People's Republic of China.",None
37639051,Enhanced therapeutic effects of mesenchymal stem cell-derived extracellular vesicles within chitosan hydrogel in the treatment of diabetic foot ulcers.,2023/Aug/28,"Yang, Shuangshuang; Chen, Siyu; Zhang, Chengpeng; Han, Jing; Lin, Chunyuan; Zhao, Xiaohui; Guo, Huizhen; Tan, Yi","Qilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.; Qilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.; Qilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.; Qilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.; Qilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.; Qilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.; Qilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.; Qilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China. pkuty@126.com.",pkuty@126.com.
37638695,"Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.",2023/Sep/19,"Fleming, Cynthia; Urva, Shweta; Suico, Jeffrey; Berg, Paul H; Linnebjerg, Helle; Ruotolo, Giacomo; Turner, P Kellie; Michael, Laura F","Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.",None
37635080,Long-Term Treatment With Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Open-Label Extension of the PARALLEL-HF Study.,2023/Dec/25,"Ohishi, Tomomi; Kumar, Pankaj; Kitamura, Toshihito",Novartis Pharma K.K.; Novartis Pharma AG.; Novartis Pharma K.K.,None
37634707,Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.,2023/Nov/07,"Petersson, Magnus; Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",ssolomon@rics.bwh.harvard.edu.
37633072,Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.,2023,"Mattheus, Michaela","Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.",Bernhard.Kraemer@umm.de.
37632469,Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.,2024/Jan/16,"Fazio, Sergio","Regeneron Pharmaceuticals Inc, Tarrytown, NY (S.F.).",None
37632455,Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.,2023/Nov/28,"Petersson, Magnus","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.P., A.M.K.).",None
37632309,Importance of the 'area under the curve' from serial NT-proBNP measurements during treatment with sacubitril/valsartan.,2023,"Ward, Jonathan H; Prescott, Margaret F","Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharmaceuticals, East Hanover, NJ, USA.",None
37627321,Enhanced Cerebroprotection of Xenon-Loaded Liposomes in Combination with rtPA Thrombolysis for Embolic Ischemic Stroke.,2023/Aug/16,"Booher, Keith","Zymo Research Corporation, Irvine, CA 92614, USA.",None
37626170,RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.,2023,"Hamilton, James; Given, Bruce; Melquist, Stacey; Zhou, Rong; Chang, Ting; San Martin, Javier","Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA.; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA.; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA.; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA.; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA.; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA.",gerald.watts@uwa.edu.au.
37622738,Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.,2023/Dec/01,"Trudel, Suzanne","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",None
37622416,Baseline characteristics of patients enrolled in the EMPACT-MI trial.,2023,"Zwiener, Isabella","Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.",None
37621213,Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants.,2023/Sep/19,"Dorais, Marc","StatSciences Inc, Notre-Dame-de-l'Île-Perrot, Quebec, Canada (M.D.).",None
37621153,Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.,2023/Sep/26,"Zeller, Cordula","Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany (C.Z.).",None
37619694,Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis.,2023,"Lech, Tara K","Division of Pharmacy, Beth Israel Lahey Health, Westwood, Massachusetts, USA.",jerrold.levy@duke.edu.
37616058,Endogenous adenine mediates kidney injury in diabetic models and predicts diabetic kidney disease in patients.,2023/Oct/16,"Tucci, Fabio C","Epigen Biosciences Inc., San Diego, California, USA.",None
37612876,"Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real-world setting: A prospective, observational post-marketing study.",2023,"Wang, Huan; Wang, Yihua; Xu, Jiawei","Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.; Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.; Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.",None
37611841,Scutellarin attenuates oxidative stress and neuroinflammation in cerebral ischemia/reperfusion injury through PI3K/Akt-mediated Nrf2 signaling pathways.,2023/Oct/15,"Fan, Lijuan; Zhang, Wei","Kunming Longjin Pharmaceutical Co., Ltd, Kunming, 650503, China.; Kunming Longjin Pharmaceutical Co., Ltd, Kunming, 650503, China.",sun-xiaobo@163.com.
37610398,Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.,2023/Sep/05,"Langkilde, Anna Maria; Petersson, Magnus; Zaozerska, Natalia; Bachus, Erasmus","Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, Gothenburg, Sweden.",john.mcmurray@glasgow.ac.uk.
37609931,Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE-MI.,2023/Sep/05,"Wang, Yi",Novartis Pharmaceuticals Corporation East Hanover NJ.,None
37607273,Combined Use of Therapeutic Hyper-CL Soft Contact Lens and Insulin Eye Drops for the Treatment of Recalcitrant Neurotrophic Keratopathy.,2024/Jan/01,"Verdiglione, Mario","Compounding Pharmacy, Farmacia Europea, Catanzaro, Italy.",None
37606870,"OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers.",2023,"Bagger, Yu; Ravis, William R; Harris, Geoff; Bukofzer, Stan","Ferring Pharmaceuticals A/S, Copenhagen, Denmark.; Ocelot Bio, Inc., 601 Marshall Street, Redwood City, CA, 94063, USA.; Ocelot Bio, Inc., 601 Marshall Street, Redwood City, CA, 94063, USA.; Ocelot Bio, Inc., 601 Marshall Street, Redwood City, CA, 94063, USA. stan@ocelotbio.com.",stan@ocelotbio.com.
37606673,Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events.,2023/Aug/22,"Helgason, Hannes; Eiriksdottir, Thjodbjorg; Ulfarsson, Magnus O; Choudhary, Abhishek; Lund, Sigrun H; Ivarsdottir, Erna V; Hjorleifsson Eldjarn, Grimur; Einarsson, Gudmundur; Ferkingstad, Egil; Moore, Kristjan H S; Honarpour, Narimon; Liu, Thomas; Wang, Huei; Hucko, Thomas; Arnar, David O; Thorgeirsson, Gudmundur; Masson, Gísli; Magnusson, Olafur Th; Saemundsdottir, Jona; Gretarsdottir, Solveig; Steinthorsdottir, Valgerdur; Thorleifsson, Gudmar; Helgadottir, Anna; Sulem, Patrick; Thorsteinsdottir, Unnur; Holm, Hilma; Gudbjartsson, Daniel; Stefansson, Kari","deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; Amgen, Inc, Thousand Oaks, California.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; Amgen, Inc, Thousand Oaks, California.; Amgen, Inc, Thousand Oaks, California.; Amgen, Inc, Thousand Oaks, California.; Amgen, Inc, Thousand Oaks, California.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.; deCODE genetics/Amgen, Inc, Reykjavik, Iceland.",None
37604649,"Long-term outcomes among stable post-acute myocardial infarction patients living in rural versus urban areas: insights from the prospective, observational TIGRIS registry.",2023,"Hedman, Katarina","BioPharmaceuticals R&D, CVRM Biometrics, AstraZeneca, Gothenburg, Sweden.",corjnicolau@incor.usp.br.
37604638,Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.,2023,"Silk, Maria; Dickson, Christina; Meszaros, Gabriella; de la Torre, Inmaculada; Issa, Maher","Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.",eric.morand@monash.edu.
37604168,[Primary and secondary prevention in hypercholesterolemia: differences relevant to patient care in the PROCYON trial].,2023,"Willfeld, Kathy; Beier, Lea","Novartis Pharma GmbH, Nürnberg.; Novartis Pharma GmbH, Nürnberg.",None
37603070,Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany.,2024,"Beier, Lea","Novartis Pharma GmbH, Nuremberg, Germany.",koenig@dhm.mhn.de.
37601066,Dapagliflozin versus empagliflozin in patients with chronic kidney disease.,2023,"Azuri, Joseph","Diabetes Clinic, Maccabi Healthcare Services, Tel Aviv, Israel.",None
37600044,Quantitative imaging biomarkers of coronary plaque morphology: insights from EVAPORATE.,2023,"Nicolaou, Anna","Elucid Bioimaging Inc., Boston, MA, United States.",None
37592106,Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.,2023,"Massaro, Monica; Petrocca, Fabio; Yeri, Ashish; Finney, Olivia; Caia, Andrea; Yang, Zhihong; Martin, Nathan; Campbell, Timothy B; Rytlewski, Julie; Fuller, Jaymes; Hege, Kristen","2SeventyBio, Inc, Cambridge, MA, USA.; 2SeventyBio, Inc, Cambridge, MA, USA.; 2SeventyBio, Inc, Cambridge, MA, USA.; 2SeventyBio, Inc, Cambridge, MA, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",lin.yi@mayo.edu.
37589970,Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.,2023/Oct/01,"Flora, Daniel B","St Elizabeth Healthcare, Edgewood, Kentucky.",None
37586482,The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.,2024,"Cutino, Antonio","Alimera Sciences, Inc, Alpharetta, Georgia.",rothretina@gmail.com.
37582952,Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.,2023,"Leip, Eric; Sullivan, Sharon T; Conte, Umberto; Elmeliegy, Mohamed; Czibere, Akos","Pfizer Inc, Cambridge, MA, USA.; Pfizer Inc, Cambridge, MA, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, San Diego, CA, USA.; Pfizer Inc, New York, NY, USA.",lesokhia@mskcc.org.
37581752,Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.,2023,"Chyla, Brenda; Sun, Yan","AbbVie, Inc, North Chicago, IL, USA.; AbbVie, Inc, North Chicago, IL, USA.",kizutsu@ncc.go.jp.
37579873,Can a best practice advisory improve anticoagulation prescribing to reduce stroke risk in patients with atrial fibrillation?,2024,"Adejare, Adeboye","Janssen Pharmaceuticals, Titusville, NJ, USA.",mark.eckman@uc.edu.
37574953,"Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.",2023,"Nurse, Christina; Yu, Ming","Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.; Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.",None
37572785,Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI.,2023,"Carrara, Greta","Advice Pharma Group, Milan, Italy.",espogiov@unina.it.
37568089,Evaluating the effect of the COVID-19 pandemic on hypertension and diabetes care in South Korea: an interrupted time series analysis.,2023/Aug/12,"Kim, Sunmi","Korea Pharmaceutical Information Service, Health Insurance Review and Assessment Service (HIRA), Wonju, Korea.",ewnam@yonsei.ac.kr.
37563310,Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.,2023,"Folkersen, Lasse","Nucleus Genomics ltd, New York, NY, USA.",j.peters@imperial.ac.uk.
37559718,Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.,2023,"Hamidi, Habib; Nielsen, Tina G; Raval, Aparna; Sareen, Rajan; Wassner-Fritsch, Elisabeth","Genentech Inc., South San Francisco, CA, United States.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Genentech Inc., South San Francisco, CA, United States.; Genentech Inc., South San Francisco, CA, United States.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.",None
37558385,Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF.,2023,"Sun, Franklin","Lexicon Pharmaceuticals Inc., The Woodlands, Texas, USA.",DLBhattMD@post.Harvard.edu.
37558088,"Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial.",2023,"Peil, Barbara","Boehringer Ingelheim Pharma, Ingelheim, Germany.",Javed.Butler@bswhealth.org.
37554980,Editorial: Cardiovascular remodeling.,2023,"Li, Gui-Rong","Nanjing Amazigh Pharma Ltd., Nanjing, China.",None
37554763,Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake.,2023,"Gomes Dos Santos, Ana L; Hornigold, David C; Baker, David; Naylor, Jacqueline; Liang, Lihuan; Corkill, Dominic J","Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Bioscience In Vivo, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals, R&D, AstraZeneca, Cambridge, United Kingdom.",None
37552807,"Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure.",2023/Aug/24,"Kato, Terukazu; Fukao, Keita; Ohara, Takafumi; Naya, Noriyuki; Matsumura, Ken-Ichi","Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.",None
37552540,Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.,2023/Sep/08,"Sjöström, C David","Late-stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
37547279,Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study.,2023,"Bray, Sarah","Global Biostatistical Science, Amgen Ltd, Cambridge, UK.",None
37544137,Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Naïve to Renin-Angiotensin System Inhibitors.,2023/Oct/01,"Shen, Xian","Novartis Pharmaceutical Corporation, East Hanover, New Jersey.",stephen.greene@duke.edu.
37541745,Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.,2023,"Tainton, Jodi; Simonyi, Susan","Allergan, an AbbVie Company, Gordon, New South Wales, Australia.; Allergan, an AbbVie company, Singapore.",paul.mitchell@sydney.edu.au.
37540060,Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.,2023,"Blatchford, Jonathan P","Elderbrook Solutions GmbH, Bietigheim-Bissingen, Germany on behalf of Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany.",None
37537544,The burden of untreated insomnia disorder in a sample of 1 million adults: a cohort study.,2023/Aug/03,"Olivieri, Antonio; Ahuja, Ajay; Büsser, Alexander","Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil, 4123, Switzerland.; Idorsia Pharmaceuticals US Inc, Radnor, PA, USA.; Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil, 4123, Switzerland. alexander.busser@idorsia.com.",alexander.busser@idorsia.com.
37536544,Homotypic targeted nanoplatform enable efficient chemoimmunotherapy and reduced DOX cardiotoxicity in chemoresistant cancer via TGF-β1 blockade.,2023,"Sun, Yiying","Yantai Saipute Analyzing Service Co. Ltd, Yantai, Shandong Province, China.",sunkx@ytu.edu.cn.
37535382,"Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.",2023/Sep/01,"Reed, Kimberly; Berliner, Alyson J; Breazna, Aurora; Chu, Karen W; Hirshberg, Boaz; Yancopoulos, George D; Vitti, Robert","Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.",None
37533132,Efficacy and safety of pentoxifylline for chronic venous leg ulcers: study protocol for a multicenter randomized controlled trial in China (ESPECT study).,2023/Aug/02,"Li, Pei; Li, Jianli; Li, Yuanyuan","CSPC Ouyi Pharmaceutical Co., Ltd., Shijiazhuang, 052160, China.; CSPC Ouyi Pharmaceutical Co., Ltd., Shijiazhuang, 052160, China.; CSPC Ouyi Pharmaceutical Co., Ltd., Shijiazhuang, 052160, China.",ranxingwu@163.com.
37532724,Genetic insights into resting heart rate and its role in cardiovascular disease.,2023/Aug/02,"Sveinbjornsson, Gardar; Arnar, David O; Gudbjartsson, Daniel F; Holm, Hilma; Stefansson, Kari","deCODE genetics / Amgen Inc., Reykjavik, 102, Iceland.; deCODE genetics / Amgen Inc., Reykjavik, 102, Iceland.; deCODE genetics / Amgen Inc., Reykjavik, 102, Iceland.; deCODE genetics / Amgen Inc., Reykjavik, 102, Iceland.; deCODE genetics / Amgen Inc., Reykjavik, 102, Iceland.",P.vanderHarst@umcutrecht.nl.
37529931,Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients.,2023,"Gillard, Kristin Khalaf; Israel, Marc K","Esperion Therapeutics, Inc, Ann Arbor, MI (K.K.G., M.K.I.).; Esperion Therapeutics, Inc, Ann Arbor, MI (K.K.G., M.K.I.).",None
37527782,A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer.,2024,"Nassar, Ayman; Pollock, Kevin G","Bristol Myers Squibb Pharmaceuticals Ltd., Uxbridge, Middlesex, United Kingdom.; Bristol Myers Squibb Pharmaceuticals Ltd., Uxbridge, Middlesex, United Kingdom.",None
37525072,Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.,2024,"Dhalwani, Nafeesa N; Bridges, Ian","Amgen Inc., Thousand Oaks, CA, USA.; Amgen Ltd., Uxbridge, UK.",Christoph.Ebenbichler@i-med.ac.at.
37523173,Aortic Stenosis Risk in Rheumatoid Arthritis.,2023/Jul/31,"Baker, Joshua F","Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.",None
37521410,Evaluation of the safety and potential lipid-lowering effects of oral hydrogen-rich coral calcium (HRCC) capsules in patients with metabolic syndrome: a prospective case series study.,2023,"Douglas, Frank L; Chung, Jia-Ru; Wang, Kuang-Yih; Chu, Chao-Fang; Chou, Hsia-Yun; Huang, Wei-Chih; Wang, Tian-Yu","HOHO Biotech Co., Ltd., Taipei, Taiwan.; HOHO Biotech Co., Ltd., Taipei, Taiwan.; HOHO Biotech Co., Ltd., Taipei, Taiwan.; HOHO Biotech Co., Ltd., Taipei, Taiwan.; HOHO Biotech Co., Ltd., Taipei, Taiwan.; HOHO Biotech Co., Ltd., Taipei, Taiwan.; HoGo Force Co., Ltd., Taipei, Taiwan.",None
37517922,Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.,2023,"Louie, Michael J; Lei, Lei","Esperion Therapeutics, Inc., Ann Arbor, MI, USA.; Esperion Therapeutics, Inc., Ann Arbor, MI, USA.",mdshapir@wakehealth.edu.
37517454,Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.,2023,"Berrey, M Michelle; Shiff, Steven J; Sawhney, Sangeeta; Capozza, Thomas; Leyva, Rina","Intercept Pharmaceuticals, Morristown, NJ, USA.; Intercept Pharmaceuticals, Morristown, NJ, USA.; Intercept Pharmaceuticals, Morristown, NJ, USA.; Intercept Pharmaceuticals, Morristown, NJ, USA.; Intercept Pharmaceuticals, Morristown, NJ, USA.",arun.sanyal@vcuhealth.org.
37516264,Temporal trends in cardiovascular outcomes and costs among patients with type 2 diabetes.,2023,"Kumar, Neela","Janssen Pharmaceuticals, Titusville, NJ.",brent.williams@ahn.org.
37512011,"Incidence of Lower Extremity Amputation in Romania: A Nationwide 5-Year Cohort Study, 2015-2019.",2023/Jun/25,"Gavan, Norina Alinta","Wörwag Pharma Romania SRL, 400267 Cluj-Napoca, Romania.",None
37503602,Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat.,2023,"Blaustein, Robert O","Merck & Co Inc, Rahway, NJ (R.O.B.).",None
37502180,Ameliorating diabetes-associated atherosclerosis and diabetic nephropathy through modulation of soluble guanylate cyclase.,2023,"Dietz, Lisa; Sandner, Peter","Pharmaceuticals Research and Development, Bayer AG, Wuppertal, Germany.; Pharmaceuticals Research and Development, Bayer AG, Wuppertal, Germany.",None
37498594,Estimated Prevalence and Testing for Albuminuria in US Adults at Risk for Chronic Kidney Disease.,2023/Jul/03,"Xia, Fang","Gilead Sciences Inc, Foster City, California.",None
37498307,Alpha-ketoglutarate supplementation reduces inflammation and thrombosis in type 2 diabetes by suppressing leukocyte and platelet activation.,2023/Dec/12,"Agarwal, Sakshi; Ghosh, Riya; Verma, Garima; Guchhait, Prasenjit","Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India.; Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India.; Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India.; Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India.",None
37497629,"Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.",2023,"Pacaud, Lida","Legend Biotech USA Inc., Somerset, NJ 08873, USA.",None
37497384,Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.,2023,"Gray, David; Duvvuri, Sridhar","Vigil Neuroscience, Inc, Watertown, MA, USA.; Cerevel Therapeutics, Boston, MA, USA.",None
37496004,"A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial.",2023/Jul/26,"Wolgen, Philippe; Walker, Gill; Bilbao, Pilar","CLINUVEL Pharmaceuticals, Melbourne, Australia.; CLINUVEL Pharmaceuticals, Melbourne, Australia.; CLINUVEL Pharmaceuticals, Melbourne, Australia.",G.Cloud@alfred.org.au.
37495323,Pulmonary Vein Myocardial Sleeve Length and its Association With Sex and 4q25/PITX2 Genotype.,2023,"Frye, Bradley; Herrmann, Tarrah; Patel, Bindiya; Touchton, Steven A","Biosense Webster Inc, Irvine, California, USA.; Biosense Webster Inc, Irvine, California, USA.; Biosense Webster Inc, Irvine, California, USA.; Biosense Webster Inc, Irvine, California, USA.",moore.b.shoemaker@vumc.org.
37488529,A network medicine approach to study comorbidities in heart failure with preserved ejection fraction.,2023/Jul/24,"Valdeolivas, Alberto","Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.",rebeccaterrall.levinson@med.uni-heidelberg.de.
37487965,"Evaluation of the efficacy and safety of Suxiao Jiuxin Pill in the treatment of stable angina: A randomized, double-blind, placebo-controlled, multi-center clinical trial.",2024/Jan/10,"Li, He-Lin","Beijing Yaohai Ningkang Pharmaceutical Technology Co., LTD, China.",wxlqy0214@163.com.
37487254,Dan-Deng-Tong-Nao softgel capsule promotes angiogenesis of cerebral microvasculature to protect cerebral ischemia reperfusion injury via activating HIF-1α-VEGFA-Notch1 signaling pathway.,2023,"Li, Dan; Hou, Jincai","Shineway Pharmaceutical Group Co. Ltd. Shijiazhuang 51430(,) China.; Shineway Pharmaceutical Group Co. Ltd. Shijiazhuang 51430(,) China.",wnsci123@163.com.
37481929,Genkwanin: An emerging natural compound with multifaceted pharmacological effects.,2023,"El Menyiy, Naoual","Laboratory of Pharmacology, National Agency of Medicinal and Aromatic Plants, Taounate 34025, Morocco. Electronic address: naoualelmenyiy@gmail.com.",a.bouyahya@um5r.ac.ma.
37479803,Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema.,2024,"Anderesi, Majid; Igwe, Franklin","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",ramin.khoramnia@med.uni-heidelberg.de.
37479782,"How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients.",2023,"Tonelli, Isabelle","Otsuka Pharmaceutical, Paris, France.",guillaume.fond@gmail.com.
37470101,Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.,2023,"Pizzato, Patricia E; Gabrielsen, Anders; Michaëlsson, Erik; Nelander, Karin; Ericsson, Hans; Holden, Julie; Folkvaljon, Folke; Mattsson, Andrea; Collén, Anna; Aurell, Malin; Whatling, Carl","Early Clinical Development, Research and Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Early Clinical Development, Research and Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Early Clinical Development, Research and Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Early Biometrics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Patient Safety, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal and Metabolism - Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Projects, Research and Early Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Early Clinical Development, Research and Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
37468185,Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial.,2023/Jul/25,"Boden, William E","VA New England Healthcare System, Bedford, Massachusetts, USA.",kmavro@emory.edu.
37466380,Nattokinase Promotes Post-stroke Neurogenesis and Cognition Recovery via Increasing Circulating Irisin.,2023/Aug/02,"Chen, Jiepeng; Duan, Lili","Sungen Biotech Company, Limited, Shantou, Guangdong 515000, People's Republic of China.; Sungen Biotech Company, Limited, Shantou, Guangdong 515000, People's Republic of China.",None
37463872,Poor recognition and undertreatment of anemia in patients with chronic kidney disease managed in primary care.,2023,"Cockburn, Elinor","Astellas Pharma A/S, Copenhagen, Denmark.",None
37462255,Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure.,2023,"Gimpelewicz, Claudio","Novartis Pharma, Basel, Switzerland.",None
37461134,Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases.,2023/Oct/01,"Chatterjee, Satabdi","Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield , Connecticut.",None
37460856,The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study.,2023,"Gunawardhana, Lhanoo; Page, Matt","Clinical Science, Marketed Products Development, Takeda Pharmaceuticals Company Limited, Cambridge, MA, USA.; Center for Post Approval Safety Studies, Takeda Pharmaceuticals Company Limited, 500 Kendall Street, Cambridge, MA, 02142, USA. matt.page@takeda.com.",matt.page@takeda.com.
37460466,Global disparities in patients with multiple myeloma: a rapid evidence assessment.,2023/Jul/18,"Aydin, Didem","Pfizer Pharmaceuticals, Istanbul, Turkey.",usmanis@mskcc.org.
37460300,[Pharmacological and clinical profiles of avacopan (TAVNEOS,2023/Sep/05,"Maruyama, Yuya; Yoshida, Takumitsu; Maruyama, Itaru","Pharmacology Research Laboratory, Kissei Pharmaceutical Co., Ltd.; Clinical Projects Management, Kissei Pharmaceutical Co., Ltd.; Pharmacology Research Laboratory, Kissei Pharmaceutical Co., Ltd.",None
37460036,KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.,2024,"Kovacic, Lidija; Wang, Lixin; Wang, Ying; Bouillaud, Emmanuel","Novartis Pharma A.G. (L.W., Y.W., E.B.), Basel, Switzerland.; Novartis Pharma A.G. (L.W., Y.W., E.B.), Basel, Switzerland.; Novartis Pharma A.G. (L.W., Y.W., E.B.), Basel, Switzerland.; Novartis Pharma A.G. (L.W., Y.W., E.B.), Basel, Switzerland.",ccwmd@retinaconsultantstexas.com.
37459570,Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study.,2023/Sep/25,"Keller, Stuart","Eli Lilly and Company, Sam Jones Expy, Indianapolis, IN 46241, USA.",None
37458205,Antihypertensive effect of patulitrin and other constituents from ,2024,"Khan, Rashid A","Pharmaceutical Reserach Centre, PCSIR Laboratories Complex, Karachi, Pakistan.",None
37458138,"Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.",2023,"Mohammadi, Kusha A; Brackin, Taylor; Manvelian, Garen; Pordy, Robert; Fazio, Sergio; Geba, Gregory P","Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.",None
37449684,"Applicability of the OPTA Questionnaire for Patients with Stable Ischemic Heart Disease in Indian Clinical Practice: A Cross-sectional, Real-word Evidence Study.",2023,"Upendra, Greeshma","Established Pharmaceuticals Division, Abbott Healthcare India Pvt Ltd, Mumbai, Maharashtra, India.",None
37449424,Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials.,2023,"Mattheus, Michaela","Boehringer Ingelheim Pharma GmbH & Co KG, Germany (M.M.).",None
37441958,Combining microfluidics and coaxial 3D-bioprinting for the manufacturing of diabetic wound healing dressings.,2023,"Uddin, Shahid","Immunocore Ltd., 92 Park Dr, Milton Park, Abingdon OX14 4RY, United Kingdom.",D.Lamprou@qub.ac.uk.
37441817,"Towards monitoring of antimicrobial resistance in the environment: For what reasons, how to implement it, and what are the data needs?",2023,"Forslund, Sofia K; Jarquín-Díaz, Víctor Hugo; Löber, Ulrike; Nekoro, Marmar","Experimental and Clinical Research Center, a cooperation between the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association and the Charité - Universitätsmedizin Berlin, Germany; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Lindenberger Weg 80, 13125 Berlin, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany; Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.; Experimental and Clinical Research Center, a cooperation between the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association and the Charité - Universitätsmedizin Berlin, Germany; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Lindenberger Weg 80, 13125 Berlin, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.; Experimental and Clinical Research Center, a cooperation between the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association and the Charité - Universitätsmedizin Berlin, Germany; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Lindenberger Weg 80, 13125 Berlin, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.; Swedish Knowledge Centre on Pharmaceuticals in the Environment, Swedish Medical Products Agency, P.O Box 26, 751 03 Uppsala, Sweden.",johan.bengtsson-palme@microbiology.se.
37434208,Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease.,2023/Jul/11,"Bu, Guojun","SciNeuro Pharmaceuticals, Rockville, MD, 20850, USA.",kanekiyo.takahisa@mayo.edu.
37434025,Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP).,2024,"Heyder, Ralf; Pley, Christina","Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, NUM Coordination Office, Berlin, Germany.; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, NUM Coordination Office, Berlin, Germany.",martin.witzenrath@charite.de.
37433904,Anticoagulant therapy and home blood pressure-associated risk for stroke/bleeding events in elderly patients with non-valvular atrial fibrillation: the sub-cohort study of ANAFIE registry.,2023,"Kimura, Tetsuya; Morishima, Yoshiyuki; Takita, Atsushi","Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Daiichi Sankyo Co., Ltd., Tokyo, Japan.",kkario@jichi.ac.jp.
37432906,Adherence and related cardiovascular outcomes to single pill vs. separate pill administration of antihypertensive triple-combination therapy.,2023/Sep/01,"Rea, Federico; Morabito, Gabriella; Savaré, Laura; Corrao, Giovanni",National Centre for Healthcare Research and Pharmacoepidemiology.; National Centre for Healthcare Research and Pharmacoepidemiology.; National Centre for Healthcare Research and Pharmacoepidemiology.; National Centre for Healthcare Research and Pharmacoepidemiology.,None
37428680,Observed consensus on research priorities for the hypertriglyceridemia patient registry.,2023,"Jandhyala, Ravi","Medialis Ltd, England, UK.",None
37427416,Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications.,2023/Sep/18,"Fischell, Tim A","Ablative Solutions Inc., Wakefield, MA, USA.",None
37427090,"Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real-world patient data repository.",2023,"Cho, Michelle","Actelion Pharmaceuticals US, Inc. Titusville New Jersey USA.",None
37425772,Rare variants in long non-coding RNAs are associated with blood lipid levels in the TOPMed Whole Genome Sequencing Study.,2023/Jun/29,"Kim, Ryan; Viaud-Martinez, Karine A","Psomagen, Inc. (formerly Macrogen USA), Rockville, MD, USA.; Illumina Laboratory Services, Illumina Inc., San Diego, CA, USA.",None
37425708,"Diversity and Scale: Genetic Architecture of 2,068 Traits in the VA Million Veteran Program.",2023/Jun/29,"Verma, Anurag; Huffman, Jennifer E; Ho, Yuk-Lam; Garcon, Helene; Costa, Lauren; Honerlaw, Jacqueline; Posner, Daniel C; Sangar, Rahul; Murray, Michael; Dochtermann, Daniel R; Devineni, Poornima; Shi, Yunling; Assimes, Themistocles L; Brunette, Charles A; Joseph, Jacob; Kember, Rachel; Kranzler, Henry; Levey, Daniel; Justice, Amy; Pyarajan, Saiju; Tsao, Philip S; O'Donnell, Christopher J; Casas, Juan P; Voight, Benjamin F; Damrauer, Scott M; Liao, Katherine P","Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, 19104, USA.; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, 02130, USA.; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, 02130, USA.; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, 02130, USA.; MVP Boston Coordinating Center, VA Boston Healthcare System, Boston, MA, 02111, USA.; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, 02130, USA.; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, 02130, USA.; MVP Boston Coordinating Center, VA Boston Healthcare System, Boston, MA, 02111, USA.; MVP Boston Coordinating Center, VA Boston Healthcare System, Boston, MA, 02111, USA.; VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, 02130, USA.; VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, 02130, USA.; VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, 02130, USA.; Medicine, Cardiology, VA Palo Alto Healthcare System, Palo Alto, CA, 94304, USA.; Research Service, VA Boston Healthcare System, Boston, MA, 02130, USA.; Medicine, Cardiology Section, VA Providence Healthcare System, Providence, RI, 02908, USA.; Mental Illness Research, Education and Clinical Center, Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, 19104, USA.; Mental Illness Research, Education and Clinical Center, Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, 19104, USA.; Medicine, VA Connecticut Healthcare System West Haven, West Haven, CT, 06516, USA.; Medicine, VA Connecticut Healthcare System West Haven, West Haven, CT, 06516, USA.; VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, 02130, USA.; Medicine, Cardiology, VA Palo Alto Healthcare System, Palo Alto, CA, 94304, USA.; Medicine, Cardiology, VA Boston Healthcare System, Boston, MA, 02130, USA.; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, 02130, USA.; Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, 19104, USA.; Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, 19104, USA.; Medicine, Rheumatology, VA Boston Healthcare System, Boston, MA, 02130, USA.",None
37421285,Antihypertensive Medication Adherence and Cardiovascular Outcomes in Patients With Cancer: A Nationwide Population-Based Cohort Study.,2023/Jul/18,"Kang, Dongwoo; Kyoung, Dae-Sung","Data Science Team, Hanmi Pharmaceutical Co., Ltd Seoul Republic of Korea.; Data Science Team, Hanmi Pharmaceutical Co., Ltd Seoul Republic of Korea.",None
37418531,Single-cell and spatial transcriptomics identify a macrophage population associated with skeletal muscle fibrosis.,2023/Jul/07,"Golann, David R; Su, Qi; Stec, Michael","Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.",None
37417824,Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.,2023,"McMullan, Ciaran J; Koglin, Joerg","Merck & Co Inc, Kenilworth, NJ (C.J.M., J.K.).; Merck & Co Inc, Kenilworth, NJ (C.J.M., J.K.).",None
37416849,"Bridging the ""Know-Do"" Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science.",2023,"Jithoo, Niraksha; Huang, Pai-Hui; Subramaniam, Kannan; Ramanjinappa, Nagendra; Koltun, Arkady; Melamed, Shari","Viatris Ltd, Johannesburg, South Africa.; Viatris Pharmaceutical Co., Ltd, Taipei, Taiwan.; Viatris Ltd, Auckland, New Zealand.; Viatris Ltd, Bangalore, India.; Viatris Ltd, Canonsburg, PA, USA.; Viatris Ltd, Canonsburg, PA, USA.",None
37414900,A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease.,2023,"Sun, Yan V; Cho, Kelly; Wilson, Peter W F","Veteran Affairs Atlanta Healthcare System, Decatur, GA, USA.; Veteran Affairs Boston Healthcare System, Boston, MA, USA.; Veteran Affairs Atlanta Healthcare System, Decatur, GA, USA.",avkhera@mgh.harvard.edu.
37414012,"γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.",2023,"Sather, Blythe D","Juno Therapeutics, Seattle, WA, USA.",dgreen@fredhutch.org.
37408180,Microvascular Leakage as Therapeutic Target for Ischemia and Reperfusion Injury.,2023/May/09,"Wülfroth, Petra","F4 Pharma, 1060 Vienna, Austria.",None
37407113,Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure.,2023/Jul/11,"Hammarstedt, Ann; Sjöstrand, Mikaela; Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.",john.mcmurray@glasgow.ac.uk.
37406819,Injectable liposomal docosahexaenoic acid alleviates atherosclerosis progression and enhances plaque stability.,2023,"Looi, Wen Donq","Bruker Daltonics, Bruker Singapore Pte. Ltd., 138671 Singapore, Singapore.",surwang@nus.edu.sg.
37405677,Direct oral anticoagulants vs vitamin K antagonist on dementia risk in atrial fibrillation: systematic review with meta-analysis.,2023,"Severiano E Sousa, Catarina; Costa, João; Ferreira, Joaquim J; Caldeira, Daniel","Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal.; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal.; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal.; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal. dgcaldeira@hotmail.com.",dgcaldeira@hotmail.com.
37403937,Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.,2023,"Pacaud, Lida","Legend Biotech USA Inc, Somerset, NJ, USA.",None
37403136,Why a distinct medical stream is necessary to support patients using cannabis for medical purposes.,2023/Jul/04,"Boivin, Michael","CommPharm Consulting Inc., Barrie, ON, Canada.",cecilia.costiniuk@mcgill.ca.
37402275,Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.,2023/Nov/24,"Modesto, Irene; Kwok, Kenneth K; Jo, Hyejin; Yndestad, Arne","Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, Oslo, Norway.",None
37401523,Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.,2023,"Prescott, Margaret F; Ward, Jonathan H","Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.",None
37399456,A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.,2023/Nov/14,"Agarwal, Shirali; Zhang, Peixin; Wu, Wendy; Amber, Vian","Jazz Pharmaceuticals, Palo Alto, CA.; Jazz Pharmaceuticals, Philadelphia, PA.; Jazz Pharmaceuticals, Palo Alto, CA.; Jazz Pharmaceuticals, Oxford, United Kingdom.",None
37398685,Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease.,2023,"Mellström, Carl","BioPharmaceuticals CVRM, AstraZeneca, Gothenburg, Sweden.",None
37398493,CETP and SGLT2 inhibitor combination therapy improves glycemic control.,2023/Jun/16,"Ditmarsch, Marc","NewAmsterdam Pharma B.V., Naarden, 1411 DC, The Netherlands.",None
37395381,Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab.,2023,"Shah, Chintal H; Schultz, Bob G","Takeda Pharmaceuticals USA, Inc, Lexington, MA, USA.; Takeda Pharmaceuticals USA, Inc, Lexington, MA, USA.",None
37393920,Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report.,2023/Jul/29,"Paolini, John F; Bondensgaard, Kent","Kiniksa Pharmaceuticals, Lexington, MA, USA.; Kiniksa Pharmaceuticals, Lexington, MA, USA.",mmohiuddin@som.umaryland.edu.
37393828,"Elucidation of the mechanism of Yiqi Tongluo Granule against cerebral ischemia/reperfusion injury based on a combined strategy of network pharmacology, multi-omics and molecular biology.",2023,"Li, Dan; Hou, Jincai","Shineway Pharmaceutical Group Co., Ltd., Shijiazhuang 051430, China.; Shineway Pharmaceutical Group Co., Ltd., Shijiazhuang 051430, China.",yyjiang@tsinghua.edu.cn.
37393245,"Assessment of availability, readiness, and challenges for scaling-up hypertension management services at primary healthcare facilities, Central Highland region, Vietnam, 2020.",2023/Jul/01,"Nguyen, Hue Kim Le; H, Hieng; Buonya, Y Dech; Le, Tram Dinh","Provincial Centers for Diseases Control of Dak Lak, Dak Lak, Vietnam.; Provincial Centers for Diseases Control of Dak Nong, Dak Nong, Vietnam.; Provincial Centers for Diseases Control of Kon Tum, Kon Tum, Vietnam.; Provincial Centers for Diseases Control of Gia Lai, Gai Lai, Vietnam.",chaisiri.a@cmu.ac.th.
37393121,Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis.,2023,"Mouro, Jorge; Costa, Bruno; Sturniolo, Michael","Worldwide Medical Affairs, Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.; Worldwide Medical Affairs, Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.; Worldwide Medical Affairs, Celgene, a Bristol-Myers Squibb Company, Princeton, NJ.",Salomon.MANIER@CHRU-LILLE.FR.
37387399,"Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study.",2023,"Vizcaya, David; Reyes, Andrés; Pujol, Pau","Integrated Evidence Generation. Bayer Pharmaceuticals, Sant Joan Despí, 08970, Spain.; Medical Affairs & Pharmacovigilance, Bayer Pharmaceuticals, Sant Joan Despí, 08970, Spain.; Medical Affairs & Pharmacovigilance, Bayer Pharmaceuticals, Sant Joan Despí, 08970, Spain.",None
37385732,Recurrent myocardial infarction and emergency department visits: a retrospective study on the Stockholm Area Chest Pain Cohort.,2023,"Doemland, Martha L; Roux, Sébastien","Idorsia Pharmaceuticals Ltd, Cherry Hill, New Jersey, USA.; Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland sebastien.roux@idorsia.com.",sebastien.roux@idorsia.com.
37385275,"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.",2023/Aug/19,"Mao, Huzhang; Zhang, Shuyu; Ahmad, Nadia N; Bunck, Mathijs C; Benabbad, Imane; Zhang, Xiaotian M","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",garveyt@uab.edu.
37384110,Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria.,2023,"Mattheus, Michaela","Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.",None
37382981,[Multicenter experience of using Fortelyzin during staged reperfusion therapy of acute ischemic stroke in anterior circulation].,2023,"Sinutin, V N","Aspectus Pharma LLC, Razvilka, Russia.",None
37381988,Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial.,2023,"Carroll, Ian A; Marshall, Debra; Graybill, Christopher A; Huebler, Sophia P; Keuer, Thomas","ARCA biopharma, Westminster, CO (I.A.C., D.M., C.A.G., S.P.H., T.K., M.R.B.).; ARCA biopharma, Westminster, CO (I.A.C., D.M., C.A.G., S.P.H., T.K., M.R.B.).; ARCA biopharma, Westminster, CO (I.A.C., D.M., C.A.G., S.P.H., T.K., M.R.B.).; ARCA biopharma, Westminster, CO (I.A.C., D.M., C.A.G., S.P.H., T.K., M.R.B.).; ARCA biopharma, Westminster, CO (I.A.C., D.M., C.A.G., S.P.H., T.K., M.R.B.).",None
37381768,"Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open-label study.",2023,"Wang, Yi; Miyakawa, Kou; Sugiura, Kenkichi; Ishida, Kazuyuki","Quantitative Clinical Pharmacology, Takeda Development Center Americas Inc., Cambridge, Massachusetts, USA.; Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.; Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.; Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.",None
37380301,Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results.,2023/Jul/04,"Lavrovsky, Yan","R-Pharm Overseas Inc, La Jolla, California, USA.",v.myachikova@gmail.com.
37379657,"Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity.",2023,"Ahmadi, Tahamtan; Sasser, A Kate","Genmab Inc, Princeton, NJ, USA.; Genmab Inc, Princeton, NJ, USA.",ebj@genmab.com.
37377397,Empty vein ablation innovative technique for chronic venous disease treatment: proof of concept and ex-vivo analysis.,2023,"Addis, Alessandro","CRABCC, Biotechnology Research Center for Cardiothoracic Applications, Rivolta D'Adda, Cremona, Italy.",daniele.bissacco@unimi.it.
37376792,Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling.,2023,"Dong, Jin; Prieto Garcia, Luna; Tang, Weifeng; Lundahl, Anna; Elebring, Marie; Ahlström, Christine; Vildhede, Anna; Någård, Mats","Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Drug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Drug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca, Gothenburg, Sweden.; Drug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca, Gothenburg, Sweden.; Drug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca, Gothenburg, Sweden.; Drug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.",None
37373223,Oxygen Nanocarriers for Improving Cardioplegic Solution Performance: Physico-Chemical Characterization.,2023/Jun/13,"Higashiyama, Takanobu","Hayashibara Co., Ltd., 675-1 Fujisaki, Naka-ku, Okayama 702-8006, Japan.",None
37373090,Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes.,2023/Jun/09,"Uckun, Fatih M; Qazi, Sanjive","Immuno-Oncology Program, Ares Pharmaceuticals, St. Paul, MN 55110, USA.; Immuno-Oncology Program, Ares Pharmaceuticals, St. Paul, MN 55110, USA.",None
37371118,"A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD.",2023/Jun/16,"Srivastava, Rai Ajit K","Integrated Pharma Solutions LLC, Boston, MA 02101-02117, USA.",None
37369234,The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.,2024,"Steurbaut, Stephane","Centre for Pharmaceutical Research, Research group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Jette, Belgium.",None
37367722,High Variation in Inner Retinal Reflectivity Predicts Poor Visual Outcome in Patients With Central Retinal Vein Occlusion: SCORE2 Report 21.,2023/Jun/01,"Oden, Neal L; VanVeldhuisen, Paul C","The Emmes Company, LLC, Rockville, MD, USA.; The Emmes Company, LLC, Rockville, MD, USA.",None
37358255,Bacteria-Derived Outer-Membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke Therapy.,2023,"Xue, Juan; Zhang, Suling","Shanghai OE Biotech Co., Ltd, Shanghai, 201114, P. R. China.; Shanghai OE Biotech Co., Ltd, Shanghai, 201114, P. R. China.",None
37357988,"Acyl coenzyme A binding protein (ACBP): An aging- and disease-relevant ""autophagy checkpoint"".",2023,"Madeo, Frank; Quesada, Victor","BioTechMed-Graz, Graz, Austria.; Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, Oviedo, Spain.",None
37357011,"Questionnaire survey of satisfaction with medication for five symptom domains of dementia with Lewy bodies among patients, their caregivers, and their attending physicians.",2023,"Toya, Shunji; Yamakage, Hajime","Medical Science, Sumitomo Pharma Co., Ltd., Tokyo, Japan.; Insight Clinical Development Group, 3H Medi Solution Inc., Toshima-ku, Tokyo, Japan.",None
37355760,The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.,2023,"Parli, Teresa; Feng, Shibao; Sterling, Lulu; Tseng, Leo; Hartsfield, Cynthia L; Agollah, Germaine D; Mansbach, Hank","89bio Inc., San Francisco, CA, USA.; 89bio Inc., San Francisco, CA, USA.; 89bio Inc., San Francisco, CA, USA.; 89bio Inc., San Francisco, CA, USA.; 89bio Inc., San Francisco, CA, USA.; 89bio Inc., San Francisco, CA, USA.; 89bio Inc., San Francisco, CA, USA.",dlbhattmd@post.harvard.edu.
37354546,Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.,2023/Jul/11,"Li, Na; Foody, JoAnne; Louie, Michael J","Esperion Therapeutics Inc, Ann Arbor, Michigan.; Esperion Therapeutics Inc, Ann Arbor, Michigan.; Esperion Therapeutics Inc, Ann Arbor, Michigan.",None
37354473,The Power and Promise of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in Heart Failure Management: National Consensus Statement.,2023,"Chatterjee, Nandini","Clinical Pharmacologist, Diabetes & Allergy-Asthma Therapeutics Specialty Clinic.",None
37354145,"Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF.",2023,"Adamsson Eryd, Samuel; Bodegård, Johan; Khordoc, Cindy; Zhang, Ruiqi","CVRM Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.; CVRM Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.; Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware, USA.; Medical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, London, United Kingdom.",gianluigi.savarese@ki.se.
37353066,Uncovering the molecular mechanisms of Fructus Choerospondiatis against coronary heart disease using network pharmacology analysis and experimental pharmacology.,2023/Aug/15,"Wang, Hongsen; Yan, Zhankuan","Jiangsu Yuanchuang Pharmaceutical Research and Development Co., Ltd, China.; Jiangsu Yuanchuang Pharmaceutical Research and Development Co., Ltd, China.",qinkm123@126.com.
37345657,Activated cGAS/STING signaling elicits endothelial cell senescence in early diabetic retinopathy.,2023/Jun/22,"Huang, Chao; Mitrousis, Nikolaos; Strassburger, Pamela; Widmer, Gabriella; Westenskow, Peter D; Feenstra, Derrick","Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.; Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.",None
37343623,Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.,2023,"Ponthieux, Anne","Novartis Pharma SAS, Rueil-Malmaison, Malmaison, France. Electronic address: anne.ponthieux@novartis.com.",anne.ponthieux@novartis.com.
37341914,Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective.,2023,"Gabb, Peter D","Health Economics and Outcomes Research Ltd., Cardiff, UK.",juanjose.garciasanchez@astrazeneca.com.
37341856,ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.,2023,"Sussell, Jesse; Lin, Chia-Wei; Ogale, Sarika","Evidence for Access, Genentech Inc., South San Francisco, CA, USA.; Evidence for Access, Genentech Inc., South San Francisco, CA, USA.; Evidence for Access, Genentech Inc., South San Francisco, CA, USA.",Vivek.Rudrapatna@ucsf.edu.
37341778,Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.,2023,"Chou, Takaaki; Yoshida, Takahiro; Mori, Ikuo","Niigata Kenshin Plaza, General Incorporated Foundation, Health Medicine Prevention Association, Niigata, Japan.; Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan.; Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan.",ken-suzuki@mtb.biglobe.ne.jp.
37341452,3D vascularised proximal tubules-on-a-multiplexed chip model for enhanced cell phenotypes.,2023/Jul/12,"Carracedo, Miguel; Hicks, Ryan; Althage, Magnus; Bak, Annette; Hansen, Pernille B L; Williams, Julie M","Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. juliem.williams@astrazeneca.com.; BioPharmaceuticals R&D Cell Therapy, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca, Gothenburg, Sweden.; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Pharmaceutical Sciences, R&D, AstraZeneca, Waltham, USA.; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. juliem.williams@astrazeneca.com.; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. juliem.williams@astrazeneca.com.",juliem.williams@astrazeneca.com.
37340026,Transcriptomics-driven drug repositioning for the treatment of diabetic foot ulcer.,2023/Jun/20,"Septama, Abdi Wira","Research Center for Pharmaceutical Ingredients and Traditional Medicine, National Research and Innovation Agency (BRIN), South Tangerang, Indonesia.",zaz@ums.edu.my.
37338893,Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial.,2023/Aug/01,"González, Victor M","Aptus Biotech, Madrid, Spain.",None
37338878,Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke.,2023/Jun/20,"Unverdorben, Martin","Global Specialty Medical Affairs, Daiichi Sankyo Inc, Basking Ridge, New Jersey.",None
37338713,On-treatment platelet reactivity through the thromboxane A,2023,"Karwatowska-Prokopczuk, Ewa; Li, Lu; Yang, Jun; Witztum, Joseph L; Tsimikas, Sotirios","Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.; Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.; Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.; Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.; Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA. stsimikas@health.ucsd.edu.",stsimikas@health.ucsd.edu.
37337866,Global blood pressure screening during the COVID-19 pandemic: results from the May Measurement Month 2021 campaign.,2023/Sep/01,"McCardle, Harsha","Khanda Ltd, London, United Kingdom.",None
37337357,Outcomes of patients with pre-existing disability managed by mobile stroke units: A sub-analysis of the BEST-MSU study.,2023,"Griffin, Laura","HCA Houston Healthcare, Houston, TX, USA.",None
37335828,Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium.,2023/Jun/20,"Matsumura, Ryosuke; Mochizuki, Shuichi; Shirai, Yuko","Pharmaceuticals and Medical Devices Agency, Tokyo, Japan (R.M., S.M., Y.S.).; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan (R.M., S.M., Y.S.).; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan (R.M., S.M., Y.S.).",None
37332054,Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings.,2023,"Zheng, Alison","Chinese Organization for Scleroderma, Chengdu City, Sichuan Province, China.",None
37331452,Salvianolic acids from Salvia miltiorrhiza Bunge and their anti-inflammatory effects through the activation of α7nAchR signaling.,2023/Dec/05,"Deng, Shuang-Bing; Liu, Yao-Qi","State Key Laboratory of Innovative Natural Medicine and TCM Injections, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Ganzhou, 341000, PR China.; State Key Laboratory of Innovative Natural Medicine and TCM Injections, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Ganzhou, 341000, PR China.",liujunshan@smu.edu.cn.
37331368,"Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.",2023/Jul/08,"Bharucha, David B; Plat, Francis; Shardonofsky, Silvia","Milestone Pharmaceuticals, Charlotte, NC, USA.; Milestone Pharmaceuticals, Charlotte, NC, USA.; Milestone Pharmaceuticals, Montréal, QC, Canada.",jcamm@sgul.ac.uk.
37330927,Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.,2023,"Isobe, Tomoyuki; Suganami, Hideki","Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Tokyo, Japan.; Data Science Center, Kowa Company, Ltd., Tokyo, Japan.",tanihara@pearl.ocn.ne.jp.
37328736,Effect of alirocumab on cataracts in patients with acute coronary syndromes.,2023/Jun/16,"Manvelian, Garen; Pordy, Robert","Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.",gabriel.steg@aphp.fr.
37328263,Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate.,2023/Jul/16,"Hinds, David R","Epidemiology & Real World Evidence, BioMarin Pharmaceutical Inc., Novato, CA.",None
37326421,Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.,2023/Jul/31,"Graham, Christine; Todtenkopf, Mark S; McDonnell, David; Simmons, Adam","Alkermes, Inc., Waltham, Massachusetts, USA.; Alkermes, Inc., Waltham, Massachusetts, USA.; Alkermes Pharma Ireland Ltd., Dublin, Ireland.; Alkermes, Inc., Waltham, Massachusetts, USA.",None
37323187,Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring ,2023,"Togashi, Akira","Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan.",None
37319107,A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis.,2023,"Chan, Gary; Kerkmann, Urs","Pfizer Inc, Groton, Connecticut, USA.; Pfizer Pharma GmbH, Berlin, Germany.",None
37318419,Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction.,2023,"Langkilde, Anna Maria; Bengtsson, Olof; Sjöstrand, Mikaela","Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",john.mcmurray@glasgow.ac.uk.
37318103,Hand grip strength in patients with advanced cancer: A prospective study.,2023,"Porthun, Jan; Weinländer, Pia; Lück, Laura C; Potthoff, Sophia K; Rösnick, Lukas; Fröhlich, Ann-Kathrin; Ramer, Luisa Valentina; Sonntag, Frederike","Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.",None
37316690,"Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome.",2023,"Paris, Maria; Cheng, Sue; Maes, Peter; Zhang, Wendy; Shi, Rebecca; Flower, Andrea; Picard, Hernan","Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.",pmease@philipmease.com.
37315111,Increased PDGFRB and NF-κB signaling caused by highly prevalent somatic mutations in intracranial aneurysms.,2023/Jun/14,"Nakaki, Ryo","Rhelixa Inc., Tokyo 104-0042, Japan.",None
37315065,"Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.",2023,"Anchoori, Vidyasagar; Poddatoori, Deepika; Chang, Yung-Nien","Up Therapeutics LLC, Frederick, MD, United States of America.; Up Therapeutics LLC, Frederick, MD, United States of America.; Up Therapeutics LLC, Frederick, MD, United States of America.",None
37314801,Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.,2023/Aug/01,"Bansilal, Sameer","US Medical Affairs, Bayer Corporation, Whippany, New Jersey.",None
37311732,"Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities.",2023,"Shin, Wonjung; Hompesch, Marcus; Byeon, JinHee; Kang, Seohyun; Choi, Jaehyuk","Hanmi Pharmaceutical Co., Ltd, Seoul, South Korea.; ProSciento Inc., San Diego, California, USA.; Hanmi Pharmaceutical Co., Ltd, Seoul, South Korea.; Hanmi Pharmaceutical Co., Ltd, Seoul, South Korea.; Hanmi Pharmaceutical Co., Ltd, Seoul, South Korea.",None
37311468,"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.",2023/Jul/29,"Li, Jiahui; Zhang, Jennie; Giuseppi, Ana Carolina; Pozharskaya, Veronika; Keeperman, Karen L; Rose, Shelonitda; Hayati, Sheida; Vodala, Sadanand; Prebet, Thomas","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",uwe.platzbecker@medizin.uni-leipzig.de.
37308786,Genome-wide association study of thoracic aortic aneurysm and dissection in the Million Veteran Program.,2023,"Klarin, Derek; Devineni, Poornima; Sendamarai, Anoop K; Karnam, Purushotham R; Tsao, Philip S; Pyarajan, Saiju","Veterans Affairs (VA) Palo Alto Healthcare System, Palo Alto, CA, USA. dklarin@stanford.edu.; Center for Data and Computational Sciences, VA Boston Healthcare System, Boston, MA, USA.; Center for Data and Computational Sciences, VA Boston Healthcare System, Boston, MA, USA.; Center for Data and Computational Sciences, VA Boston Healthcare System, Boston, MA, USA.; Veterans Affairs (VA) Palo Alto Healthcare System, Palo Alto, CA, USA.; Center for Data and Computational Sciences, VA Boston Healthcare System, Boston, MA, USA.",scott.damrauer@pennmedicine.upenn.edu.
37308218,Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.,2023,"Palac, Hannah; Dilley, Deanne; Liu, Jianzhong; Strengholt, Sander","AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.",RFleischmann@dfwra.com.
37306994,The Impact of Cataracts on the Measurement of Macular Choriocapillaris Flow Deficits Using Swept-Source OCT Angiography.,2023/Jun/01,"de Sisternes, Luis; Lewis, Warren H","Research and Development, Carl Zeiss Meditec, Inc., Dublin, CA, USA.; Bayside Photonics, Inc., Yellow Springs, OH, USA.",None
37306492,Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study.,2023,"Eschenfelder, Christoph C","Human Pharma Germany, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.",None
37305967,Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study.,2023/Oct/11,"Ben-Joseph, Rami H; Saad, Ragy; Black, Jed; Dabrowski, Elizabeth C; Taylor, Ben; Gallucci, Sophia","Jazz Pharmaceuticals, Palo Alto, CA, USA.; Jazz Pharmaceuticals, Palo Alto, CA, USA.; Jazz Pharmaceuticals, Palo Alto, CA, USA.; Aetion, Inc., New York, NY, USA.; Aetion, Inc., New York, NY, USA.; Aetion, Inc., New York, NY, USA.",None
37302348,COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.,2023,"Oligino, Eric; Flora, Daniel B","Cardio-Oncology, Hartford HealthCare Cancer, Hartford, CT, United States.; St. Elizabeth Healthcare, Edgewood, KY, United States.",anohria@bwh.harvard.edu.
37300760,Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.,2023,"Zhang, Haixin; Thomas, Ryan B; Cyr, Sonya L","Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",annie.zhang@sanofi.com.
37294244,Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status.,2023,"Petersson, Magnus; Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R and D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R and D, AstraZeneca, Gothenburg, Sweden.",ssolomon@bwh.harvard.edu.
37293139,Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF.,2023,"Misselwitz, Frank","Actimed Therapeutics, Berkshire, UK.",None
37289463,Accuracy of Artificial Intelligence in Estimating Best-Corrected Visual Acuity From Fundus Photographs in Eyes With Diabetic Macular Edema.,2023/Jul/01,"Moini, Hadi; Du, Weiming; Amer, Fouad; Chu, Karen; Vitti, Robert; Sepehrband, Farshid","Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.",None
37289366,"Clinical factors for predicting cardiovascular risk, need for renal replacement therapy, and mortality in patients with non-dialysis-dependent stage 3-5 chronic kidney disease from the Salford Kidney Study.",2023,"Filipa Alexandre, Ana; Stoelzel, Matthias; Kiran, Amit; Morga, Antonia","Astellas Pharma Europe B.V., Leiden, The Netherlands. anafalexandre@gmail.com.; Astellas Pharma Europe B.V., Leiden, The Netherlands.; Astellas Pharma Europe Limited, Addlestone, UK.; Astellas Pharma Europe Limited, Addlestone, UK.",anafalexandre@gmail.com.
37287398,Safety of intravenous lacosamide in hospitalized children and neonates.,2023,"Kaur, Moninder; Foskett, Nadia; Roebling, Robert; Stoltenberg, Meredin; Williams, Paulette; Yuen, Nancy","UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.; UCB Pharma, Monheim am Rhein, Germany.; UCB Pharma, Copenhagen, Denmark.; UCB Pharma, Raleigh, North Carolina, USA.; UCB Pharma, Raleigh, North Carolina, USA.",None
37286795,Real-time measurements of vascular permeability in the mouse eye using vitreous fluorophotometry.,2023/Jun/07,"Colé, Nadine; Thoele, Janina; Ullmer, Christoph; Foxton, Richard H","Ophthalmology Discovery, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Ophthalmology Discovery, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Ophthalmology Discovery, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Ophthalmology Discovery, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. richard.foxton@roche.com.",richard.foxton@roche.com.
37280022,Tolerability of bedtime diuretics: a prospective cohort analysis.,2023/Jun/06,"Bakal, Jeffrey; Yeung, Jack M S","Provincial Research Data Services, Alberta Health Services, Edmonton, Alberta, Canada.; Provincial Research Data Services, Alberta Health Services, Edmonton, Alberta, Canada.",scott.garrison@ualberta.ca.
37279840,Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation.,2023,"Kar, Saibal; Christen, Thomas; Allocco, Dominic J","Los Robles Medical Center, Thousand Oaks, CA. Electronic address: Saibal.Kar@HCAHealthcare.com.; Boston Scientific Corporation, Marlborough, MA.; Boston Scientific Corporation, Marlborough, MA.",Saibal.Kar@HCAHealthcare.com.
37278412,Simulation of long-term impact of intravitreal anti-VEGF therapy on patients with severe non-proliferative diabetic retinopathy.,2023,"Ponomareva, Ekaterina; Chauhan, Ankita; Rao, Rohini; Sherman, Steven","Axtria Inc, Berkeley Heights, New Jersey, USA.; Axtria Inc, Berkeley Heights, New Jersey, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.",ndquan@stanford.edu.
37277454,Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.,2023,"Lheureux, Stephanie; O'Connell, Joseph; Schonhoft, Joseph D; Wainszelbaum, Marisa; Fretland, Adrian J; Manley, Peter; Xu, Yi; Ulanet, Danielle; Rimkunas, Victoria; Zinda, Mike; Koehler, Maria; Silverman, Ian M","Princess Margaret Cancer Centre, Toronto, ON, Canada.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.",tyap@mdanderson.org.
37277084,Mailuoning oral liquid attenuates convalescent cerebral ischemia by inhibiting AMPK/mTOR-associated apoptosis and promoting CREB/BDNF-mediated neuroprotection.,2023/Dec/05,"Zhang, Hui","Jinling Pharmaceutical Co., Ltd., Nanjing, 210009, China.",nhtan@cpu.edu.cn.
37274265,Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage ,2023,"Szymczak, Sylwia; Szpurka, Anna M; Chao, Bo H","Loxo@Lilly, Eli Lilly and Company, Warsaw, Poland.; Loxo@Lilly, Eli Lilly and Company, Indianapolis, IN, United States.; Loxo@Lilly, Eli Lilly and Company, New York, NY, United States.",Loxo@Lilly
37273234,Genome-wide Association Study for AKI.,2023/Jul/01,"Palevsky, Paul M","Kidney Medicine Section, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.",None
37269177,Development and characterization of canine-specific computational models to predict pulsatile arterial hemodynamics and ventricular-arterial coupling.,2023,"Hotek, Julia C; Detwiler, Theodore J; Regan, Hillary K; Regan, Christopher P","Preclinical Development (PCD), Merck & Co., Inc., West Point, Pennsylvania, USA.; Preclinical Development (PCD), Merck & Co., Inc., West Point, Pennsylvania, USA.; Preclinical Development (PCD), Merck & Co., Inc., West Point, Pennsylvania, USA.; Preclinical Development (PCD), Merck & Co., Inc., West Point, Pennsylvania, USA.",None
37268257,Multi-omics approach for identification of molecular alterations of QiShenYiQi dripping pills in heart failure with preserved ejection fraction.,2023/Oct/28,"Guo, Kaimin; Li, Xiaoqiang; Wang, Wenjia; Hu, Yunhui","Cloudphar Pharmaceuticals Co., Ltd, Shenzhen, 518000, China.; Cloudphar Pharmaceuticals Co., Ltd, Shenzhen, 518000, China.; Cloudphar Pharmaceuticals Co., Ltd, Shenzhen, 518000, China.; Cloudphar Pharmaceuticals Co., Ltd, Shenzhen, 518000, China. Electronic address: tsl-huyunhui@tasly.com.",guanwei.fan@tjutcm.edu.cn.
37267479,Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis.,2023/Aug/01,"Pavo, Imre; Haupt, Axel; Duffin, Kevin L; Yang, Zhengyu; Wiese, Russell J; Wilson, Jonathan M; Hemmingway, Andrea","Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.",None
37266425,Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.,2023,"Brownstein, Michael J","Azevan Pharmaceuticals, Bethlehem, PA, United States.",None
37265696,"Telemedicine for diabetes management during COVID-19: what we have learnt, what and how to implement.",2023,"Rosta, Laszlo","Primary Healthcare Centre, Felsorajk, Hungary.",None
37265385,Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction: A randomized non-inferiority trial.,2024/Feb/05,"Yang, Qin","Guangzhou Recomgen Biotech Co., Ltd, Guangzhou, Guangdong 510530, China.",None
37263777,Inhibition of microRNA-33b in humanized mice ameliorates nonalcoholic steatohepatitis.,2023,"Kotera, Jun; Oka, Kozo; Fujita, Ryo; Sasaki, Takashi; Takemiya, Akihiro","Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, Fujisawa-shi, Japan.; Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, Fujisawa-shi, Japan.; Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, Fujisawa-shi, Japan.; Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, Fujisawa-shi, Japan.; Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, Fujisawa-shi, Japan.",kohono@kuhp.kyoto-u.ac.jp.
37262981,Assessment of thrombectomy procedure difficulty by neurointerventionalists based on vessel geometry parameters from carotid artery 3D reconstructions.,2023,"Carniato, Sarena","Stryker Corporation, Kalamazoo, MI, USA.",matthew.gounis@umassmed.edu.
37259866,New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing.,2023,"Khera, Amit V; Kathiresan, Sekar; Harms, Matthew J; Oakes, Benjamin L","Verve Therapeutics, Boston, MA (A.V.K., S.K.).; Verve Therapeutics, Boston, MA (A.V.K., S.K.).; Scribe Therapeutics, Alameda, CA (M.J.H., B.L.O.).; Scribe Therapeutics, Alameda, CA (M.J.H., B.L.O.).",None
37258625,"Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study.",2023,"Yan, Jie; Xu, Wen-Jie; Li, Ying; Li, Jin-Feng; He, Shi-Ying","Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, China.; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, China.; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, China.; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, China.; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, China.",jiguangwang@rjh.com.cn.
37256880,Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan.,2023,"Inoue, Kei; Ichikawa, Daisuke","SUSMED, Inc, Tokyo, Japan.; SUSMED, Inc, Tokyo, Japan.",None
37254075,Identification of urgent gaps in public and policymaker knowledge of heart failure: Results of a global survey.,2023/May/30,"Pohja-Hutchison, Paula","AstraZeneca, Global Corporate Affairs, CB2 8PA, Cambridge, UK.",butlzih@gmail.com.
37252442,"Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11.",2023,"Conde, Lorena Garcia; Han, Jackie","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.",None
37248298,Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation.,2023,"Yen, Katharine; Su, Michael; Schenkein, David","Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.",birgit.geoerger@gustaveroussy.fr.
37237109,Author Correction: The power of genetic diversity in genome-wide association studies of lipids.,2023,"Baras, Aris; Ho, Yuk-Lam; Cho, Kelly; O'Donnell, Christopher J; Gaziano, John M","Regeneron Pharmaceuticals, Tarrytown, NY, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.",cristen@umich.edu.
37235964,Fucoxanthin alleviated atherosclerosis by regulating PI3K/AKT and TLR4/NFκB mediated pyroptosis in endothelial cells.,2023,"Wang, Lina; Han, Danxiang","Beijing Noahpharm Co., Ltd, Beijing 100000, China.; Demeter Biotech (Zhuhai) Co. Ltd., Zhuhai 519075, China.",linxu2018@whu.edu.cn.
39044797,"Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditis.",2023,"Fang, Fang; Zou, Liangxing; Paolini, John F","Kiniksa Pharmaceuticals Corp., Lexington, MA, USA (at time of study).; Kiniksa Pharmaceuticals Corp., Lexington, MA, USA (at time of study).; Kiniksa Pharmaceuticals Corp., Lexington, MA, USA (at time of study).",None
37232450,Bioassay-guided identification of antithrombotic compounds from ,2024,"García-Sosa, Karlina; Peña Rodríguez, Luis Manuel","Organic Chemistry Group, Biotechnology Unit, Yucatan Scientific Research Center, Merida, Yucatan, Mexico.; Organic Chemistry Group, Biotechnology Unit, Yucatan Scientific Research Center, Merida, Yucatan, Mexico.",None
37231835,High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders.,2023,"Reddy, Guru; Jermasek, Douglas; Gupta, Pramod","Preclinical Research and Development, Unicycive Therapeutics, Inc., Los Altos, California, USA.; Corporate Strategy, Unicycive Therapeutics, Inc., Los Altos, California, USA.; Pharmaceutical and Business Operations, Unicycive Therapeutics, Inc., Los Altos, California, USA.",None
37231821,Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.,2023,"Agiro, Abiy; Brahmbhatt, Yasmin Ghanshyam; Oluwatosin, Yemmie; Schilling, Craig G","AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USA.; AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USA.; AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USA.; AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USA.",None
37230521,"Evaluation of the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with hyperkalaemia: protocol for the multicentre, randomised, controlled DIALIZE-Outcomes study.",2023/May/25,"Al-Shurbaji, Ayman; Lisovskaja, Vera; Sekar, Priya; Katona, Brian; Guzman, Nicolas; Herzog, Charles","BioPharmaceuticals R&D, AstraZeneca Sweden, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca Sweden, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USA.; BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USA.; BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USA.; Division of Cardiology, Hennepin Healthcare, Minneapolis, Minnesota, USA.",sfishbane@northwell.edu.
37230428,"Mapping the characteristics, methodological quality and standards of reporting of network meta-analyses on antithrombotic therapies: An overview.",2023/Sep/01,"Mainka, Felipe Fernando; Tonin, Fernanda Stumpf","Pharmaceutical Sciences Postgraduate Programme, Universidade Federal do Paraná, Curitiba, Brazil. Electronic address: felipemainka@ufpr.br.; Pharmaceutical Sciences Postgraduate Programme, Universidade Federal do Paraná, Curitiba, Brazil; Health & Technology Research Centre, Escola Superior de Tecnologia da Saúde (H&TRC-ESTeSL), Instituto Politécnico de Lisboa, Lisbon, Portugal. Electronic address: fer_stumpf_tonin@hotmail.com.",pontarolo@ufpr.br.
37229273,Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice.,2023,"Ranjekar, Prabhakar","Innovation Biologicals Pvt., Ltd., Pune, Maharashtra, India.",None
37227456,[The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].,2023,"Despang, Patrick","Medizinische Abteilung, APONTIS PHARMA GmbH & Co. KG, Monheim, Deutschland.",wolfram.doehner@bih-charite.de.
37226448,"Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.",2023,"Petersson, Magnus; Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R and D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R and D, AstraZeneca, Gothenburg, Sweden.",ssolomon@bwh.harvard.edu.
37226245,Cardiovascular complications of diabetes: role of non-coding RNAs in the crosstalk between immune and cardiovascular systems.,2023/May/24,"Jusic, Amela","HAYA Therapeutics SA, Lausanne, Switzerland.",fabio.martelli@grupposandonato.it.
37223825,In-Hospital Outcomes of Heart Failure Patients with Valvular Heart Disease: Insights from Real-World Claims Data.,2023,"Iwasaki, Kosuke; Takeshima, Tomomi; Murphy, Shannon M E","Milliman Inc., Tokyo, Japan.; Milliman Inc., Tokyo, Japan.; Edwards Lifesciences Corporation, Irvine, CA, USA.",None
37220172,"Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.",2023/Jun/25,"Zaozerska, Natalia; Wilderäng, Ulrica; Bengtsson, Olof","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
37220093,Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.,2023/Aug/14,"Petersson, Magnus; Maria Langkilde, Anna","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
37217263,"Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study.",2023/May/22,"Arnold, Matthew; Barone, Salvatore; Peach, Emily; Wittbrodt, Eric; Chen, Hungta; Järbrink, Krister","Real World Evidence Data & Analytics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.; Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Cardiovascular, Renal and Metabolism Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.; Medical/Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.; Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.",ntangri@sogh.mb.ca.
37217188,NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial.,2023/Aug/14,"Edwards, Christopher; Barros, Marianela; Novosadova, Maria; Takagi, Koji","Momentum Research Inc, Durham, NC, USA.; Momentum Research Inc, Durham, NC, USA.; Momentum Research Inc, Durham, NC, USA.; Momentum Research Inc, Durham, NC, USA.",None
37212758,Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.,2023/Jul/04,"Ward, Jonathan H; Sarwat, Samiha; Williamson, Kristin M","Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.",robert.mentz@duke.edu.
37212191,Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US.,2023/Aug/01,"Quarta, C Cristina","Alexion Pharmaceuticals Inc, Boston, Massachusetts.",None
37211958,"Physician knowledge, attitudes, and practices regarding physical activity restrictions in pediatric hemodialysis patients.",2023,"Chand, Deepa H","Novartis Pharmaceuticals, Bannockburn, Illinois, USA.",None
37211686,Single-Cell RNA Sequencing and Spatial Transcriptomics Reveal Pathogenesis of Meningeal Lymphatic Dysfunction after Experimental Subarachnoid Hemorrhage.,2023,"Wang, Zelin; Lu, Jianan","Bioinformatics, Shuzhi Biotech LLC, Guangzhou, 510805, China.; Clinical Research Center for Neurological Diseases of Zhejiang Province, Hangzhou, 310003, China.",None
37210743,Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.,2023/Aug/14,"Ward, Jonathan H; Williamson, Kristin M; Lefkowitz, Martin","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",None
37210742,Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.,2023/Aug/14,"McDermott, James J; Sartipy, Peter","Biopharmaceuticals, Medical Affairs, AstraZeneca, Wilmington, DE 19803, USA.; Cardiovascular, Renal and Metabolism, AstraZeneca, BioPharmaceuticals R&D, Gothenburg 431 83, Sweden.",None
37208998,Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial.,2023/Jul/01,"Langkilde, Anna Maria; Bengtsson, Olof; Petersson, Magnus","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.",None
37204675,Cost-Effectiveness and Budget Impact of a Novel Antithrombotic Drug Removal System to Reduce Bleeding Risk in Patients on Preoperative Ticagrelor Undergoing Cardiac Surgery.,2023,"Zhang, Jingwei; Lee, Victoria; Deliargyris, Efthymios N","CytoSorbents Corporation, Princeton, NJ, USA.; CytoSorbents Corporation, Princeton, NJ, USA.; CytoSorbents Corporation, Princeton, NJ, USA.",padula@usc.edu.
37201662,"Integrating UPLC-Q-Exactive Orbitrap/MS, network pharmacology and experimental validation to reveal the potential mechanism of Tibetan medicine Rhodiola granules in improving myocardial ischemia-reperfusion injury.",2023/Oct/05,"Ren, Dongsheng; Li, Yuying; Mi, Jiao; Zhang, Fengming","Tibet Rhodiola Pharmaceutical Holding Co. Ltd, Lasa, China.; Tibet Rhodiola Pharmaceutical Holding Co. Ltd, Lasa, China.; Tibet Rhodiola Pharmaceutical Holding Co. Ltd, Lasa, China.; Tibet Rhodiola Pharmaceutical Holding Co. Ltd, Lasa, China.",winter9091@163.com.
37199158,Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.,2023,"Iwata, Tomoko","Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany (T.I.).",None
37193692,A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides.,2023/May/16,"Blank, Jack; Ahfeldt, Tim","Prime Medicine, Inc, Cambridge, MA, USA.; Recursion Pharmaceuticals, Salt Lake City, UT, USA.",britz@ucla.edu.
37191845,The Profile of Early Sedation Depth and Clinical Outcomes of Mechanically Ventilated Patients in Korea.,2023/May/15,"Gil, Ha-Yeong","Medical Research Project Team, IM Medical, Pfizer Korea Pharmaceuticals Limited Company, Seoul, Korea.",cmlim@amc.seoul.kr.
37187238,The Societal Impact of Inclisiran in England: Evidence From a Population Health Approach.,2023,"Gerritzen, Tim; Durand, Adeline","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals, London, England, UK.",maike.schmitt@wifor.com.
37186398,Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management.,2023,"Amer, Karim; Purcell, Simon; Tan, Susan","Pfizer Ltd., London, UK.; Pfizer Ltd., London, UK.; Envision Pharma Group, Sydney, Australia.",None
37185641,EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies.,2023/Apr/26,"Nordon, Clementine; Rhodes, Kirsty; Marshall, Jonathan; Ouwens, Mario; Müllerová, Hana","Medical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK nordon.clementine@gmail.com.; Medical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Medical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Medical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Medical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.",nordon.clementine@gmail.com.
37185136,"Preclinical evaluation of ZL006-05, a new antistroke drug with fast-onset antidepressant and anxiolytic effects.",2023/Dec/29,"Hua, Yao; Ren, Jian","NeuroDawn Pharmaceutical Co., Ltd, Nanjing, China.; NeuroDawn Pharmaceutical Co., Ltd, Nanjing, China.",dyzhu@njmu.edu.cn
37184839,Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers: A Phase 3 Randomized Clinical Trial.,2023/May/01,"Kulkarni, Sudhir A; Deshpande, Supreet K","NovaLead Pharma, Pvt Ltd, Pune, India.; NovaLead Pharma, Pvt Ltd, Pune, India.",None
37183836,Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia.,2023,"Caicedo, J; Nieto, N; Bullano, M; Schultz, B G","US Medical Affairs, Takeda Pharmaceuticals USA Inc, Lexington, MA, USA.; US Medical Affairs, Takeda Pharmaceuticals USA Inc, Lexington, MA, USA.; US Medical Affairs, Takeda Pharmaceuticals USA Inc, Lexington, MA, USA.; US Medical Affairs, Takeda Pharmaceuticals USA Inc, Lexington, MA, USA.",None
37180506,IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.,2023,"Bieler, Stewart; He, Ping; Inrig, Jula; Komers, Radko; Mercer, Alex; Rote, William","Travere Therapeutics Inc., San Diego, California, USA.; Travere Therapeutics Inc., San Diego, California, USA.; Travere Therapeutics Inc., San Diego, California, USA.; Travere Therapeutics Inc., San Diego, California, USA.; JAMCO Pharma Consulting, Stockholm, Sweden.; Travere Therapeutics Inc., San Diego, California, USA.",None
37180505,Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.,2023,"Meier, Matthias; Kollins, Dmitrij; Papachristofi, Olympia; Charney, Alan","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.",None
37179817,The Potential of Single Nucleotide Polymorphisms (SNPs) as Biomarkers and Their Association with the Increased Risk of Coronary Heart Disease: A Systematic Review.,2023,"Barliana, Melisa Intan","Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, West Java, Indonesia.",None
37178804,Rhodiola wallichiana var.cholaensis protects against myocardial ischemia-reperfusion injury by attenuating oxidative stress-mediated apoptosis via enhancing Nrf2 signaling.,2023/Aug/01,"Li, Xu; Wang, Xin; Xiao, Wei","Jiangsu Kanion Parmaceutical CO. LTD., Lianyungang 222047, China.; State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Lianyungang 222001, Jiangsu, China.; Jiangsu Kanion Parmaceutical CO. LTD., Lianyungang 222047, China.; State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Lianyungang 222001, Jiangsu, China.; Jiangsu Kanion Parmaceutical CO. LTD., Lianyungang 222047, China.; State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Lianyungang 222001, Jiangsu, China. Electronic address: xw_kanion@163.com.",xw_kanion@163.com.
37178575,Transient Receptor Potential Vanilloid (TRPV4) channel inhibition: A novel promising approach for the treatment of lung diseases.,2023,"Goyary, Danswrang; Chattopadhyay, Pronobesh","Division of Pharmaceutical Technology, Defence Research Laboratory, Tezpur, Assam 784001, India.; Division of Pharmaceutical Technology, Defence Research Laboratory, Tezpur, Assam 784001, India. Electronic address: chattopadhyay.drl@gmail.com.",chattopadhyay.drl@gmail.com.
37173636,The effect of catheter-based sham renal denervation in hypertension: systematic review and meta-analysis.,2023/May/12,"David, Cláudio; Costa, João; Ferreira, Joaquim J; Caldeira, Daniel","Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. dgcaldeira@hotmail.com.",dgcaldeira@hotmail.com.
37171998,"Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction.",2023/Jul/05,"Bloomfield, Dan; Khder, Yasser","Anthos Therapeutics, Cambridge, MA, USA.; Anthos Therapeutics, Cambridge, MA, USA.",None
37170767,Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension.,2023,"Wunder, Frank; Stasch, Johannes-Peter; Knorr, Andreas; Mondritzki, Thomas; Brockschnieder, Damian; Becker-Pelster, Eva-Maria; Sandner, Peter; Tinel, Hanna; Redlich, Gorden; Hartung, Ingo V; Vakalopoulos, Alexandros; Follmann, Markus","Lead Identification & Characterization, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Pharmacokinetics, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Synthetic Modalities, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Synthetic Modalities, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Synthetic Modalities, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.",None
37170244,Bradykinin B,2023/May/11,"Mambungu, Cindy A; Clagett, Adrienne R; Ikizler, T Alp","Veterans Administration Tennessee Valley Healthcare System, Nashville, TN, USA.; Veterans Administration Tennessee Valley Healthcare System, Nashville, TN, USA.; Veterans Administration Tennessee Valley Healthcare System, Nashville, TN, USA.",jorge.gamboa@vanderbilt.edu.
37165705,Recognizing early signs in the translational phase is essential for drug development in cardiovascular medicine.,2023,"Pollesello, Piero","Content and Communications Function, Orion Pharma, Espoo, Finland.",None
37164523,Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.,2023/May/16,"Iwata, Tomoko","Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.",Javed.Butler@bswhealth.org.
37164146,Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry.,2023,"Gamble, Cory L; Hamersky, Carol; Rajpura, Jigar","Novo Nordisk Inc., Plainsboro, NJ.; Novo Nordisk Inc., Plainsboro, NJ.; Novo Nordisk Inc., Plainsboro, NJ.",sva1024@yahoo.com.
37163635,Baxdrostat for Treatment-Resistant Hypertension. Reply.,2023/May/11,"Freeman, Mason W; Halvorsen, Yuan-Di","CinCor Pharma, Boston, MA.; CinCor Pharma, Boston, MA.",morris.brown@qmul.ac.uk.
37163358,"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study.",2023/Jul/25,"Li, Chuang","Amgen Inc, Thousand Oaks, CA.",None
37161694,A cyanoacrylate/triethyl citrate/nanosilica-based closure glue with wet-adhesion capability for treatment of superficial varicose veins.,2023/May/24,"Tian, Xia; Wang, Zhanguang; Liang, Yonghan; Wang, Wei","Venaend(Beijing) Medical Technology co., LTD, 3 Yongchangbei road, 100176, China. 450853873@qq.com.; Venaend(Beijing) Medical Technology co., LTD, 3 Yongchangbei road, 100176, China. 450853873@qq.com.; Venaend(Beijing) Medical Technology co., LTD, 3 Yongchangbei road, 100176, China. 450853873@qq.com.; Venaend(Beijing) Medical Technology co., LTD, 3 Yongchangbei road, 100176, China. 450853873@qq.com.",liyunlanrr@163.com.
37159983,High-throughput quantitation of serological dimethylarginines by LC/MS/MS: Potential cardiovascular biomarkers for rheumatoid arthritis.,2023/Aug/05,"Huang, Qianyang; Jia, Fujian; Pu, Chunchao; Ma, Dandan; Xu, Lei; Zhang, Hua; Liu, Xin; Liu, Kang","Shenzhen Kanghua Juntai Biotech Co. Ltd., B 215, Unit No.7, Shahe Rd W, Nanshan, Shenzhen, Guangdong Province 518063, China.; Shenzhen Kanghua Juntai Biotech Co. Ltd., B 215, Unit No.7, Shahe Rd W, Nanshan, Shenzhen, Guangdong Province 518063, China.; Shenzhen Kanghua Juntai Biotech Co. Ltd., B 215, Unit No.7, Shahe Rd W, Nanshan, Shenzhen, Guangdong Province 518063, China.; Shenzhen Kanghua Juntai Biotech Co. Ltd., B 215, Unit No.7, Shahe Rd W, Nanshan, Shenzhen, Guangdong Province 518063, China.; Shenzhen Kanghua Juntai Biotech Co. Ltd., B 215, Unit No.7, Shahe Rd W, Nanshan, Shenzhen, Guangdong Province 518063, China.; Shenzhen Kanghua Juntai Biotech Co. Ltd., B 215, Unit No.7, Shahe Rd W, Nanshan, Shenzhen, Guangdong Province 518063, China.; Shenzhen Kanghua Juntai Biotech Co. Ltd., B 215, Unit No.7, Shahe Rd W, Nanshan, Shenzhen, Guangdong Province 518063, China. Electronic address: xin_liu@kanghuajuntai.com.; Shenzhen Kanghua Juntai Biotech Co. Ltd., B 215, Unit No.7, Shahe Rd W, Nanshan, Shenzhen, Guangdong Province 518063, China. Electronic address: kellen0101@live.com.",kellen0101@live.com.
37157782,Efficacy and safety of bromelain: A systematic review and meta-analysis.,2023,"Sunsandee, Niti","The Government Pharmaceutical Organization, Bangkok, Thailand.",None
37156863,Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion.,2023,"Moini, Hadi; Gibson, Andrea","Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",ddhoot@yahoo.com.
37155355,Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation.,2023/Jul/01,"Chen, Yan Q; Qian, Yue-Wei; Konrad, Robert J","Lilly Research Laboratories, Eli Lilly and Company, 893 Delaware St, Indianapolis, IN 46225, USA.; Lilly Research Laboratories, Eli Lilly and Company, 893 Delaware St, Indianapolis, IN 46225, USA.; Lilly Research Laboratories, Eli Lilly and Company, 893 Delaware St, Indianapolis, IN 46225, USA.",None
37153730,Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy.,2023,"Seetharam, Raviraja N; Muttigi, Manjunatha S","Centre for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, 576104, India.; Centre for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, 576104, India.",None
37150579,American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update.,2023,"Christofides, Elena A","Endocrinology Associates, Inc., Columbus, Ohio.",None
37147690,Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.,2023/May/05,"Kroll, Stew; Greenfeld, Chuck R; Hodges, Tony","La Jolla Pharmaceutical Company, Waltham, MA, USA.; La Jolla Pharmaceutical Company, Waltham, MA, USA.; La Jolla Pharmaceutical Company, Waltham, MA, USA.",JChow@mfa.gwu.edu.
37140727,"Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study.",2023,"Petrone, Marcella; Yang, Ye; Hoang, Thuong; Hazlett, Sheila; Hansen, Lars; Flor, Armando","Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, UK.; Early Biometrics and Statistical Innovation, Data Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Jazz Pharmaceuticals, Cambridge, UK.; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. armando.flor@astrazeneca.com.",armando.flor@astrazeneca.com.
37140510,Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF.,2023,"Michaëlsson, Erik; Lagerström-Fermér, Maria; Gabrielsen, Anders; Garkaviy, Pavlo","Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",Carolyn.lam@duke-nus.edu.sg.
37137910,Identification of biomarkers for glycaemic deterioration in type 2 diabetes.,2023/May/03,"Efanov, Alexander; Duffin, Kevin; Syed, Samreen K; Shaw, Janice L; Cabrera, Over","Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, US.; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, US.; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, US.; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, US.; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, US.",g.rutter@imperial.ac.uk.
37137660,"Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.",2023,"Blaustein, Robert O","Merck and Co, Inc, Kenilworth, New Jersey, USA.",paul.armstrong@ualberta.ca.
37137641,Disruption in Blood Pressure Control With the COVID-19 Pandemic: The PCORnet Blood Pressure Control Laboratory.,2023,"Todd, Jonathan V","OCHIN Inc, Portland, OR.",chamberlain.alanna@mayo.edu.
37137588,"Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes.",2023/May/09,"Hu, Xingdi; Cristino, Joaquim Rosado; Browne, Auris","Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.",pnatarajan@mgh.harvard.edu.
37137586,1-Year Outcomes of Transcatheter Tricuspid Valve Repair.,2023/May/09,"Hermiller, James; Mitchel, Lucas","St Vincent Heart Center of Indiana, Indianapolis, Indiana, USA.; St Vincent Heart Center of Indiana, Indianapolis, Indiana, USA.",skodali@columbia.edu.
37137553,BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.,2023,"Nesheiwat, Tonia; Pacaud, Lida","Legend Biotech USA Inc, Piscataway, New Jersey, USA.; Legend Biotech USA Inc, Piscataway, New Jersey, USA.",sraghu2@emory.edu.
37137527,Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial.,2023,"Nordahl Christensen, Helene; Harty, Brian J; Mitchell, Julie; Soule, Benjamin P; Zacherle, Emily; Cziraky, Mark; Willey, Vincent J","Clinical Development & Outcomes Research, Novo Nordisk Inc, Plainsboro, New Jersey, USA.; Clinical Research - Biostatistics, HealthCore, Inc, Watertown, Massachusetts, USA.; Commercial Clinical Operations, Anthem Inc, Milwaukee, Wisconsin, USA.; Clinical Development & Outcomes Research, Novo Nordisk Inc, Plainsboro, New Jersey, USA.; Clinical Development & Outcomes Research, Novo Nordisk Inc, Plainsboro, New Jersey, USA.; Scientific Affairs, HealthCore Inc, Wilmington, Delaware, USA.; Scientific Affairs, HealthCore Inc, Wilmington, Delaware, USA vwilley@healthcore.com.",vwilley@healthcore.com.
37133647,Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study.,2023,"Peach, Emily J; Franzén, Stefan; Barone, Salvatore","Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Medical & Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.; Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.",ntangri@sogh.mb.ca.
37131694,Single-cell and spatial transcriptomics identify a macrophage population associated with skeletal muscle fibrosis.,2023/Apr/18,"Golann, David R; Su, Qi; Stec, Michael","Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",None
37130434,BETTER BASELINE VISION LEADS TO BETTER OUTCOMES AFTER THE 0.19-mg FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN DIABETIC MACULAR EDEMA.,2023/Aug/01,"Cutino, Antonio; Coughlin, Brandon; Kasper, Jonathan","Alimera Sciences, Inc, Alpharetta, Georgia.; Alimera Sciences, Inc, Alpharetta, Georgia.; Alimera Sciences, Inc, Alpharetta, Georgia.",None
37130317,"The Bidirectional Association of Chronic Kidney Disease, Type 2 Diabetes, Atherosclerotic Cardiovascular Disease, and Heart Failure: The Cardio-Renal-Metabolic Syndrome.",2023,"Chatterjee, Satabdi","Health Economics and Outcomes Research, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.",None
37125529,Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial.,2023,"Prescott, Margaret F","Novartis Pharmaceutical Corporation, East Hanover, NJ (M.F.P.).",None
37121662,Burn wound conversion: clinical implications for the treatment of severe burns.,2023/May/01,"Asuku, Malachy","Mallinckrodt Pharmaceuticals, Hampton, NJ, US.",None
37121256,Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States.,2023,"Fonseca, Ana F; Byrne, Hannah; Laguna, Andres; Itani, Taha; Studer, Rachel; Ferber, Philippe","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Dublin, Ireland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",None
37120724,Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.,2023/Jul/17,"Thomas, Ryan B","Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.",None
37116789,Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome.,2023,"Pordy, Robert","Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.",gabriel.steg@aphp.fr.
37116641,Clinical and Echocardiographic Diversity Associated With Physical Fitness in the Project Baseline Health Study: Implications for Heart Failure Staging.,2023,"Mega, Jessica L","Verily Inc., South San Francisco, CA, USA.",nicholas.cauwenberghs@kuleuven.be.
37115488,Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease.,2023,"Volkl, Albert A; Moore, Kenneth Todd","Janssen Pharmaceuticals, Inc, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA. avolkl@its.jnj.com.; Janssen Pharmaceuticals, Inc, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA.",avolkl@its.jnj.com.
37108643,Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats.,2023/Apr/19,"Batta, Rohit; Salvail, Dan; Raud, Johan","Vicore Pharma AB, 11127 Stockholm, Sweden.; IPS Therapeutique Inc., Sherbrooke, QC J1L 2T9, Canada.; Vicore Pharma AB, 11127 Stockholm, Sweden.",None
37102226,The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.,2023/Sep/29,"Veenit, Vandana; Ahlström, Christine; Greasley, Peter J; van Zuydam, Natalie; Hansen, Pernille B L; Menzies, Robert I","Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Biostatistics Sweden, Data Science and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
37101608,Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada.,2023,"Charron, Jean-Nicolas","PeriPharm Inc., Montreal, QC, Canada.",None
37101398,Sex differences in the generalizability of randomized clinical trials in heart failure with reduced ejection fraction.,2023,"Suzart-Woischnik, Kiliana; Dyszynski, Tomasz; Herrera, Ronald; Waechter, Sandra; Fatoba, Samuel; Cronin, Maureen","Medical Affairs & Pharmacovigilance, Berlin, Germany.; Medical Affairs & Pharmacovigilance, Berlin, Germany.; Medical Affairs & Pharmacovigilance, Berlin, Germany.; Vifor Pharma Ltd, Glattbrugg, Switzerland.; Medical Affairs & Pharmacovigilance, Berlin, Germany.; Cronin Pharma Consulting, Lucerne, Switzerland.",None
37100955,Apoptotic cell death in disease-Current understanding of the NCCD 2023.,2023,"Haupt, Ygal","VITTAIL Ltd, Melbourne, VIC, Australia.",deadoc80@gmail.com.
37100536,"Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes.",2023,"Chen, Cathy","Cardiovascular, Metabolic and Renal Disease Therapeutic Area, Global Clinical Development, Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, USA.",ssolomon@bwh.harvard.edu.
37100486,Health Status and Clinical Outcomes in Older Adults With Chronic Coronary Disease: The ISCHEMIA Trial.,2023/May/02,"Boden, William E","Veteran Affairs, New England Healthcare System, Boston, Massachusetts, USA.",dannguyen1@saintlukeskc.org.
37099883,Development and validation of LC-MS/MS methods for the determination of EVT201 and its five metabolites in human urine: Application to a mass balance study.,2023/May/15,"Pan, Chunmiao","Zhejiang Jingxin Pharmaceutical Co. LTD, Zhejiang, PR China.",manliu26@163.com.
37099675,Tailored Apoptotic Vesicle Delivery Platform for Inflammatory Regulation and Tissue Repair to Ameliorate Ischemic Stroke.,2023/May/09,"Li, Suke; Lei, Jigang","Cellular Biomedicine Group, Inc., 85 Faladi Road, Building 3, Zhangjiang, Pudong New Area, Shanghai 201210, China.; Cellular Biomedicine Group, Inc., 85 Faladi Road, Building 3, Zhangjiang, Pudong New Area, Shanghai 201210, China.",None
37099283,Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial.,2023/Jun/01,"Gasparyan, Samvel B; Wilderäng, Ulrica; Bengtsson, Olof; Petersson, Magnus; Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
37096493,Prescription patterns and therapeutic effects of second-line drugs in Japanese patients with type 2 diabetes mellitus: Analysis of claims data for metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycemic agents.,2023,"Takeshima, Tomomi; Iwasaki, Kosuke; Aoi, Sumiko","Milliman Inc, Tokyo, Japan.; Milliman Inc, Tokyo, Japan.; Medical Affairs, Sumitomo Pharma Co Ltd, Tokyo, Japan.",None
37096396,Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.,2023/Sep/29,"Luo, Wenli; Vargo, Dennis L; Zhang, Zhiqun","Akebia Therapeutics, Inc., Cambridge, MA, USA.; Akebia Therapeutics, Inc., Cambridge, MA, USA.; Akebia Therapeutics, Inc., Cambridge, MA, USA.",None
37095689,Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension.,2023,"Jung, Jin-A","Hanmi Pharm.Co.,Ltd., Songpa-gu, Seoul, Republic of Korea.",None
37095342,Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials.,2023,"Yamada, Takashi; Miyazaki, Ken; Yamashita, Takuto; Kato, Takuya; Ohara, Kenichi; Nakamura, Yusuke","Research and Development, Bayer Yakuhin Ltd, 2-4-9 Umeda, Kita-Ku, Osaka, 530-0001, Japan.; Research and Development, Bayer Yakuhin Ltd, 2-4-9 Umeda, Kita-Ku, Osaka, 530-0001, Japan.; Research and Development, Bayer Yakuhin Ltd, 2-4-9 Umeda, Kita-Ku, Osaka, 530-0001, Japan.; Research and Development, Bayer Yakuhin Ltd, 2-4-9 Umeda, Kita-Ku, Osaka, 530-0001, Japan.; Market Access, Bayer Yakuhin Ltd, Marunouchi Kitaguchi Bldg. 1-6-5, Marunouchi, Chiyoda-Ku, Tokyo, 100-8265, Japan. kenichi.ohara@bayer.com.; Market Access, Bayer Yakuhin Ltd, Marunouchi Kitaguchi Bldg. 1-6-5, Marunouchi, Chiyoda-Ku, Tokyo, 100-8265, Japan.",kenichi.ohara@bayer.com.
37095320,Review of cardiac safety in onasemnogene abeparvovec gene replacement therapy: translation from preclinical to clinical findings.,2023,"Chand, Deepa H; Sun, Rui; Tukov, Francis Fonyuy","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Deepa.chand@novartis.com.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",Deepa.chand@novartis.com.
37087950,"Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.",2023,"Braverman, Julia; Dhanda, Devender S; Campbell, Timothy B","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",michel.delforge@uzleuven.de.
37087503,Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial.,2023,"von der Leyen, Heiko","Orgenesis, Inc, Germantown, USA.",bavendiek.udo@mh-hannover.de.
37087163,Fluid retention and heart failure in the PRECISION trial - Authors' reply.,2023/Apr/22,"Bellet, Marc","Global Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland.",markus.schlaich@uwa.edu.au.
37086871,"Qilong capsule alleviates ponatinib-induced ischemic stroke in a zebrafish model by regulating coagulation, inflammation and apoptosis.",2023/Oct/05,"Liang, Huiliang; Li, Zhen; Ye, Suyan","Shandong Jining Huaneng Pharmaceutical Factory, Jining, China.; Shandong Jining Huaneng Pharmaceutical Factory, Jining, China.; Shandong Jining Huaneng Pharmaceutical Factory, Jining, China.",heqx@sdas.org.
37086091,Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.,2023,"Beaudet, Amélie","Actelion Pharmaceuticals Ltd, Global Market Access, Allschwil, Switzerland.",None
37086045,The orexin story and orexin receptor antagonists for the treatment of insomnia.,2023,"Muehlan, Clemens; Roch, Catherine; Vaillant, Cedric; Dingemanse, Jasper","Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.; Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.; Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.; Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.",None
37084589,Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice.,2023,"Boolell, Mitra","Theramex HQ UK Ltd., Sloane Square House, 1 Holbein Place, London SW1W 8NS, United Kingdom. Electronic address: Mitra.Boolell@theramex.com.",Mitra.Boolell@theramex.com.
37083162,Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma.,2023,"Daniele, Patrick; Mamolo, Carla; Cappelleri, Joseph C; Bell, Timothy; Neuhof, Alexander; Tremblay, Gabriel; Musat, Mihaela; Forsythe, Anna","Purple Squirrel Economics, a Cytel Company, Montreal, QC H3J 1M1, Canada.; Previously of Pfizer Inc., Groton, CT 06340, USA.; Pfizer Inc., Groton, CT 06340, USA.; Previously of Pfizer Inc., New York, NY 10017, USA.; Pfizer Pharma GmbH, 10785, Berlin, Germany.; Purple Squirrel Economics, a Cytel Company, Montreal, QC H3J 1M1, Canada.; Purple Squirrel Economics, a Cytel Company, New York, NY 10010, USA.; Purple Squirrel Economics, a Cytel Company, New York, NY 10010, USA.",None
37082967,Infarcts in a New Territory: Insights From the ESCAPE-NA1 Trial.,2023,"Tymianski, Michael","NoNO Inc., Toronto, Canada (M.T.).",None
37082807,Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale.,2023,"Joseph, Jacob; Peeples, Sheronda R; Knowlton, Kirk U","VA Providence Healthcare System, Providence, Rhode Island, USA.; VA Boston Healthcare System, Boston, Massachusetts, USA.; Intermountain Healthcare, Salt Lake City, Utah, USA.",None
37080567,Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.,2023,"Hajari Case, Amy; Smith, Peter; Deng, Chunqin; Shen, Eric","Piedmont Healthcare, Atlanta, GA, USA.; United Therapeutics, Research Triangle Park, NC, USA.; United Therapeutics, Research Triangle Park, NC, USA.; United Therapeutics, Research Triangle Park, NC, USA.",abwaxman@bwh.harvard.edu.
37078291,BCL6B Contributes to Ocular Vascular Diseases via Notch Signal Silencing.,2023,"Yunoki, Kaori; Sato, Yuji; Yoshino, Kohichiro","Carna Biosciences, Inc., Kobe, Japan (K. Yunoki, Y.S., M.S., K. Yoshino).; Carna Biosciences, Inc., Kobe, Japan (K. Yunoki, Y.S., M.S., K. Yoshino).; Carna Biosciences, Inc., Kobe, Japan (K. Yunoki, Y.S., M.S., K. Yoshino).",None
37078276,Heart Failure Across the Range of Mildly Reduced and Preserved Ejection Fraction in the United States.,2023,"Tang, Wenxi; Steffen, David R; Viola, Marta G","Analysis Group Inc, NY (W.T., D.R.S., M.G.V.).; Analysis Group Inc, NY (W.T., D.R.S., M.G.V.).; Analysis Group Inc, NY (W.T., D.R.S., M.G.V.).",None
37076782,Global differences in acute heart failure treatment: analysis of the STRONG-HF site feasibility questionnaire.,2023,"Novosadova, Maria; Gianchetti, Lauren; Takagi, Koji; Morishetty, Priyanka; Gaeta, Lauren; Edwards, Christopher; Davison, Beth A; Cotter, Gad","Momentum Research, Inc., Durham, NC, USA.; Momentum Research, Inc., Durham, NC, USA.; Momentum Research, Inc., Durham, NC, USA.; Momentum Research, Inc., Durham, NC, USA.; Momentum Research, Inc., Durham, NC, USA.; Momentum Research, Inc., Durham, NC, USA.; Momentum Research, Inc., Durham, NC, USA.; Momentum Research, Inc., Durham, NC, USA.",None
37075984,Gastrodia elata Blume: A review of its mechanisms and functions on cardiovascular systems.,2023,"Zhang, Xin","Eucure (Beijing) Biopharma Limited Company, 100025 Beijing, China.",yaokuiwu@126.com.
37075941,Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock.,2023,"Simmons, Phillip; Soffer, Joseph; Simonson, Steven","Windtree Therapeutics, Warrington, PA, USA.; Windtree Therapeutics, Warrington, PA, USA.; Windtree Therapeutics, Warrington, PA, USA.",gadcotter@momentum-research.com.
37075696,Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials.,2023,"Sasiela, William J; Zhang, Yang","Esperion Therapeutics, Inc, Ann Arbor, MI, USA.; Esperion Therapeutics, Inc, Ann Arbor, MI, USA.",e.s.stroes@amsterdamumc.nl.
37074705,Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.,2023/Jun/01,"Arlert, Petra; Lophaven, Katja Wendicke; Kurbasic, Azra; Soldbro, Lise; Vest, Natacha Strange","LEO Pharma A/S, Ballerup, Denmark.; LEO Pharma A/S, Ballerup, Denmark.; LEO Pharma A/S, Ballerup, Denmark.; LEO Pharma A/S, Ballerup, Denmark.; LEO Pharma A/S, Ballerup, Denmark.",None
37072177,"Effects of Cannabidiol, Hypothermia, and Their Combination in Newborn Rats with Hypoxic-Ischemic Encephalopathy.",2023,"Hind, William","Jazz Pharmaceuticals, Cambridge CB24 9BZ, United Kingdom.",franciscojose.alvarezdiaz@osakidetza.eus.
37072105,Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results.,2024,"Lindstedt, Eva-Lotte; Gustavsson, Andreas; Nelander, Karin; Garkaviy, Pavlo; Gabrielsen, Anders","Research and Early Clinical Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Early Biometrics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Early Biometrics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Research and Early Clinical Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Research and Early Clinical Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",carolyn.lam@duke-nus.edu.sg.
37070436,"Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.",2023/May/30,"Massey, Daniel","Elderbrook Solutions GmbH on behalf of Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany (D.M.).",None
37069359,Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.,2023,"Vainstein-Haras, Abi; Sorani, Ella; Gliko-Kabir, Irit; Goldstein, Inbal; Ickowicz, Debby; Shemesh-Darvish, Liron; Kadosh, Shaul","BioLineRx, Ltd., Modi'in, Israel.; BioLineRx, Ltd., Modi'in, Israel.; BioLineRx, Ltd., Modi'in, Israel.; BioLineRx, Ltd., Modi'in, Israel.; BioLineRx, Ltd., Modi'in, Israel.; BioLineRx, Ltd., Modi'in, Israel.; StatExcellence, Ltd., Kyriat Mozkin, Israel.",zcrees@wustl.edu.
37068350,[Patients insuffisants cardiaques chroniques rarement adressés à un cardiologue libéral ou régulièrement suivis par un médecin généraliste et un cardiologue libéral : étude descriptive transversale (MIRROR-HF)].,2023,"Hugon, Géraldine; Tindel, Malka","Novartis Pharma SAS, Rueil-Malmaison, France.; Novartis Pharma SAS, Rueil-Malmaison, France.",fmouquet@ovh.fr.
37067768,Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis.,2023,"Azuri, Joseph","Diabetes Clinic, Central District, Maccabi Healthcare Services, Tel Aviv, Israel.",h.alnsasra@gmail.com.
37063260,Baicalein-corrected gut microbiota may underlie the amelioration of memory and cognitive deficits in APP/PS1 mice.,2023,"Yao, Jianbiao","Zhejiang CONBA Pharmaceutical Co Ltd, Hangzhou, China.",None
37062866,Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.,2023,"Iwata, Tomoko","Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.",None
37062851,Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial.,2023,"Pfarr, Egon; Petrini, Michaela","Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.",None
37062120,"Bleeding related to oral anticoagulants: Trends in US emergency department visits, 2016-2020.",2023,"Geller, Andrew I; Shehab, Nadine; Lovegrove, Maribeth C; Weidle, Nina J; Budnitz, Daniel S","Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. Electronic address: ageller@cdc.gov.; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA; Lantana Consulting Group, Atlanta, GA, USA.; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA; Eagle Global Scientific, LLC, Atlanta, GA, USA.; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.",ageller@cdc.gov.
37061138,Self-propelling thrombin powder enables hemostasis with no observable recurrent bleeding or thrombosis over 3 days in a porcine model of upper GI bleeding.,2023,"Baylis, James R","CoMotion Drug Delivery Systems Inc, Vancouver, British Columbia, Canada.",None
37059488,5-Aminolevulinic acid hydrochloride enhances bupivacaine-induced hypotension in spontaneously hypertensive rats.,2023,"Ito, Hidenori; Hara, Takeshi; Otsuka, Noboru; Ishizuka, Masahiro","SBI Pharmaceuticals Co., Ltd., 1-6-1 Roppongi, Minato-ku, Tokyo, 106-6020, Japan.; SBI Pharmaceuticals Co., Ltd., 1-6-1 Roppongi, Minato-ku, Tokyo, 106-6020, Japan.; SBI Pharmaceuticals Co., Ltd., 1-6-1 Roppongi, Minato-ku, Tokyo, 106-6020, Japan.; SBI Pharmaceuticals Co., Ltd., 1-6-1 Roppongi, Minato-ku, Tokyo, 106-6020, Japan.",abe.masanori@nihon-u.ac.jp.
37059375,Multi-pathway neuroprotective effects of a novel salidroside derivative SHPL-49 against acute cerebral ischemic injury.,2023/Jun/15,"Xu, Wenwen; Zhan, Changsen","Shanghai Hutchison Pharmaceuticals Limited, Shanghai Engineering Research Center for Innovation of Solid Preparation of TCM, Shanghai, China.; Shanghai Hutchison Pharmaceuticals Limited, Shanghai Engineering Research Center for Innovation of Solid Preparation of TCM, Shanghai, China.",jgzhang@shutcm.edu.cn.
37058293,Estimated Use of Prescription Medications Among Individuals Incarcerated in Jails and State Prisons in the US.,2023/Apr/07,"Winkelman, Tyler N A","Division of General Internal Medicine, Hennepin Healthcare, Minneapolis, Minnesota.",None
37054808,Role of the iNOS isoform in the cardiovascular dysfunctions of male rats with 6-OHDA-induced Parkinsonism.,2023/May/01,"Crestani, Carlos César","Faculdade de Ciências Farmacêuticas de Araraquara, Departamento de Princípios Ativos Naturais e Toxicologia, Universidade Estadual Paulista - UNESP, Araraquara, Brazil.",martinspinge@uel.br.
37052966,"Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group.",2023,"Mulder, Renée L; Mavinkurve-Groothuis, Annelies; de Baat, Esmée; Asogwa, Ogechukwu A; Lieke Feijen, E A M; van der Pal, Helena; van Dalen, Elvira C","Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.",matthew.ehrhardt@stjude.org.
37051919,Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.,2023/May/30,"Fabien, Vincent; Wächter, Sandra","Vifor Pharma Ltd, Glattbrugg, Switzerland (V.F., S.W.).; Vifor Pharma Ltd, Glattbrugg, Switzerland (V.F., S.W.).",None
37051752,Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial.,2023/Jun/25,"Lefkowitz, Martin P","Novartis Pharmaceuticals, East Hanover, NJ, USA.",None
37047475,SMTP-44D Inhibits Atherosclerotic Plaque Formation in Apolipoprotein-E Null Mice Partly by Suppressing the AGEs-RAGE Axis.,2023/Mar/30,"Hasumi, Keiji","TMS Co., Ltd., KeioFuchu1chome Bldg. 11F, 1-9 Fuchucho, Fuchu-shi, Tokyo 183-0055, Japan.",None
37046084,Clonal haematopoiesis and risk of chronic liver disease.,2023,"Banerjee, Rajarshi; Nicholls, Rowan C; Dennis, Andrea; Kelly, Matt","Perspectum Ltd, Oxford, UK.; Perspectum Ltd, Oxford, UK.; Perspectum Ltd, Oxford, UK.; Perspectum Ltd, Oxford, UK.",pnatarajan@mgh.harvard.edu.
37042286,Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure.,2023/Apr/18,"Ward, Jonathan H",Novartis Pharmaceuticals East Hanover NJ.,None
37042253,Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction.,2023,"Pieper, Michael","Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (M.P.).",None
37042062,Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trial.,2023,"Cadena, Alberto; Zhou, Yinong","Clínica de la Costa LTDA, Barranquilla, Colombia.; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.",None
37041085,Cytochrome P450 and Other Drug-Metabolizing Enzymes As Therapeutic Targets.,2023,"Foti, Robert S","ADME & Discovery Toxicology, Merck & Co., Inc., Boston, Massachusetts robert.foti@merck.com.",robert.foti@merck.com.
37040763,DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates.,2023/May/02,"Zheng, Zuowen","Spring Biological Technology Development Co., Ltd, Fangchenggang, Guangxi 538000, China.",echenum@umich.edu.
37040336,"New Generation of sGC Stimulators: Discovery of Imidazo[1,2-",2023/Jun/08,"Vakalopoulos, Alexandros; Wunder, Frank; Hartung, Ingo V; Redlich, Gorden; Jautelat, Rolf; Buchgraber, Philipp; Hassfeld, Jorma; Gromov, Alexey V; Lindner, Niels; Bierer, Donald; Gries, Jörg; Kroh, Walter; Paulsen, Holger; Mittendorf, Joachim; Lang, Dieter; Becker-Pelster, Eva; Brockschnieder, Damian; Geiss, Volker; Li, Volkhart; Straub, Alexander; Knorr, Andreas; Mondritzki, Thomas; Trübel, Hubert; Raschke, Marian; Schaefer, Martina; Thomas, Dirk; Sandner, Peter; Stasch, Johannes-Peter; Follmann, Markus","Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.",None
37039015,"Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.",2023/May/30,"Hammarstedt, Ann; Sjöstrand, Mikaela; Bengtsson, Olof; Greasley, Peter J","BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (A.H., M.S., O.B., P.J.G.).; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (A.H., M.S., O.B., P.J.G.).; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (A.H., M.S., O.B., P.J.G.).; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (A.H., M.S., O.B., P.J.G.).",None
37038330,The win ratio method in heart failure trials: lessons learnt from EMPULSE.,2023,"Blatchford, Jonathan P; Zeller, Cordula","Elderbrook Solutions GmbH on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.",None
37038246,"Dyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: a genome-wide study.",2023/Jun/01,"Helgadóttir, Anna; Sveinbjornsson, Garðar; Arnar, David O; Thorgeirsson, Gudmundur; Thorsteinsdottir, Unnur; Gudbjartsson, Daníel F; Hólm, Hilma; Stefánsson, Kári","deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; deCODE genetics/Amgen Inc., Reykjavik, Iceland.",None
37037115,Inhibition of the hERG potassium ion channel by different non-nucleoside human cytomegalovirus polymerase antiviral inhibitor series and the exploration of variations on a pyrroloquinoline core to reduce cardiotoxicity potential.,2023/May/01,"Rahim, Mohammad; Lin, Fusen; Gu, Zhengxian; Qi, Xinyi; Zhang, Xuecheng; Dong, Haiheng; Chen, Ying","Rane Pharmaceuticals, Inc., Edmonton, Alberta T6E 5V2, Canada.; WuXi AppTec (Shanghai) Co., Ltd., Shanghai 200131, China.; WuXi AppTec (Shanghai) Co., Ltd., Shanghai 200131, China.; WuXi AppTec (Shanghai) Co., Ltd., Shanghai 200131, China.; WuXi AppTec (Shanghai) Co., Ltd., Shanghai 200131, China.; WuXi AppTec (Shanghai) Co., Ltd., Shanghai 200131, China.; WuXi AppTec (Shanghai) Co., Ltd., Shanghai 200131, China.",jnieman@ualberta.ca.
37036268,Impact of coronary artery disease on clinical outcomes after TAVR: Insights from the BRAVO-3 randomized trial.,2023,"Anthopoulos, Prodromos","European Medical, Arena Pharmaceuticals Inc, Zurich, Switzerland.",None
37034649,Multi-ancestry genome-wide study in >2.5 million individuals reveals heterogeneity in mechanistic pathways of type 2 diabetes and complications.,2023/Mar/31,"Lorenz, Kim M; Thorleifsson, Gudmar; Steinthorsdottir, Valgerdur; Thorsteinsdottir, Unnur; Stefansson, Kari; Chang, Kyong-Mi; Vujkovic, Marijana; Voight, Benjamin F","Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA.; deCODE Genetics, Amgen Inc., Reykjavik, Iceland.; deCODE Genetics, Amgen Inc., Reykjavik, Iceland.; deCODE Genetics, Amgen Inc., Reykjavik, Iceland.; deCODE Genetics, Amgen Inc., Reykjavik, Iceland.; Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA.; Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA.; Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA.",None
37032446,Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.,2023/Jul/21,"Chen, Yun-Fei; Sun, Luna; Schloebe, Andrea; Riedl, Elisabeth","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",None
37031887,The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial).,2023,"Shi, Victor; Lefkowitz, Martin","Novartis Pharmaceuticals, East Hanover, New Jersey.; Novartis Pharmaceuticals, East Hanover, New Jersey.",tor.biering@gmail.com.
37029121,E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma.,2023/Apr/07,"Magnani, John L","GlycoMimetics Inc., Rockville, MD, USA.",abdelkareem.azab@utsouthwestern.edu.
37028991,Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.,2023,"Rokszin, György","RxTarget Ltd, Szolnok, Hungary.",papptimeabianka@gmail.com.
37026551,"Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study.",2023/Apr/18,"Yarimizu, Daisuke; Morita, Yohei; Eguchi, Shunsuke; Iekushi, Kazuma",Medical Affairs Division Novartis Pharma K.K. Tokyo Japan.; Medical Affairs Division Novartis Pharma K.K. Tokyo Japan.; Medical Affairs Division Novartis Pharma K.K. Tokyo Japan.; Medical Affairs Division Novartis Pharma K.K. Tokyo Japan.,None
37025553,Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes.,2023,"Kent, Shia T","Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA.",None
37025086,Computed tomographic angiography in coronary artery disease.,2023/Apr/03,"Taylor, Charles A","HeartFlow, Inc., Redwood City, CA, USA.",None
37025083,Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis.,2023,"Fazeli, Mir Sohail; Crotty, Christopher","Evidinno Outcomes Research Inc., Vancouver, Canada.; Evidinno Outcomes Research Inc., Vancouver, Canada.",None
37024467,"A scalable, virtual weight management program tailored for adults with type 2 diabetes: effects on glycemic control.",2023/Apr/06,"Bullard, Tiffany; Foster, Gary D; Cardel, Michelle I","WW International, Inc., New York, NY, USA.; WW International, Inc., New York, NY, USA.; WW International, Inc., New York, NY, USA.",John.Apolzan@pbrc.edu.
37024420,"Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.",2023,"Li, Yunan; Zhang, Renyi","Medical Affairs, Xian Janssen Pharmaceutical Ltd., Beijing, China.; Medical Affairs, Xian Janssen Pharmaceutical Ltd., Shanghai, China.",wangjx@ihcams.ac.cn.
37023056,Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database.,2023,"Mori, Asuka; Kato, Kenichi","Integrated Market Access, Janssen Pharmaceutical K.K., Tokyo, Japan.; Medical Affairs, Janssen Pharmaceutical K.K., Tokyo, Japan.",None
37022762,Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.,2023/Jul/07,"Yang, Ya-Wen","Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA.",None
37021797,"ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.",2023/Nov/01,"Soriano, Armand; Rigo, Frank; Jafar-Nejad, Paymaan","Ionis Pharmaceuticals, Carlsbad, California, USA.; Ionis Pharmaceuticals, Carlsbad, California, USA.; Ionis Pharmaceuticals, Carlsbad, California, USA.",None
37019896,Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.,2023/Apr/05,"Stewart, A Keith","Princess Margaret Cancer Center, Toronto, ON, Canada.",lin.yi@mayo.edu.
37015244,"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.",2023/May/13,"Diva, Ulysses; Inrig, Jula; Komers, Radko; Mercer, Alex; Rote, William","Travere Therapeutics, San Diego, CA, USA.; Travere Therapeutics, San Diego, CA, USA.; Travere Therapeutics, San Diego, CA, USA.; JAMCO Pharma Consulting, Stockholm, Sweden.; Travere Therapeutics, San Diego, CA, USA.",h.j.lambers.heerspink@umcg.nl.
37014667,Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.,2023/Jun/01,"Marchione, Dylan M","Servier Pharmaceuticals, Boston, Massachusetts.",None
37014289,Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF).,2023,"Seo, B Woun","AltaThera Pharmaceuticals, Chicago, Illinois, USA.",dlakkireddy@kchri.org.
37014287,Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial.,2023,"de Vries, Annick","Sanquin Pharma&Biotech Services, Sanquin, Amsterdam, The Netherlands.",None
37013423,Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study.,2023,"Pollack, Michael; Kruse, Lisa; Feigler, Norbert; Patel, Sushma","US Medical, BioPharmaceuticals, AstraZeneca, 1800 Concord Pike, Wilmington, DE 19850, USA.; US Medical, BioPharmaceuticals, AstraZeneca, Wilmington, DE, USA.; US Medical, BioPharmaceuticals, AstraZeneca, Wilmington, DE, USA.; US Medical, BioPharmaceuticals, AstraZeneca, Wilmington, DE, USA.",None
37006723,Investigating the Mechanism of Action of ,2023,"Bai, Yunfeng","Shaanxi Dongtai Pharmaceutical Co., Ltd, Shaanxi, People's Republic of China.",None
37005831,[Research and application of model fruit fly in prevention and treatment of neuropsychiatric disorders by traditional Chinese medicine and natural compounds: a review].,2023,"Yang, Ming","Jiangxi Guxiang Jinyun Comprehensive Health Industry Co., Ltd. Nanchang 330029, China.",None
37004864,"PROMIS: Physical, Mental and Social Health Outcomes Improve From Before to Early After LVAD Implant: Findings From the Mechanical Circulatory Support: Measures of Adjustment and Quality of Life (MCS A-QOL) Study.",2023,"Walsh, Mary N","Ascension St. Vincent Heart Center, Indianapolis, IN.",e-hahn@northwestern.edu.
37003273,"Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.",2023,"Essex, Margaret Noyes; Lawrence, David; Jones, Philip L S; Liu, Jie; Adamsons, Ingrid","Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Ltd, Sandwich, Kent, UK.; Merck & Co, Inc, Rahway, NJ, USA.; Merck & Co, Inc, Rahway, NJ, USA.",richard.pratley.md@adventhealth.com.
37001534,"Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.",2023,"Lopez, Paty; Amber, Vian","Jazz Pharmaceuticals, Palo Alto, CA, USA.; Jazz Pharmaceuticals, Oxford, UK.",grupp@chop.edu.
36999536,Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis.,2024/Apr/01,"Lee, Richard","Ionis Pharmaceuticals, Carlsbad, California, USA.",None
36997729,Curcumin and chemokines: mechanism of action and therapeutic potential in inflammatory diseases.,2023,"Majeed, Muhammed","Sabinsa Corporation, East Windsor, NJ, USA.",sahebkara@mums.ac.ir.
36997325,"BI-Y, an Neuropilin-1 Antagonist, Enhances Revascularization and Prevents Vascular Endothelial Growth Factor-A Induced Retinal Hyperpermeability in Rodent Models of Retinopathies.",2023,"Thomas, Leo; Low, Sarah; Hansen, Gale; Bakker, Remko A; Zippel, Nina","Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany (L.T., R.A.B., N.Z.) and Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (S.L., G.H.).; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany (L.T., R.A.B., N.Z.) and Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (S.L., G.H.).; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany (L.T., R.A.B., N.Z.) and Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (S.L., G.H.).; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany (L.T., R.A.B., N.Z.) and Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (S.L., G.H.).; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany (L.T., R.A.B., N.Z.) and Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (S.L., G.H.) nina.zippel@boehringer-ingelheim.com.",nina.zippel@boehringer-ingelheim.com.
36997233,Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.,2023,"Ambrose, Christopher S; Cook, Bill; Spahn, Joseph","Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.",jcorren@ucla.edu.
36994719,Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.,2023/Jul/01,"Ostroff, Rachel; Alexander, Leigh; Chen, Yu; Brass, Clifford; Duffin, Kevin","SomaLogic Inc, Boulder, Colorado, USA.; SomaLogic Inc, Boulder, Colorado, USA.; Lilly Research Laboratories, Eli Lilly and Company Ltd (LLY), Indianapolis, Indiana, USA.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.; Lilly Research Laboratories, Eli Lilly and Company Ltd (LLY), Indianapolis, Indiana, USA.",None
36994503,Extravasation of biodegradable microspheres in the rat brain.,2023,"Steendam, Rob; Zuidema, Johan","InnoCore Pharmaceuticals, Groningen, The Netherlands.; InnoCore Pharmaceuticals, Groningen, The Netherlands.",None
36991098,Cell-autonomous effect of cardiomyocyte branched-chain amino acid catabolism in heart failure in mice.,2023,"Miller, Russell A","La Ronde Pharmaceuticals, Cambridge, MA, USA.",gaoc3@ucmail.uc.edu.
36990544,Blood Levels of Angiotensinogen and Hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA).,2023/Apr/04,"Brambatti, Michela; Mullick, Adam E; Morgan, Erin S; Tami, Yvonne","Ionis Pharmaceuticals, Carlsbad, California, USA.; Ionis Pharmaceuticals, Carlsbad, California, USA.; Ionis Pharmaceuticals, Carlsbad, California, USA.; Ionis Pharmaceuticals, Carlsbad, California, USA.",andrew.defilippis@vumc.org.
36987918,"Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients With Use of Single-Pill Combinations: Results From the START-Study.",2023,"Mevius, Antje; Wilke, Thomas","Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM), Wismar, Germany (A.M., T.W.).; Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM), Wismar, Germany (A.M., T.W.).",None
36987470,Bempedoic Acid for Lipid Management in the Indian Population: An Expert Opinion.,2023,"Shetty, Sadanand; Jadhao, Vibhuti; Suryawanshi, Sachin; Barkate, Hanmant","Cardiology, Sadanand Healthy Living Center (P) Ltd. Sion (East), Mumbai, IND.; Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, IND.; Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, IND.; Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, IND.",None
36986635,Approved Nanomedicine against Diseases.,2023/Feb/26,"Jia, Yuanchao","Nanjing Vtrying Pharmatech Co., Ltd., Nanjing 211122, China.",None
36986565,"Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis.",2023/Mar/21,"Gini, Rosa; Bartolini, Claudia; Paoletti, Olga","Tuscan Regional Healthcare Agency, 50100 Florence, Italy.; Tuscan Regional Healthcare Agency, 50100 Florence, Italy.; Tuscan Regional Healthcare Agency, 50100 Florence, Italy.",None
36978133,Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation.,2023/Mar/28,"Perfetti, Riccardo","Applied Therapeutics, New York, NY, USA.",gary.lopaschuk@ualberta.ca.
36974770,Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT-HF.,2023,"Obergfell, Achim; Schweizer, Anja","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",None
36974746,Health status across major subgroups of patients with heart failure and preserved ejection fraction.,2023,"Iwata, Tomoko","Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.",UnIC@RISE
36973405,Home vision monitoring in patients with maculopathy: current and future options for digital technologies.,2023,"Drawnel, Faye; Mavromaras, George","F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc., San Francisco, CA, USA.",k.balaskas@nhs.net.
36972579,Real-World Outcomes of Ranibizumab Treatment in French Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion: 24-Month Results from the BOREAL-RVO Study.,2023,"San Nicolas, Nathalie","Novartis Pharma SAS, Rueil-Malmaison, France.",None
36971587,Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions.,2024,"Boivin, Michael","CommParm Consulting, Inc., Barrie, Ontario, Canada.",None
36970211,Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice ,2023,"Zhang, Mengying; Guo, Kaimin; Wang, Wenjia; Zhou, Shuiping; Sun, He; Yan, Kaijing; Yan, Xijun; Hu, Yunhui","Cloudphar Pharmaceuticals Co., Ltd., Shenzhen 518000, China.; Cloudphar Pharmaceuticals Co., Ltd., Shenzhen 518000, China.; Cloudphar Pharmaceuticals Co., Ltd., Shenzhen 518000, China.; The State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin 300410, China.; Cloudphar Pharmaceuticals Co., Ltd., Shenzhen 518000, China.; Cloudphar Pharmaceuticals Co., Ltd., Shenzhen 518000, China.; The State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin 300410, China.; Cloudphar Pharmaceuticals Co., Ltd., Shenzhen 518000, China.",None
36964557,Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.,2023/Mar/24,"Brown, Katelyn; Cui, Xuewei; O'Neill, Ciara; Fernández Landó, Laura; Patel, Hiren","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA. hpatel@lilly.com.",hpatel@lilly.com.
36963659,Valvular heart disease in Japan: Characteristics and treatment of patients in acute care hospitals in 2019.,2023,"Iwasaki, Kosuke; Takeshima, Tomomi; Murphy, Shannon","Milliman Inc., Tokyo, Japan.; Milliman Inc., Tokyo, Japan.; Edwards Lifesciences Corporation, Irvine, CA, USA.",atarui1@mac.com.
36963395,The Type 2 Diabetes Knowledge Portal: An open access genetic resource dedicated to type 2 diabetes and related traits.,2023/Apr/04,"Thomas, Melissa K; Reilly, Dermot F","Tailored Therapeutics-Diabetes, Eli Lilly and Company, Lilly Corporate Center DC 0545, Indianapolis, IN 46285, USA.; Janssen Pharmaceuticals Inc., Titusville, NJ 08560, USA.",jason.flannick@childrens.harvard.edu.
36961551,Integrating network pharmacology and experimental validation to decipher the mechanism of action of Jingfang Granule in the treatment of viral myocarditis.,2023,"Zhang, Guimin","State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co., Ltd., Linyi, 276006, China. lunanzhangguimin@yeah.net.",lichao71795@hotmail.com.
36958525,20-Hydroxyecdysone inhibits inflammation via SIRT6-mediated NF-κB signaling in endothelial cells.,2023,"Ding, Rongcheng; Wang, Jianjiang","Xinjiang Rongcheng Hake Pharmaceutical Co. Ltd, Altay region 836500, Xinjiang, PR China.; Xinjiang Rongcheng Hake Pharmaceutical Co. Ltd, Altay region 836500, Xinjiang, PR China.",linrong@xjtu.edu.cn.
36958367,Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.,2023,"Brass, Clifford","Novartis Pharmaceuticals, East Hanover, NJ, USA.",quentin.anstee@newcastle.ac.uk.
36943907,"Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.",2023,"Prescott, Margaret F; Lefkowitz, Martin P","Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.F.P., M.P.L.).; Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.F.P., M.P.L.).",None
36942550,Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.,2023/Apr/04,"Hunt, Beverly J","Kings Healthcare Partners, London, England.",None
36941451,PCYT2-regulated lipid biosynthesis is critical to muscle health and ageing.,2023,"Abot, Anne","Enterosys SAS, Prologue Biotech, Labège, France.",josef.penninger@ubc.ca.
36941402,Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes.,2023,"Nolan, Andrew","Ipsen UK Ltd, Slough, UK.",s.sivaprasad@ucl.ac.uk.
36940929,LC-MS Analysis of Ginsenosides in Different Parts of Panax quinquefolius and Their Potential for Coronary Disease Improvement.,2023,"Yu, Hongxia","Wendeng Daodishen Industry Co. Ltd., Weihai, China.",None
36939661,Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction.,2023,"Komtebedde, Jan","Corvia Medical Inc, Tewksbury, Massachusetts, USA.",litwins@musc.edu.
36936405,Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study.,2023,"Hu, Xingdi; Cristino, Joaquim; Mehta, Rina","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; TG Therapeutics, Inc., New York, NY, USA.",None
36934339,Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study.,2023/Mar/01,"Steurbaut, Stephane","Centre for Pharmaceutical Research, Research group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, 1090 Jette, Belgium.",None
36932133,The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice.,2023/Mar/17,"Kotobuki, Yutaro; Nishiya, Yoichi; Pieper, Michael Paul","Medicine Division, Nippon Boehringer Ingelheim Co., Ltd., 2-1-1 Osaki, Shinagawa-ku, Tokyo, 141-6017, Japan.; Medicine Division, Nippon Boehringer Ingelheim Co., Ltd., 2-1-1 Osaki, Shinagawa-ku, Tokyo, 141-6017, Japan.; CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, Biberach an der Riss, 88397, Germany.",yamamoto.mailserver@gmail.com.
36930849,"Arylation of Cyclopropanol with Pyrrole: Asymmetric Synthesis of Indolizidine 167B, Indolizidine 209D, and Monomorine I.",2023/Mar/31,"Fu, Lin","Central Nervous System Drug Key Laboratory of Sichuan Province, Luzhou, Sichuan 646000, China.",None
36928817,Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.,2023,"Roncador, Giovanna; Gonzalez, Patricia; Amann, Maria","Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Research Centre CNIO, Madrid, Spain.; Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Research Centre CNIO, Madrid, Spain.; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.",jamcliment@unav.es.
36928267,Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan.,2023/Nov/01,"Mitani, Hironobu; Suzuki, Kota; Iekushi, Kazuma","Medical Affairs Division, Novartis Pharma K.K.; Medical Affairs Division, Novartis Pharma K.K.; Medical Affairs Division, Novartis Pharma K.K.",None
36927957,A Review of the Cardiovascular Safety of Prucalopride in Patients With Chronic Idiopathic Constipation.,2023/Jun/01,"Terreri, Brian; Boules, Mena","Takeda Pharmaceuticals USA, Lexington, Massachusetts, USA.; Takeda Pharmaceuticals USA, Lexington, Massachusetts, USA.",None
36927711,Association of hydrochlorothiazide treatment compared with alternative diuretics with overall and skin cancer risk: a propensity-matched cohort study.,2023/Jun/01,"Hardtstock, Fänce; Krieger, Julia; Schulz, Martin","Cytel Inc., Wismar/Berlin.; Cytel Inc., Wismar/Berlin.; Drug Commission of German Pharmacists.",None
36927680,Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.,2023/May/01,"Lawatscheck, Robert","Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany.",None
36927451,"CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.",2023/Mar/16,"Hompesch, Marcus; Ranta, Kari","ProSciento Inc., San Diego, CA, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",oliver.schnell@lrz.uni-muenchen.de.
36924142,Patient-reported outcome measures and patient engagement in heart failure clinical trials: multi-stakeholder perspectives.,2023,"Gordon, Jason; Jensen, Klaus; Murakami, Masahiro","HEOR- Health Economics and Outcomes Research, Ltd, Cardiff, UK.; Vifor Pharma, Zürich, Switzerland.; Diabetes-Cardiovascular, Eli Lilly & Company, Indianapolis, IN, USA.",None
36923707,S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes.,2023,"Törngren, Marie; Eriksson, Helena","Active Biotech AB, Lund, Sweden.; Active Biotech AB, Lund, Sweden.",None
36920859,Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia.,2023,"Boice, Judith A; Jorgenson, James","Tremeau Pharmaceuticals, Concord, Massachusetts, USA.; Visante Inc, St. Paul, Minnesota, USA.",None
36919676,Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity.,2023,"Sun, Yiying","Yantai Saipute Analyzing Service Co. Ltd, Yantai, Shandong Province, China.",None
36918792,An Overview of Dietary Flavonoids as a Nutraceutical Nanoformulation Approach to Life-threatening Diseases.,2023,"Maheshwari, Pratik","Fresenius Kabi India Pvt Ltd, Ghaziabad, U.P., India.",None
36915227,Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial.,2023,"Cotter, Gad; Davison, Beth A; Severin, Thomas; Gimpelewicz, Claudio","Momentum Research, Inc., Durham, NC, USA.; Momentum Research, Inc., Durham, NC, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",None
36914876,The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions.,2023,"Galarneau, Geneviève; Clementi, Caterina; Fontanillas, Pierre; Tung, Joyce Y; Yurttas-Beim, Piraye","Celmatix Inc., New York, NY, USA.; Celmatix Inc., New York, NY, USA.; 23andMe, Inc., Sunnyvale, CA, USA.; 23andMe, Inc., Sunnyvale, CA, USA.; Celmatix Inc., New York, NY, USA.",krina.zondervan@wrh.ox.ac.uk.
36914591,"CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers.",2023,"Schumacher, Christoph; Steele, Ronald Edward","DAMIAN Pharma AG, Walchwil, Switzerland.; DAMIAN Pharma AG, Walchwil, Switzerland.",None
36914553,Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort.,2023,"Arlegui, H; De Rycke, Y; Sbidian, É; Tubach, F","AP-HP, Hôpital Pitié-Salpêtrière, Centre de Pharmaco-épidémiologie (Cephépi), INSERM, CIC-1901, Paris, France.; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmaco-épidémiologie (Cephépi), CIC-1901, 75013 Paris, France.; Service de Dermatologie, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France; Hôpital Henri Mondor, Clinical Investigation Centre, Université Paris-Est Créteil (UPEC), Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379, Créteil, France.; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmaco-épidémiologie (Cephépi), CIC-1901, 75013 Paris, France. Electronic address: florence.tubach@aphp.fr.",florence.tubach@aphp.fr.
36908609,The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis.,2023,"Konietschke, Frank; Olszewska, Maja","Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Berlin, Germany.; NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.",None
36897458,"A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.",2023,"Prieto González-Albo, Isabel; Lillie, Tom; Stacey, Andrea; Parfitt, Lola","Akamis Bio Ltd, Abingdon, Oxford, UK.; Akamis Bio Ltd, Abingdon, Oxford, UK.; Akamis Bio Ltd, Abingdon, Oxford, UK.; Akamis Bio Ltd, Abingdon, Oxford, UK.",khalild@mskcc.org.
36897413,"Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.",2023,"Ochi, Haruka; Ohsawa, Shino","Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.",masahiko@v101.vaio.ne.jp.
36893438,RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence.,2023/Jul/01,"Karcher, Helene; Lozama, Anthony; Mayhook, Andrew; Oshagbemi, Olorunfemi A; Zorina, Olessia","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, Minneapolis, Minnesota.; Oxford PharmaGenesis, Oxford, UK.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",None
36889610,Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.,2023/Apr/25,"Banka, Puja; Rodgers, Anthony; Mendizabal, Geraldine; Mitchel, Yale","Merck & Co, Inc, Rahway, New Jersey, USA.; Merck & Co, Inc, Rahway, New Jersey, USA.; Merck & Co, Inc, Rahway, New Jersey, USA.; Merck & Co, Inc, Rahway, New Jersey, USA.",cmb@bcm.edu.
36883922,[The therapeutic management and economic burden of patients with chronic kidney disease non-dialysis-dependent with anemia and ESA treated: findings from a real-world study in Italy].,2023/Feb/27,"Di Rienzo, Paolo","Astellas Pharma Italia S.P.A., Milano.",None
36881400,Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial.,2023,"Schnaidt, Sven; Schnee, Janet M","Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany.; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.",petercarson@mac.com.
36881399,Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum.,2023,"Petersson, Magnus; Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R and D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R and D, AstraZeneca, Gothenburg, Sweden.",john.mcmurray@glasgow.ac.uk.
36881396,Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF.,2023,"Miao, Zi Michael; Heitner, Stephen B; Kupfer, Stuart; Malik, Fady I","Cytokinetics Inc, South San Francisco, California, USA.; Cytokinetics Inc, South San Francisco, California, USA.; Cytokinetics Inc, South San Francisco, California, USA.; Cytokinetics Inc, South San Francisco, California, USA.",dlanfea1@hfhs.org.
36881394,Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.,2023,"Blaustein, Robert O","Merck and Co, Inc, Rahway, New Jersey, USA.",pkaul@ualberta.ca.
36879424,Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.,2023/Mar/05,"Fazio, Sergio; Manvelian, Garen; Pordy, Robert","Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.",None
36878239,Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.,2023,"Fredriksson, Martin; Johansson, Peter A; Gause-Nilsson, Ingrid A M; Langkilde, Anna Maria","BioPharmaceuticals Research & Development, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals Research & Development, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals Research & Development, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals Research & Development, AstraZeneca, Gothenburg, Sweden.",ofrim@hadassah.org.il.
36877894,CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.,2023/Jun/08,"Kwiatkowski, Nicholas","Kymera Therapeutics, Watertown, MA.",None
36877670,Prevalence of Diabetes and Cardiovascular Risk in the Middle East and Africa: Primary Results of the PACT-MEA Study.,2023/Apr/18,"Yadav, Gourav","Novo Nordisk Saglik Urunleri Tic Ltd Sti, Istanbul, Turkey (G.Y.).",None
36877177,Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.,2023/Apr/18,"Gaynor, Tanya; Pak, Jonathan; Senyucel, Cagri","Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut.; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut.; Eli Lilly and Company, Indianapolis, Indiana.",None
36877118,Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial.,2023/May/09,"Onal, Birce; Cerkvenik, Jeffrey","Medtronic, Inc, Minneapolis, MN (B.O., J.C.).; Medtronic, Inc, Minneapolis, MN (B.O., J.C.).",None
36872281,[Network Meta-analysis of single Hirudo prescriptions in treatment of ischemic cerebrovascular disease].,2023,"Yu, Kang-da","Beijing Inruida Pharmaceutical Technology Co., Ltd. Beijing 102218, China.",None
36872213,"Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis.",2023,"Iwata, Tomoko; Zeller, Cordula","Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany.; Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany.",UnIC@RISE
36872068,"Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.",2023,"Banks, Phillip; Girard, Manon; Davies, Michael J","Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.",None
36871215,Eliminating Medication Copayments for Low-Income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial.,2023/May/16,"Mitchell, Chad","Pharmaceutical Branch, Alberta Health, Government of Alberta, Edmonton, Canada (C.M.).",None
36871212,Self-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial.,2023/May/16,"Mitchell, Chad","Pharmaceutical and Supplementary Benefits Division, Alberta Health, Government of Alberta, Edmonton, Canada (C.M.).",None
36870313,Clusterin regulates TRPM2 to protect against myocardial injury induced by acute myocardial infarction injury.,2023,"Fan, Rong","Yantai Raphael Biotechnology Co., Ltd, Yantai 264005, PR China.",katiefhydong@sina.com.
36868031,"A versatile drug-controlled release polymer brush hybrid non-glutaraldehyde bioprosthetic heart valves with enhanced anti-inflammatory, anticoagulant and anti-calcification properties, and superior mechanical performance.",2023,"Kuang, Dajun","Venus Medtech (Hangzhou) Inc., China.",yunbing.wang@scu.edu.cn.
36866412,Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.,2023/Jun/02,"Song, Xun; Perini, Rodolfo F; Xie, Ran; Bapat, Urmi","Clinical Research, Merck & Co., Inc., Rahway, NJ, USA.; Clinical Research, Merck & Co., Inc., Rahway, NJ, USA.; Biostatistics, Eisai Inc., Nutley, NJ, USA.; Clinical Research, Eisai Inc., Nutley, NJ, USA.",None
36864892,A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.,2023,"Wilson, Daniel","US Medical Affairs, Bayer US LLC Pharmaceuticals, Whippany, NJ, USA.",None
36864741,Sex Differences in Oral Anticoagulation Therapy in Patients Hospitalized With Atrial Fibrillation: A Nationwide Cohort Study.,2023/Mar/07,"McIntyre, Shauna; Bloor, Nicholas; Sandler, Belinda; Lister, Steven; Pollock, Kevin G; Qureshi, Ayesha C",Bristol Myers Squibb Pharmaceuticals Ltd London United Kingdom.; Pfizer Ltd Tadworth United Kingdom.; Bristol Myers Squibb Pharmaceuticals Ltd London United Kingdom.; Bristol Myers Squibb Pharmaceuticals Ltd London United Kingdom.; Bristol Myers Squibb Pharmaceuticals Ltd London United Kingdom.; Bristol Myers Squibb Pharmaceuticals Ltd London United Kingdom.,None
36861123,Rethinking of Alzheimer's disease: Lysosomal overloading and dietary therapy.,2023,"Jiang, Si-Cong","Haisco Pharmaceutical Group Comp. Ltd., Chengdu, China.",None
36858705,Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure.,2023/Mar/07,"Mendelsohn, Farrell O; Bouchard, Alain; Jenkins, Margaret; Yaroshinsky, Alex; Hayes, Jack; Rutman, Olga; James, Christopher W; Rose, Eric; Itescu, Silviu","Princeton Baptist Medical Center, Cardiology PC Research, Birmingham, Alabama, USA.; Princeton Baptist Medical Center, Cardiology PC Research, Birmingham, Alabama, USA.; Global Pharma Consulting Pty, Ltd, Melbourne, Victoria, Australia.; Vital Systems, Inc, Rolling Meadows, Illinois, USA.; Mesoblast, Inc, New York, New York, USA.; Mesoblast, Inc, New York, New York, USA.; Mesoblast, Inc, New York, New York, USA.; Mesoblast, Ltd, Melbourne, Victoria, Australia.; Mesoblast, Ltd, Melbourne, Victoria, Australia.",eperin@texasheart.org.
36858576,Arctigenin Prevents Retinal Edema in a Murine Retinal Vein Occlusion Model.,2023,"Takajo, Yuichi; Inamasu, Satoshi; Yomoda, Satoshi","Kracie Holdings, Ltd.; Kracie Holdings, Ltd.; Kracie Holdings, Ltd.",None
36858414,[Effect of electroacupuncture on transforming growth factor-β1 and renal tubular epithelial mesenchymal transformation in renal tissue of spontaneously hypertensive rats].,2023/Feb/25,"Yang, Shao-Zheng","Shanghai Huilun Pharmaceutical Co., Ltd., Shanghai 200023.",None
36858174,Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.,2023,"Kotobuki, Yutaro; Murata, Tatsunori; Nitta, Daisuke","Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan. Electronic address: yutaro.kotobuki@boehringer-ingelheim.com.; CRECON Medical Assessment Inc, Tokyo, Japan.; Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan.",yutaro.kotobuki@boehringer-ingelheim.com.
36857997,Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice.,2023,"Gay, Alain","Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany.",nihar.desai@yale.edu.
36857035,Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.,2023/May/01,"Gause-Nilsson, Ingrid; Langkilde, Anna Maria; Fredriksson, Martin","BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
36855515,Efficacy and Mechanism of Qianshan Huoxue Gao in Acute Coronary Syndrome via Regulation of Intestinal Flora and Metabolites.,2023,"Zhang, Yu","Beijing Xiuzheng Pharmaceutical Company, Beijing, People's Republic of China.",None
36853627,"Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials.",2023/May/01,"Barman, Neil C; Claude, Lisa; Augustin, Dimitri","ReCor Medical Inc, Palo Alto, California.; ReCor Medical Inc, Palo Alto, California.; ReCor Medical Inc, Palo Alto, California.",None
36853250,Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.,2023/Feb/28,"Claude, Lisa; Reeve-Stoffer, Helen","ReCor Medical, Inc, Palo Alto, California.; ReCor Medical, Inc, Palo Alto, California.",None
36851087,Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?,2023/Jan/17,"Lundstrom, Kenneth","PanTherapeutics, Route de Lavaux 49, CH1095 Lutry, Switzerland.",None
36848017,Development and Preliminary Validation of an Instrument to Measure Symptoms and Impacts in Patients with Proliferative Diabetic Retinopathy.,2023,"Rofail, Diana; Sherman, Steven; Hartford, Christopher; Rao, Rohini","Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA. diana.rofail@regeneron.com.; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA.; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA.; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA.",diana.rofail@regeneron.com.
36838965,Lactose and Galactose Promote the Crystallization of Human Galectin-10.,2023/Feb/19,"Jiang, Si-Cong","Haisco Pharmaceutical Group Comp. Ltd., Chengdu 611138, China.",None
36835405,The Pre-Stroke Induction and Normalization of Insulin Resistance Respectively Worsens and Improves Functional Recovery.,2023/Feb/16,"Klein, Thomas","Boehringer Ingelheim Pharma GmbH & Co., KG, 88400 Biberach, Germany.",None
36831143,Urea Transporter Inhibitor 25a Reduces Ascites in Cirrhotic Rats.,2023/Feb/17,"Zuo, Yinglin","The State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871, China.",None
36830792,Clinical and Pharmacotherapeutic Profile of Patients with Type 2 Diabetes Mellitus Admitted to a Hospital Emergency Department.,2023/Jan/18,"Lopes, António Cabral","Pharmaceutical Services of Unity Local of Health of Guarda (ULS da Guarda), 6300-035 Guarda, Portugal.",None
36829102,Adherence to Triple Single-Pill Combination of Perindopril/Indapamide/Amlodipine: Findings from Real-World Analysis in Italy.,2023,"Snyman, Jacques R","Forte Research (Pty Ltd) and Private Practice, Pretoria, South Africa.",claudio.borghi@unibo.it.
36829046,Author Correction: FinnGen provides genetic insights from a well-phenotyped isolated population.,2023,"Graham, Robert R; Green, Eric M; Matakidou, Athena; Mozaffari, Sahar V; Paul, Dirk S; Petrovski, Slavé; Platt, Adam; Tachmazidou, Ioanna; Yang, Robert","Maze Therapeutics, South San Francisco, CA, USA.; Maze Therapeutics, South San Francisco, CA, USA.; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Maze Therapeutics, South San Francisco, CA, USA.; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Janssen Biotech, Beerse, Belgium.",aarno.palotie@helsinki.fi.
36821829,"Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy.",2023/May/01,"Wikstrom, Per; Walum, Erik","Glucox Biotech AB, Stockholm, Sweden.; Glucox Biotech AB, Stockholm, Sweden.",None
36821609,"Gout among Patients with Dialysis: Prevalence, Associated Factors, Treatment Patterns, and Outcomes-Population-Based Retrospective Cohort Study.",2023/Feb/01,"Marder, Brad A; Cohen, Amy R; LaMoreaux, Brian","Horizon Therapeutics plc, Deerfield, Illinois.; Horizon Therapeutics plc, Deerfield, Illinois.; Horizon Therapeutics plc, Deerfield, Illinois.",None
36815271,Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.,2023,"Ping, Jerry; Hauns, Bernhard; Arango-Hisijara, Israel","Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.; Janssen Pharmaceuticals, Raritan, NJ, USA.",None
36815023,Computational integration and meta-analysis of abandoned cardio-(vascular/renal/metabolic) therapeutics discontinued during clinical trials from 2011 to 2022.,2023,"Mero, Deniel","Dock Therapeutics, Inc., Lewes, DE, United States.",None
36814444,Cardiomyocyte infection by ,2023,"Biagi, Diogo","LizarBio Therapeutics, Sao Paulo, Brazil.",None
36813809,In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization.,2023/Feb/22,"Ait-Oudhia, Sihem","Quantitative Pharmacology and Pharmacometrics (QP2), Merck & Co., Inc, Kenilworth, NJ, USA. sb.manuscript.submission@gmail.com.",sb.manuscript.submission@gmail.com.
36812948,Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.,2023/Apr/18,"Lefkowitz, Martin","Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.",ssolomon@rics.bwh.harvard.edu.
36811901,Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.,2023/Apr/01,"Petersson, Magnus; Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
36806740,Lipid Nanoparticles Deliver the Therapeutic VEGFA mRNA In Vitro and In Vivo and Transform Extracellular Vesicles for Their Functional Extensions.,2023,"Heydarkhan-Hagvall, Sepideh; González-King Garibotti, Hernán; Jing, Yujia; Kohl, Franziska; Hultin, Leif; Kull, Bengt; Christoffersson, Jonas; Jennbacken, Karin; Wiseman, John; Bidar, Abdel Wahad; Lindfors, Lennart","BioPharmaceuticals R&D, Early Cardiovascular, Renal and Metabolism (CVRM), Bioscience Cardiovascular, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.; BioPharmaceuticals R&D, Early Cardiovascular, Renal and Metabolism (CVRM), Bioscience Cardiovascular, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.; BioPharmaceuticals R&D, Discovery Sciences, Translational Genomics, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.; BioPharmaceuticals R&D, Clinical Pharmacology and Safety Science, Imaging and Data Analytics, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.; BioPharmaceuticals R&D, Early Cardiovascular, Renal and Metabolism (CVRM), Bioscience Cardiovascular, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.; BioPharmaceuticals R&D, Early Cardiovascular, Renal and Metabolism (CVRM), Bioscience Cardiovascular, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.; BioPharmaceuticals R&D, Early Cardiovascular, Renal and Metabolism (CVRM), Bioscience Cardiovascular, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.; BioPharmaceuticals R&D, Discovery Sciences, Translational Genomics, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.; BioPharmaceuticals R&D, Discovery Sciences, Translational Genomics, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.",None
36805562,CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model.,2023,"Shin, Eunji; Lee, Kang In; Lee, Jae Young","ToolGen, Inc., Seoul, Republic of Korea.; ToolGen, Inc., Seoul, Republic of Korea.; ToolGen, Inc., Seoul, Republic of Korea.",chungbh@catholic.ac.kr.
36802845,Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.,2023/Mar/07,"Ketchum, Steven B; Doyle, Ralph T; Juliano, Rebecca A; Jiao, Lixia","Amarin Pharma, Inc. Bridgewater NJ USA.; Amarin Pharma, Inc. Bridgewater NJ USA.; Amarin Pharma, Inc. Bridgewater NJ USA.; Amarin Pharma, Inc. Bridgewater NJ USA.",None
36802715,Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.,2023/Mar/28,"Baek, Seungjae","Hanmi Pharmaceutical, Songpa-gu, Seoul, Korea (S.B.).",None
36802049,Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.,2023,"Deberdt, Walter; Issa, Maher; Haladyj, Ewa; De La Torre, Inmaculada; Grond, Susanne","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",peter.taylor@kennedy.ox.ac.uk.
36800152,"Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management.",2023,"Canosa, Juliana M; Cha, Amy","Pfizer Brasil Ltda., São Paulo, SP, Brazil. juliana.machadocanosa@pfizer.com.; Pfizer Inc., New York, NY, USA.",juliana.machadocanosa@pfizer.com.
36799120,Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis.,2023,"Van Ganse, E","Research on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon1, Lyon, France.",None
36796671,"Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.",2023,"Ward, Jonathan H; Sarwat, Samiha; Williamson, Kristin","Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharmaceuticals, East Hanover, NJ, USA.",robert.mentz@duke.edu.
36795067,Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries.,2023,"García Rodríguez, Luis Alberto; Ruigómez, Ana; Balabanova, Yanina; Suzart-Woischnik, Kiliana","Centre for Pharmacoepidemiological Research (CEIFE), Madrid, Spain.; Centre for Pharmacoepidemiological Research (CEIFE), Madrid, Spain.; Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Leverkusen, Germany.; Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Leverkusen, Germany.",None
36794404,Brain-targeted delivery of Valsartan using solid lipid nanoparticles labeled with Rhodamine B; a promising technique for mitigating the negative effects of stroke.,2023,"Khedr, Shaimaa M","Pharmaceutical and Fermentation Industries Development Centre (PFIDC), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab, Alexandria, Egypt.",None
36792604,Augmenting hematoma-scavenging capacity of innate immune cells by CDNF reduces brain injury and promotes functional recovery after intracerebral hemorrhage.,2023/Feb/15,"Huttunen, Henri J; Kulesskaya, Natalia","Herantis Pharma Ltd, Plc, Bertel Jungin aukio 1, FI-02600, Espoo, Finland.; Herantis Pharma Ltd, Plc, Bertel Jungin aukio 1, FI-02600, Espoo, Finland.",hockkean@tzuchi.com.tw.
36792039,Disconnect between COX-2 selective inhibition and cardiovascular risk in preclinical models.,2023,"Koshman, Yevgeniya E; Bielinski, Aimee L; Bird, Brandan M; Green, Jonathon R; Kowalkowski, Kenneth L; Lai-Zhang, Jie; Mahalingaiah, Prathap Kumar; Sawicki, James W; Talaty, Nari N; Wilsey, Amanda S; Zafiratos, Mark T; Van Vleet, Terry R","AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America. Electronic address: yevgeniya.koshman@abbvie.com.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.; AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States of America.",yevgeniya.koshman@abbvie.com.
36791659,Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention.,2023,"O'Brien, Meagan P","Regeneron Pharmaceuticals Inc., Tarrytown, USA.",rs3895@cumc.columbia.edu.
36790596,"Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects.",2023,"Freeman, Mason W; Bond, Mary; Murphy, Brian; Hui, James; Isaacsohn, Jonathan","CinCor Pharma, Inc., Waltham, MA, USA. mfreeman@cincor.com.; CinRx Pharma, LLC, Cincinnati, OH, USA.; CinRx Pharma, LLC, Cincinnati, OH, USA.; CinCor Pharma, Inc., Waltham, MA, USA.; CinRx Pharma, LLC, Cincinnati, OH, USA.",mfreeman@cincor.com.
36787993,"Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.",2023,"Bhana, Suleman","Pfizer, Inc, New York, New York, USA.",p.machado@ucl.ac.uk.
36780442,Ventricular anatomical complexity and sex differences impact predictions from electrophysiological computational models.,2023,"Gonzalez-Martin, Pablo; Butakoff, Constantine","ELEM Biotech S.L., Barcelona, Spain.; ELEM Biotech S.L., Barcelona, Spain.",None
36778268,EMBER multi-dimensional spectral microscopy enables quantitative determination of disease- and cell-specific amyloid strains.,2023/Feb/03,"Tengeiji, Atsushi; Yamanoi, Shigeo; Inoue, Masahiro","Daiichi Sankyo Co. Ltd, Tokyo, Japan.; Daiichi Sankyo Co. Ltd, Tokyo, Japan.; Daiichi Sankyo Co. Ltd, Tokyo, Japan.",None
36777695,Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib.,2023,"Jo, Hyejin; Kwok, Kenneth; Vranic, Ivana; Fleishaker, Dona L; Fallon, Lara; Yndestad, Arne","Pfizer Inc, Groton, CT, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, Tadworth Surrey, UK.; Pfizer Inc, Groton, CT, USA.; Pfizer Inc, Montreal, QC, Canada.; Pfizer Inc, Drammensveien 288, 0283 Oslo, Norway.",None
36774843,"Integrated pharmacokinetics and pharmacometabolomics to reveal the synergistic mechanism of a multicomponent Chinese patent medicine, Mailuo Shutong pills against thromboangiitis obliterans.",2023,"Li, Bing","State Key Laboratory of Common Technology of Traditional Chinese Medicine and Pharmaceuticals, Lunan Pharmaceutical Group Co., Ltd., Linyi, China.",dushuzhang911@163.com.
36774155,"An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.",2023/Feb/11,"Audhya, Paul K; Smith, Michael D; Yea, Christopher M; Lee, Daniel K; Feener, Edward P","KalVista Pharmaceuticals, Cambridge, MA, USA.; KalVista Pharmaceuticals, Cambridge, MA, USA.; KalVista Pharmaceuticals, Salisbury, UK.; KalVista Pharmaceuticals, Cambridge, MA, USA.; KalVista Pharmaceuticals, Cambridge, MA, USA.",marcus.maurer@charite.de.
36773739,TRPV4 channels promote vascular permeability in retinal vascular disease.,2023,"Watanabe, Shuzo","RaQualia, Pharma Inc., Nagoya, Japan.",shimazawa@gifu-pu.ac.jp.
36773525,Salvianolic acid A improve mitochondrial respiration and cardiac function via inhibiting apoptosis pathway through CRYAB in diabetic cardiomyopathy.,2023,"Du, Li-da","Shandong Soteria Pharmaceutical Co Ltd., Jinan 250022, China. Electronic address: l.du@utoronto.ca.",fanglh@imm.ac.cn.
36770687,Cyclic Glycine-Proline (cGP) Normalises Insulin-Like Growth Factor-1 (IGF-1) Function: Clinical Significance in the Ageing Brain and in Age-Related Neurological Conditions.,2023/Jan/19,"Shorten, Paul","AgResearch Ltd., Ruakura Research Centre, Hamilton 3214, New Zealand.",None
36768859,Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.,2023/Jan/28,"Kolkhof, Peter","Cardiovascular Precision Medicines, Research and Early Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany.",None
36764050,Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses.,2023,"Schorr, Jessica J; Klebs, Sven H G","Novartis Pharma GmbH, Nuremberg, 90429, Germany.; Novartis Pharma GmbH, Nuremberg, 90429, Germany.",Paulina.Stuerzebecher@medizin.uni-leipzig.de.
36763878,Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.,2023/Feb/10,"Holzwarth, Katrin; Dutronc, Yves; McCollam, Jill; Yang, Fan Emily; Stanley, Sarah; Wu, Wen-Shuo; Sinclair, Rodney","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Sinclair Dermatology, Melbourne, Victoria, Australia.",None
36763537,"Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.",2023/Oct/10,"Reece, Donna","Princess Margaret Cancer Centre, Toronto, ON, Canada.",None
36757373,"A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.",2023,"Kim, SungHyun; Ahn, KeumYoung; Park, TaeHong; Ju, Hana; Kwon, Soonbum","Celltrion, Inc., Yeonsu-gu, Incheon, Republic of Korea.; Celltrion, Inc., Yeonsu-gu, Incheon, Republic of Korea.; Celltrion, Inc., Yeonsu-gu, Incheon, Republic of Korea.; Celltrion, Inc., Yeonsu-gu, Incheon, Republic of Korea.; Celltrion, Inc., Yeonsu-gu, Incheon, Republic of Korea.",None
36757039,"Virtual Screening and Multi-targets Investigation of Novel Diazine Derivatives as Potential Xanthine Oxidase Inhibitors Based on QSAR, Molecular Docking, ADMET Properties, Dynamics Simulation and Network Pharmacology.",2023,"Zhang, Zhiping","Chongqing Ruepeak Pharmaceutical Co., Ltd, Chongqing, 400054, China.",None
36754548,"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.",2023,"Liu, John; Lacerda, Ana P; Palac, Hannah; Shaw, Tim","AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Ltd, Maidenhead, UK.",gerd.burmester@charite.de.
36754528,Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States.,2023,"Lautsch, Dominik; Hilkert, Robert","Merck & Co, Inc, Rahway, New Jersey, USA.; Merck & Co, Inc, Rahway, New Jersey, USA.",stephen.greene@duke.edu.
36754006,Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database.,2023/Feb/01,"Skversky, Amy L; Eissing, Thomas; Kaiser, Andreas; Breitenstein, Stefanie","Bayer AG, Pharmaceuticals Research & Development, Leverkusen/Wuppertal/Berlin, Germany.; Bayer AG, Pharmaceuticals Research & Development, Leverkusen/Wuppertal/Berlin, Germany.; Bayer AG, Pharmaceuticals Research & Development, Leverkusen/Wuppertal/Berlin, Germany.; Bayer AG, Pharmaceuticals Research & Development, Leverkusen/Wuppertal/Berlin, Germany.",None
36752268,Chymase Inhibition Resolves and Prevents Deep Vein Thrombosis Without Increasing Bleeding Time in the Mouse Model.,2023/Feb/21,"Tinel, Hanna; Heitmeier, Stefan","Bayer AG, Research and Development, Pharmaceuticals Wuppertal Germany.; Bayer AG, Research and Development, Pharmaceuticals Wuppertal Germany.",None
36750595,Mechanisms of amyloid-β34 generation indicate a pivotal role for BACE1 in amyloid homeostasis.,2023/Feb/07,"Kulic, Luka","Roche Pharma Research & Early Development, F.Hoffmann-La Roche Ltd., 4070, Basel, Switzerland.",gerhard.multhaup@mcgill.ca.
36740996,Shear stress control of vascular leaks and atheromas through Tie2 activation by VE-PTP sequestration.,2023/Apr/11,"Peters, Kevin G","Aerpio Therapeutics, Inc., Blue Ash, OH, USA.",None
36739041,"The mechanism of rh-endostatin-induced cardiotoxicity and its protection by dihydromyricetin[in vivo/in vitro, C57BL/6 mice, AC16 and hiPSC-CMs].",2023/Mar/15,"Zhao, Qun","Shandong Simcere Bio-Pharmaceutical Co., Ltd, Yantai 264006, China.",bzmczcx@163.com.
36736895,Longitudinal Quantitative Ultrawide-field Fluorescein Angiography Dynamics in the RUBY Diabetic Macular Edema Study.,2023,"Chu, Karen; Moini, Hadi; Vitti, Robert","Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.",ehlersj1@yahoo.com.
36735537,Utilization and Outcomes of Clinically Indicated Invasive Cardiac Care in Veterans with Acute Coronary Syndrome and Chronic Kidney Disease.,2023/Apr/01,"Weisbord, Steven D; Mor, Maria K; Kim, Nadejda; Fine, Michael J; Palevsky, Paul M","From the Renal Section, VA Pittsburgh Healthcare System, Pittsburgh Pennsylvania.; Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.; Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.; Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.; From the Renal Section, VA Pittsburgh Healthcare System, Pittsburgh Pennsylvania.",None
36732377,Integrating avatar technology into a telemedicine application in heart failure patients : A pilot study.,2023,"Schnur, Ivana; Pearl, Cathy","Sense.ly company, San Francisco, USA.; Sense.ly company, San Francisco, USA.",arno.gingele@mumc.nl.
36732099,Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization.,2023,"Rojas-Fernandez, Carlos; Kok, Melanie","Novartis Pharmaceuticals Canada Inc, Montreal, Quebec, Canada.; Novartis Pharmaceuticals Canada Inc, Montreal, Quebec, Canada.",svirani3@providencehealth.bc.ca.
36730098,A Thrombin-Activated Peptide-Templated Nanozyme for Remedying Ischemic Stroke via Thrombolytic and Neuroprotective Actions.,2024,"Yang, Yili","China Regional Research Centre, International Centre of Genetic Engineering and Biotechnology, Taizhou, 212200, P. R. China.",None
36725171,Transcatheter Edge-to-Edge Repair in Patients With Anatomically Complex Degenerative Mitral Regurgitation.,2023/Feb/07,"Hermiller, James","St Vincent Heart Center of Indiana, Indianapolis, Indiana, USA.",Joerg.Hausleiter@med.uni-muenchen.de.
36725094,Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study.,2023/Feb/01,"Ranch, Lise Skov","Biostatistics and Pharmacoepidemiology, LEO Pharma A/S, Ballerup, Denmark.",mreilev@health.sdu.dk.
36724238,Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events.,2023,"Clemens, Andreas; Mehan, Pawan","Medical Affairs Region Europe, Novartis Pharma AG, Basel CH-4056, Switzerland.; TRD Biologics & CGT, Novartis Pharma AG, Basel CH-4056, Switzerland.",None
36720582,Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.,2023,"Vranic, Ivana; Wu, Joseph; Wang, Cunshan; Kwok, Kenneth; Menon, Sujatha; Connell, Carol A; Yndestad, Arne","Pfizer Ltd, Tadworth, Surrey, UK.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, New York, New York, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Oslo, Norway.",maxime.dougados@aphp.fr.
36720386,Hereditary Angioedema With Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice Patterns.,2023,"Danese, Mark; Danese, Sherry; Ulloa, Julie; Audhya, Paul K","Outcomes Insights, Inc, Agoura Hills, Calif.; Outcomes Insights, Inc, Agoura Hills, Calif.; Outcomes Insights, Inc, Agoura Hills, Calif.; KalVista Pharmaceuticals, Inc, Cambridge, Mass.",mriedl@health.ucsd.edu.
36720180,Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.,2023,"Fan, Xiaohu","Nanjing Legend Biotech Inc., Nanjing, China.",zhaowanhong68@163.com.
36719035,The Pre-Adaptation of a Stroke-Specific Self-Management Program Among Older Adults.,2023,"Bhavnani, Suresh K","Cardiovascular, Renal, Metabolism, Novartis Pharmaceuticals Field Medical Division, Houston, TX, USA.",None
36718529,Cardioprotective efficacy of limb remote ischaemic preconditioning in rats: discrepancy between a meta-analysis and a three-centre in vivo study.,2023/Jun/13,"Gömöri, Kamilla; Szabados, Tamara; Bencsik, Péter","Pharmahungary Group, Szeged, Hungary.; Pharmahungary Group, Szeged, Hungary.; Pharmahungary Group, Szeged, Hungary.",None
36716212,Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.,2023,"Yasui, Atsutaka; Lei, Weiyu; Lee, Sunwoo; Kyaw, Moe H","Nippon Boehringer Ingelheim Co. Ltd, Tokyo, Japan.; Boehringer Ingelheim Taiwan Ltd, Taipei, Taiwan.; Boehringer Ingelheim Korea Ltd, Seoul, South Korea.; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.",None
36709617,The grading quality markers identification of Panax notoginseng under the guidance of traditional experience using untargeted metabolomics and anti-myocardial ischemia evaluation of zebrafish.,2023,"Zhang, Yong; Guo, Shengya; Gao, Bo; Luo, Chuan","Hunter Biotechnology Co. Ltd., Zhejiang Hangzhou 310051, China.; Hunter Biotechnology Co. Ltd., Zhejiang Hangzhou 310051, China.; Anhui Huarun Jinchan Pharmaceutical Co. Ltd., Anhui Huaibei 235000, China.; China Resources Sanjiu modern traditional Chinese Medicine Pharmaceutical Co. Ltd., Guangdong Huizhou 518110, China.",hyzhao@icmm.ac.cn.
36709525,"Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States.",2023/Apr/01,"Sutton, Megan B; Xie, Jipan; Fine, Jennifer T; Gao, Wei","MyoKardia, Inc., a wholly owned subsidiary of Bristol-Myers Squibb, Brisbane, Brisbane, California.; Analysis Group, Inc., Los Angeles, California.; MyoKardia, Inc., a wholly owned subsidiary of Bristol-Myers Squibb, Brisbane, Brisbane, California.; Analysis Group, Inc., Boston, Massachusetts.",nihar.desai@yale.edu.
36708138,"A Randomized, Double-Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers.",2023,"Slatkin, Neal E; Franklin, Howard","Salix Pharmaceuticals, Bridgewater, New Jersey, USA.; Salix Pharmaceuticals, Bridgewater, New Jersey, USA.",None
36706918,Gut Microbiota-Derived Glutamine Attenuates Liver Ischemia/Reperfusion Injury via Macrophage Metabolic Reprogramming.,2023,"Zhao, Xianzhe","Shanghai Rat & Mouse Biotech Co, Ltd, Shanghai, China.",xuning@renji.com.
36705566,"Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open-label interventional study.",2023/Jan/27,"Deutsch, Lisa","BioStats Statistical Consulting Ltd, Modiin, Israel.",None
36705285,Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement.,2023,"Palli, Swetha R; Donato, Bonnie Mk; Pimple, Pratik; Bovier, Jacqueline; Manolis, Chronis","Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.; Pharmacy services, UPMC Health Plan, Pittsburgh, PA.; Pharmacy services, UPMC Health Plan, Pittsburgh, PA.",None
36702739,Patterns of immunosuppressive drug use during pregnancy in women with systemic vasculitis: A nationwide population-based cohort study.,2023,"Chouchana, Laurent","Unité de Recherche Clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France; Département de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: laurent.chouchana@aphp.fr.",laurent.chouchana@aphp.fr.
36702528,Risk factors for serious infections in ANCA-associated vasculitis.,2023,"Monach, Paul","VA Boston Healthcare System, West Roxbury, Massachusetts, USA.",ak2283@cam.ac.uk.
36700904,"Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients.",2023/Jan/01,"LaMoreaux, Brian; Marder, Brad","Horizon Therapeutics, Deerfield, Illinois.; Horizon Therapeutics, Deerfield, Illinois.",None
36700391,"Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes.",2023,"Mattheus, Michaela; Bég, Sami A","Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.; Proactive Living Inc, Columbia, South Carolina, USA.",None
36697158,Cause-Specific Mortality in Patients With Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial.,2023/Jan/23,"Mathew, Roy O","Veterans Affairs Loma Linda Healthcare System, Loma Linda, California, USA.",SidhuM@amc.edu.
36696747,Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study.,2023,"Bridges, Ian; Dhalwani, Nafeesa","Amgen Ltd, Uxbridge, UK.; Amgen Inc., Thousand Oaks, CA, USA.",k.ray@imperial.ac.uk.
36695059,Obesity among African American people in the United States: A review.,2023,"Hunt, Rameck R","Penn Medicine Princeton Health, Plainsboro Township, New Jersey, USA.",None
36694463,Preferential delivery of lipid-ligand conjugated DNA/RNA heteroduplex oligonucleotide to ischemic brain in hyperacute stage.,2023/Apr/05,"Yamamoto, Syunsuke; Hirabayashi, Hideki","Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.",tak-yokota.nuro@tmd.ac.jp.
36693807,Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure-volume analysis of the APOLLO study.,2023,"Vest, John; White, Matthew T","Alnylam Pharmaceuticals, Cambridge, MA, USA.; Alnylam Pharmaceuticals, Cambridge, MA, USA.",None
36691905,"Homeostatic, Non-Canonical Role of Macrophage Elastase in Vascular Integrity.",2023/Feb/17,"Lakheram, Deaneira; Kim, Sung-Kwon","Alexion Pharmaceuticals, New Haven, CT (D.L., S.-K.K.).; Alexion Pharmaceuticals, New Haven, CT (D.L., S.-K.K.).",None
36691793,Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing.,2023/Mar/30,"Tanaka, Yuji; Ishiguro, Yoko; Matsumoto, Tomoko; Myung, Jae-Eun","Healthcare Economics and Government Affairs, Medtronic Japan Co., Ltd., 1-2-70 Konan, Minato-ku, Tokyo 108-0075, Japan.; Healthcare Economics and Government Affairs, Medtronic Japan Co., Ltd., 1-2-70 Konan, Minato-ku, Tokyo 108-0075, Japan.; Healthcare Economics and Government Affairs, Medtronic Japan Co., Ltd., 1-2-70 Konan, Minato-ku, Tokyo 108-0075, Japan.; Government Affairs and Market Access, Medtronic Korea Ltd., #534, Teheran-ro, Gangnam-gu, Seoul 06181, Korea.",None
36681529,A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.,2023/Feb/10,"Tricou, Vianney; Mojares, Zenaida; Loeliger, Edde; Mandaric, Sanja; Rauscher, Martina; Brose, Manja; Lefevre, Inge; Folschweiller, Nicolas; Wallace, Derek","Takeda Pharmaceuticals International AG, 8152 Glattpark-Opfikon (Zurich), Switzerland. Electronic address: vianney.tricou@takeda.com.; Takeda Pharmaceuticals International AG, 8152 Glattpark-Opfikon (Zurich), Switzerland.; Takeda Pharmaceuticals International AG, 8152 Glattpark-Opfikon (Zurich), Switzerland.; Takeda Pharmaceuticals International AG, 8152 Glattpark-Opfikon (Zurich), Switzerland.; Takeda Pharmaceuticals International AG, 8152 Glattpark-Opfikon (Zurich), Switzerland.; Takeda Pharmaceuticals International AG, 8152 Glattpark-Opfikon (Zurich), Switzerland.; Takeda Pharmaceuticals International AG, 8152 Glattpark-Opfikon (Zurich), Switzerland.; Takeda Pharmaceuticals International AG, 8152 Glattpark-Opfikon (Zurich), Switzerland.; Global Dengue Program, Takeda Vaccines, Inc., Boston, 02139 MA, USA.",vianney.tricou@takeda.com.
36678139,Unknown,2023/Jan/05,"Wongsaroj, Lampet; Saninjuk, Kritsakorn","Porcinotec Co., Ltd., Nonthaburi 11000, Thailand.; Porcinotec Co., Ltd., Nonthaburi 11000, Thailand.",None
36677853,An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight.,2023/Jan/13,"Azmi, Sarfuddin","Molecular Microbiology Biology Division, Scientific Research Centre (SRC), Prince Sultan Military Medical City (PSMMC), Riyadh 11159, Saudi Arabia.",None
36674357,Presence of Depression Is Associated with Functional Impairment in Middle-Aged and Elderly Chinese Adults with Vascular Disease/Diabetes Mellitus-A Cross-Sectional Study.,2023/Jan/16,"Teopiz, Kayla M; Lui, Leanna M W; McIntyre, Roger S","Mood Disorders Psychopharmacology Unit, Toronto, ON M5T 2S8, Canada.; Mood Disorders Psychopharmacology Unit, Toronto, ON M5T 2S8, Canada.; Mood Disorders Psychopharmacology Unit, Toronto, ON M5T 2S8, Canada.",None
36662635,Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.,2023/Mar/01,"Langkilde, Anna Maria","6Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
36658531,Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.,2023/Jan/19,"Lesén, Eva; Agiro, Abiy; Järbrink, Krister","Medical & Payer Evidence, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; US Evidence, Medical Affairs, BioPharmaceuticals R&D, AstraZeneca, DE, Wilmington, USA.; Medical & Payer Evidence, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",kms.cds.kanda@gmail.com.
36658490,"Patient perspectives on considerations, tradeoffs, and experiences with multiple myeloma treatment selection: a qualitative descriptive study.",2023/Jan/19,"Chandler, David","Amgen, Inc, Thousand Oaks, CA, USA.",amy.corneli@duke.edu.
36656377,Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure.,2023,"Severin, T; Gimpelewicz, C","Novartis Pharma, Basel, Switzerland.; Novartis Pharma, Basel, Switzerland.",a.a.voors@umcg.nl.
36656352,Retrospective analysis of gastrointestinal bleedings with direct oral anticoagulants reported to EudraVigilance.,2023,"Moudallel, Souad; van den Eynde, Celien; Rydant, Silas; Steurbaut, Stephane","Centre for Pharmaceutical Research, Research Group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Jette, Belgium. souad_moudallel@hotmail.com.; Centre for Pharmaceutical Research, Research Group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Jette, Belgium.; Centre for Pharmaceutical Research, Research Group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Jette, Belgium.; Centre for Pharmaceutical Research, Research Group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Jette, Belgium.",souad_moudallel@hotmail.com.
36653595,Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes.,2023,"Nolan, Andrew","Ipsen UK Ltd, Slough, UK.",s.sivaprasad@ucl.ac.uk.
36653562,FinnGen provides genetic insights from a well-phenotyped isolated population.,2023,"Graham, Robert R; Green, Eric M; Matakidou, Athena; Mozaffari, Sahar V; Paul, Dirk S; Petrovski, Slavé; Platt, Adam; Tachmazidou, Ioanna; Yang, Robert","Maze Therapeutics, South San Francisco, CA, USA.; Maze Therapeutics, South San Francisco, CA, USA.; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Maze Therapeutics, South San Francisco, CA, USA.; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Janssen Biotech, Beerse, Belgium.",aarno.palotie@helsinki.fi.
36652192,Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?,2023,"Tedford, Ryan J","Critical Care, Orion Pharma, Espoo, Finland.",danielemasarone@gmail.com.
36651217,International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs.,2023,"Chemuturi, Nagendra; Maass, Katie F; Bantseev, Vladimir; Huang, Qihong; Choules, Mary P; Nussbaum, Jesse C; Thompson, Christopher; Durairaj, Chandrasekar","Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.; Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.; Merck & Co., Inc., South San Francisco, California, USA.; Decibel Therapeutics, Boston, Massachusetts, USA.; Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.",None
36650020,Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.,2023,"Törngren, Marie; Eriksson, Helena","Active Biotech AB, Lund, Sweden.; Active Biotech AB, Lund, Sweden.",kim.de.veirman@vub.be.
36649967,Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.,2023,"Ellis, Alicia M; Fleurinck, Carmen; Marten, Alexander; Massow, Ute; Oortgiesen, Marga; Shepherd-Smith, Julie; Vaux, Thomas","UCB Pharma, Raleigh, North Carolina, USA.; UCB Pharma, Brussels, Belgium.; UCB Pharma, Monheim, Germany.; UCB Pharma, Monheim, Germany.; UCB Pharma, Raleigh, North Carolina, USA.; UCB Pharma, Slough, UK.; UCB Pharma, Slough, UK.",deodhara@ohsu.edu.
36649251,Trajectory and correlates of pulmonary congestion by lung ultrasound in patients with acute myocardial infarction: insights from PARADISE-MI.,2023/Apr/03,"Lefkowitz, Martin P; Gong, Jianjian","Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.",None
36647691,"Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE-HF trial.",2023,"Lechat, Elmira","Vifor Pharma Management Ltd., Glattbrugg, Switzerland.",None
36647690,Bayesian inference for a principal stratum estimand on recurrent events truncated by death.,2023,"Lyu, Tianmeng; Bornkamp, Björn; Mueller-Velten, Guenther; Schmidli, Heinz","Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",None
36647687,Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.,2023,"Tai, Dean; Chng, Elaine L K; Ren, Yayun; Boudes, Pol; Shlevin, Harold","HistoIndex Pte. Ltd., Singapore, Singapore.; HistoIndex Pte. Ltd., Singapore, Singapore.; HistoIndex Pte. Ltd., Singapore, Singapore.; Galectin Therapeutics Inc., Norcross, USA.; Galectin Therapeutics Inc., Norcross, USA.",None
36643627,UHPLC-ESI-QE-Orbitrap-MS based metabolomics reveals the antioxidant mechanism of icaritin on mice with cerebral ischemic reperfusion.,2023,"Tang, Yunfeng; Zhao, Yun; Yao, Jingchun; Feng, Zhong; Liu, Zhong; Zhang, Guimin; Sun, Chenghong","State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co. Ltd., Linyi, Shandong Province, China.; State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co. Ltd., Linyi, Shandong Province, China.; State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co. Ltd., Linyi, Shandong Province, China.; State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co. Ltd., Linyi, Shandong Province, China.; State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co. Ltd., Linyi, Shandong Province, China.; State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co. Ltd., Linyi, Shandong Province, China.; State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co. Ltd., Linyi, Shandong Province, China.",None
36642226,Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study.,2023,"Tarakji, Khaldoun G; Patel, Mithun","Medtronic Inc, Mounds View, MN.; Apple Inc., Cupertino, CA.",Charlesmichaelgibson@gmail.com.
36641358,Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.,2023,"Ferrari, Renda H; Ren, Kaili; Stull, Dawn Marie","Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA.; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA.",michael.thompson@tempus.com.
36640220,"Quantitative Oculomotor Assessment in Hereditary Ataxia: Discriminatory Power, Correlation with Severity Measures, and Recommended Parameters for Specific Genotypes.",2024,"Garces, Pilar","Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland.",alexander.tarnutzer@access.uzh.ch.
36634694,"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.",2023,"Berglind, Anna; Cummings, Celeste; Griffin, M Pamela; Takas, Therese; Yuan, Yuan; Wählby Hamrén, Ulrika; Leach, Amanda; Villafana, Tonya","Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Clinical Development, Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Durham, NC, USA.; Clinical Development, Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Clinical Development, Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Clinical Pharmacology and Quantitative Pharmacology, R&D, AstraZeneca, Gothenburg, Sweden.; Clinical Development, Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Clinical Development, Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Electronic address: tonya.villafana@astrazeneca.com.",tonya.villafana@astrazeneca.com.
36631458,A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.,2023/Jan/12,"Twumasi-Ankrah, Philip; Villarreal, Miguel; Dash, Ajeeta B; Vorog, Alexander; Zhang, Xiaoquan; Suryanarayan, Kaveri; Labotka, Richard","Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.",mdccwj@nus.edu.sg.
36630913,T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.,2023/Jan/10,"Briukhovetska, Daria; Suarez-Gosalvez, Javier; Voigt, Cornelia; Markota, Anamarija; Schübel, Maryam; Jobst, Jakob; Dörr, Janina; Märkl, Florian; Majed, Lina; Müller, Philipp Jie; May, Peter; Gottschlich, Adrian; Tokarew, Nicholas; Oner, Arman; Schwerdtfeger, Melanie; Andreu-Sanz, David; Grünmeier, Ruth; Seifert, Matthias; Michaelides, Stefanos; König, Lars M; Cadilha, Bruno Loureiro; Rothenfusser, Simon; Endres, Stefan; Kobold, Sebastian","Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), 85764 Neuherberg, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), 85764 Neuherberg, Germany; Center for Translational Cancer Research (DKTK), Partner Site Munich, 80336 Munich, Germany.; Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), 85764 Neuherberg, Germany; Center for Translational Cancer Research (DKTK), Partner Site Munich, 80336 Munich, Germany. Electronic address: sebastian.kobold@med.uni-muenchen.de.",sebastian.kobold@med.uni-muenchen.de.
36628268,Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study.,2023,"Santos, Karine; Hartmann, Oliver","4TEEN4 Pharmaceuticals GmbH, Hennigsdorf/Berlin, Germany.; 4TEEN4 Pharmaceuticals GmbH, Hennigsdorf/Berlin, Germany.",None
36627831,Venous Stent Placement for Malignant Vena Cava Syndrome in a Patient with Liposarcoma.,2023/Jan/11,"Iwasawa, Shunichiro","Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.",None
36627123,"Discovery of Novel 3,11-Bispeptide Ester Arenobufagin Derivatives with Potential in Vivo Antitumor Activity and Reduced Cardiotoxicity.",2023,"Luo, Chuan","Anhui China Resources Jinchan Pharmaceutical Co., Ltd., 39 Longfa Road, Huaibei, 235000, P. R. China.",None
36627064,Longitudinal monitoring of circulating immune cell phenotypes in anti-neutrophil cytoplasmic antibody-associated vasculitis.,2023,"Yoshida, Hiroto; Magi, Mayu; Noguchi-Sasaki, Mariko","Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan.; Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan.; Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan.",aa615119@keio.jp.
36624527,The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants.,2023/Jan/09,"Aguinaga-Barrilero, Ana","Amicus Therapeutics, SLU, Madrid, Spain.",sanchez_rosmar@gva.es.
36624408,Cancer incidence in immunocompromised patients: a single-center cohort study.,2023/Jan/09,"Chung, Karen C; Wood, Brenda M","GRAIL, LLC, a subsidiary of Illumina, Inc., currently held separate from Illumina Inc, Menlo Park, CA, USA.; GRAIL, LLC, a subsidiary of Illumina, Inc., currently held separate from Illumina Inc, Menlo Park, CA, USA.",diana.brixner@utah.edu.
36620965,Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.,2023,"Vikarunnessa, Sheikh; Talloczy, Zsolt; Zang, Xiao; Maheux, Pierre; Lesogor, Anastasia","Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharma, Basel, Switzerland.; Novartis Pharma, Basel, Switzerland.",k.ray@imperial.ac.uk.
36617559,How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome.,2023/Jan/09,"Rohr, Martina","Vifor Pharma Deutschland GmbH, Baierbrunner Straße 29, 81379, Munich, Germany. ma-rohr@web.de.",ma-rohr@web.de.
36607599,"Contribution of single-pill combinations in the management of hypertension: perspectives from China, Europe and the USA.",2023,"Gottwald-Hostalek, Ulrike","Merck Healthcare KGaA, Darmstadt, Germany.",None
36607147,"Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.",2023,"Cranmer, Holly; Dabora, Jonathan; Cherepanov, Dasha","Takeda Pharmaceuticals International AG, Zurich, Switzerland.; Takeda Pharmaceuticals America, Inc., Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.",None
36601956,Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial.,2023,"Garito, Tania","Novartis Pharma AG, Basel, Switzerland (T.G.).",None
36600185,"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.",2023,"Gunay, Levent M; Sugiyama, Naonobu; Connell, Carol A; Wang, Cunshan; Wu, Joseph; Menon, Sujatha; Vranic, Ivana","Pfizer Inc, Istanbul, Turkey.; Pfizer Japan Inc, Tokyo, Japan.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Ltd, Tadworth, UK.",jrcurtis@uabmc.edu.
36600183,The provisional OMERACT ultrasonography score for giant cell arteritis.,2023,"Keen, Helen Isobel","Medicine and Pharmacology, UWA, Murdoch, Perth, Australia.",christian.dejaco@gmx.net.
36599831,Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.,2023/Jan/04,"Berlanga, Oscar","The Binding Site Group Ltd, Birmingham, United Kingdom.",niels.weinhold@med.uni-heidelberg.de.
36599608,Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.,2023/Jan/03,"Paige, Sharon L; Heitner, Stephen B; Kupfer, Stuart; Malik, Fady I; Meng, Lisa; Wohltman, Amy","Cytokinetics Incorporated, South San Francisco, California, USA.; Cytokinetics Incorporated, South San Francisco, California, USA.; Cytokinetics Incorporated, South San Francisco, California, USA.; Cytokinetics Incorporated, South San Francisco, California, USA.; Cytokinetics Incorporated, South San Francisco, California, USA.; Cytokinetics Incorporated, South San Francisco, California, USA.",martin.maron@lahey.org.
36599553,Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER.,2023,"Petersson, Magnus; Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",ssolomon@rics.bwh.harvard.edu.
36599549,Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan.,2023,"Prescott, Margaret F; Ward, Jonathan H","Novartis Pharmaceuticals, East Hanover, New Jersey, USA.; Novartis Pharmaceuticals, East Hanover, New Jersey, USA.",JJanuzzi@partners.org.
36597161,Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis.,2023/Jan/03,"Yoshida, Hiroto; Magi, Mayu; Matsumoto, Yoshihiro; Noguchi-Sasaki, Mariko","Chugai Pharmaceutical Co. Ltd., 200 Kajiwara, Kamakura, Kanagawa, Japan.; Chugai Pharmaceutical Co. Ltd., 200 Kajiwara, Kamakura, Kanagawa, Japan.; Chugai Pharmaceutical Co. Ltd., 200 Kajiwara, Kamakura, Kanagawa, Japan.; Chugai Pharmaceutical Co. Ltd., 200 Kajiwara, Kamakura, Kanagawa, Japan.",aa615119@keio.jp.
36596641,Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK.,2023,"Gonzalez Perez, Antonio; Vizcaya, David; Sáez, Maria E; Garcia Rodriguez, Luis A","Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain agonzalez@ceife.es.; Bayer Pharmaceuticals, Sant Joan Despi, Spain.; Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.; Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.",agonzalez@ceife.es.
36594446,Analysis of prescription status of antihypertensive drugs in Chinese patients with hypertension based on real-world study.,2023,"Yang, Renren; Tang, Jia; Kuang, Ming; Liu, Hongying","Medical Affairs, Hangzhou Kang Sheng Health Consulting CO., Ltd, Hangzhou, China.; Medical Affairs, Hangzhou Kang Sheng Health Consulting CO., Ltd, Hangzhou, China.; Medical Affairs, Hangzhou Kang Sheng Health Consulting CO., Ltd, Hangzhou, China.; Medical Affairs, Hangzhou Kang Sheng Health Consulting CO., Ltd, Hangzhou, China.",None
36592719,Systematic Review of Signs and Symptoms Associated with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy.,2023,"Tsong, Wan H","Omeros Corporation, Health Economics and Outcomes Research, Medical Affairs, Seattle, Washington.",Christopher.Dandoy@CCHMC.org.
36592046,IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.,2023,"Lindholm, Daniel; Hammarstedt, Ann; Boulton, David W; Greasley, Peter J; Langkilde, Anna Maria","Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.; Early Research and Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",john.mcmurray@glasgow.ac.uk.
36587878,"Preparation methods, structural characteristics, and biological activity of polysaccharides from Salvia miltiorrhiza: A review.",2023/Apr/06,"Zhu, Lihao","Sishui Siheyuan Culture and Tourism Development Company, Ltd, Sishui, 273200, China.",yhliu@sdutcm.edu.cn.
36587792,Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan.,2023,"Matsukawa, Miyuki; Nakamura, Yumiko; Aihara, Miki; Sano, Hiromi","Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.; Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.; Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.; Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.",kinugawa@med.u-toyama.ac.jp.
36583355,Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.,2023/Feb/01,"Kolkhof, Peter","Research & Development, Pharmaceuticals Cardiovascular Precision Medicines, Bayer AG, Wuppertal.",None
36574581,Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.,2023,"Young, Bradford A; Pine, Polly; Shi, Ju; Zhang, Peixin","B.A.Y. Biotech Consulting, Annapolis, Maryland.; Jazz Pharmaceuticals, Palo Alto, California.; Jazz Pharmaceuticals, Palo Alto, California.; Jazz Pharmaceuticals, Palo Alto, California.",wsaber@mcw.edu.
36572274,[Study of the impact of a post-acute coronary syndrome pharmaceutical interview in hospital].,2023,"Martin, M; Fourtage, M; Wisniewski, S; Gourieux, B","Service de pharmacie, CHU de Strasbourg, 67091 Strasbourg, France. Electronic address: m.martinbarthel@gmail.com.; Service de pharmacie, CHU de Strasbourg, 67091 Strasbourg, France.; Service de pharmacie, CHU de Strasbourg, 67091 Strasbourg, France.; Service de pharmacie, CHU de Strasbourg, 67091 Strasbourg, France.",m.martinbarthel@gmail.com.
36565199,Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.,2023/Jan/03,"Zannad, Faiez",Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany.,None
36564486,Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study.,2023,"Asubonteng, Kobby; Guindeuil, Gwennaëlle","Jazz Pharmaceuticals, Philadelphia, PA, USA.; Jazz Pharmaceuticals, Lyon, France.",mohamad.mohty@inserm.fr.
36563762,Identification of ligustrazine-based analogs of piperlongumine as potential anti-ischemic stroke agents.,2023,"Xi, Lan","Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai 201203, China.",zouyu@wust.edu.cn.
36563553,"Risk stratification, prognosis, and survival in a pulmonary arterial hypertension cohort in Latin America. A multicenter study.",2023,"Chávez, Ángel; Secco, Lucrecia","Medical Affairs, Bayer Pharmaceuticals, Munro, Argentina.; Medical Affairs, Bayer Pharmaceuticals, Munro, Argentina.",jcaneva@ffavaloro.org.
36546453,Adjusted comparison of outcomes between patients from CARTITUDE-1 ,2023/Aug/01,"Diels, Joris; Thilakarathne, Pushpike; Perualila, Nolen J; Cabrieto, Jedelyn; Strulev, Vadim; Nesheiwat, Tonia; Pacaud, Lida","Janssen Pharmaceutica NV, Beerse.; Janssen Pharmaceutica NV, Beerse.; Janssen Pharmaceutica NV, Beerse.; Janssen Pharmaceutica NV, Beerse.; EMEA Medical Affairs, Janssen Pharmaceutica NV, Beerse.; Legend Biotech USA Inc., Piscataway, NJ.; Legend Biotech USA Inc., Piscataway, NJ.",mvmateos@usal.es.
36542081,"PHASE 2 RANDOMIZED STUDY (ORION-1) OF A NOVEL, BIODEGRADABLE DEXAMETHASONE IMPLANT (AR-1105) FOR THE TREATMENT OF MACULAR EDEMA DUE TO CENTRAL OR BRANCH RETINAL VEIN OCCLUSION.",2023/Jan/01,"Williams, Stuart; McKee, Hayley; Kerr, Kevin; Pegoraro, Tyler; Trevino, Leo; Kopczynski, Casey C; Hollander, David A","Aerie Pharmaceuticals, Inc, Durham, North Carolina.; Aerie Pharmaceuticals, Inc, Durham, North Carolina.; Aerie Pharmaceuticals, Inc, Durham, North Carolina.; Aerie Pharmaceuticals, Inc, Durham, North Carolina.; Aerie Pharmaceuticals, Inc, Durham, North Carolina.; Aerie Pharmaceuticals, Inc, Durham, North Carolina.; Aerie Pharmaceuticals, Inc, Durham, North Carolina.",None
36539949,The Effect of the Drug-Related Problems Prevention Bundle on Early Readmissions in Patients From the Emergency Department: A Randomized Clinical Trial.,2023,"Gilabert, Antoni; Guiu, Josep M","Catalan Healthcare Consortium, Catalan Health Service, Barcelona, Spain.; Catalan Healthcare Consortium, Catalan Health Service, Barcelona, Spain.",None
36535535,"Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.",2023,"Hariri, Ali; Modur, Vijay","Eloxx Pharmaceuticals, Watertown, Massachusetts.; Eloxx Pharmaceuticals, Watertown, Massachusetts.",rperrone@tuftsmedicalcenter.org.
36529695,Hyaluronic Acid-Guided Cerasome Nano-Agents for Simultaneous Imaging and Treatment of Advanced Atherosclerosis.,2023,"Yang, Ling; Wei, Yaohua; He, Chaoyong; Wang, Wenshan; Sun, Jiefang","Beijing Inno Medicine Co. Ltd., Beijing, 100195, P. R. China.; Beijing Inno Medicine Co. Ltd., Beijing, 100195, P. R. China.; Beijing Inno Medicine Co. Ltd., Beijing, 100195, P. R. China.; Beijing Inno Medicine Co. Ltd., Beijing, 100195, P. R. China.; Beijing Inno Medicine Co. Ltd., Beijing, 100195, P. R. China.",None
36529659,Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects.,2023,"Karwatowska-Prokopczuk, Ewa; Lesogor, Anastasia; Yan, Jing-He; Hurh, Eunju; Hoenlinger, Angelika; Margolskee, Alison; Xia, Shuting","Ionis Pharmaceuticals, Carlsbad, CA, USA.; Novartis Pharma AG, Basel Switzerland.; Novartis Pharma AG, Basel Switzerland.; Akcea Therapeutics, Boston, MA, USA.; Novartis Pharma AG, Basel Switzerland.; Novartis Pharma AG, Basel Switzerland.; Ionis Pharmaceuticals, Carlsbad, CA, USA.",stsimikas@health.ucsd.edu.
36528138,A machine learning approach to identifying patients with pulmonary hypertension using real-world electronic health records.,2023/Mar/01,"Kogan, Emily; Lee, Eileen; Nnewihe, Anderson; Mataraso, Samson; Quinn, Deborah; Chehoud, Christel; Bridges, Charles","Janssen Pharmaceuticals Inc., Spring House, PA, USA. Electronic address: ekogan@ITS.JNJ.com.; Janssen Pharmaceuticals Inc., Spring House, PA, USA.; Janssen Pharmaceuticals Inc., Spring House, PA, USA.; Dascena, Inc., San Francisco, CA, USA.; Janssen Pharmaceuticals Inc., Spring House, PA, USA.; Janssen Pharmaceuticals Inc., Spring House, PA, USA.; Janssen Pharmaceuticals Inc., Spring House, PA, USA.",ekogan@ITS.JNJ.com.
36528035,"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.",2023,"Pescosta, Norbert","Reparto Ematologia, Ospedale Provinciale Bolzano, Bolzano, Italy.",francesca.gay@unito.it.
36526515,Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.,2023/Feb/07,"Lindholm, Daniel; Bengtsson, Olof","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R and D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R and D, AstraZeneca, Gothenburg, Sweden.",mkosiborod@saint-lukes.org.
36526000,NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.,2023,"Torstenson, Richard; Patterson, Scott D; Thakker, Paresh; Billin, Andrew N; Schoelch, Corinna","Astrazeneca, Regulatory Affairs, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Gothenburg, Sweden.; Gilead Sciences, Inc, Foster City, California, USA.; Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, MA 02421, USA.; Gilead Sciences, Inc, Foster City, California, USA.; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.",dgr@nordicbio.com.
36522120,Effect of triamcinolone acetonide on retinal inflammation and angiogenesis induced by pericyte depletion in mouse.,2023,"Otsuka, Tomohiro; Masuda, Tomomi; Takahashi, Yuji; Suzuki, Ayako; Arakawa, Reijiro; Okabe, Takeshi; Naito, Akira","Sagami Research Laboratories, Wakamoto Pharmaceutical Co., Ltd., Japan.; Sagami Research Laboratories, Wakamoto Pharmaceutical Co., Ltd., Japan.; Sagami Research Laboratories, Wakamoto Pharmaceutical Co., Ltd., Japan.; Sagami Research Laboratories, Wakamoto Pharmaceutical Co., Ltd., Japan.; Sagami Research Laboratories, Wakamoto Pharmaceutical Co., Ltd., Japan. Electronic address: reijiro.arakawa@wakamoto-pharm.co.jp.; Sagami Research Laboratories, Wakamoto Pharmaceutical Co., Ltd., Japan.; Sagami Research Laboratories, Wakamoto Pharmaceutical Co., Ltd., Japan.",reijiro.arakawa@wakamoto-pharm.co.jp.
36516908,Detoxification mechanisms of ginseng to aconite: A review.,2023/Mar/25,"Hou, Xinlian; Hao, Li","Huarun Sanjiu (Ya'an) Pharmaceutical Group Co., LTD, Ya'an, 625000, PR China.; Huarun Sanjiu (Ya'an) Pharmaceutical Group Co., LTD, Ya'an, 625000, PR China.",20660306@qq.com.
36515129,Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.,2023,"Shoji, Shingo; Kosakai, Yoshinori; Koga, Tadashi; Asakawa, Keiko; Rokuda, Mitsuhiro","Medical Affairs, Astellas Pharma Inc., Tokyo, Japan.; Medical Affairs, Astellas Pharma Inc., Tokyo, Japan.; Clinical Research Professionals, Clinical Study Support, Inc., Nagoya, Japan.; Medical Affairs, Astellas Pharma Inc., Tokyo, Japan.; Medical Affairs, Astellas Pharma Inc., Tokyo, Japan.",None
36515033,Alkaloids Extract from ,2023,"Merakeb, Mohamed Sofiane; Bribi, Noureddine; Ferhat, Riad; Aziez, Meriem; Yanat, Betitera","Laboratoire de Biotechnologie Végétale et Ethnobotanique, Faculté des Sciences de la Nature et de la Vie, Université de Bejaia, Bejaia, 06000, Algeria.; Laboratoire de Biotechnologie Végétale et Ethnobotanique, Faculté des Sciences de la Nature et de la Vie, Université de Bejaia, Bejaia, 06000, Algeria.; Laboratoire de Biotechnologie Végétale et Ethnobotanique, Faculté des Sciences de la Nature et de la Vie, Université de Bejaia, Bejaia, 06000, Algeria.; Laboratoire de Biotechnologie Végétale et Ethnobotanique, Faculté des Sciences de la Nature et de la Vie, Université de Bejaia, Bejaia, 06000, Algeria.; Laboratoire de Biotechnologie Végétale et Ethnobotanique, Faculté des Sciences de la Nature et de la Vie, Université de Bejaia, Bejaia, 06000, Algeria.",None
36512425,TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.,2023/Feb/15,"Driessens, Gregory","iTeos Therapeutics, Gosselies, Belgium.",None
36510662,High plasma concentrations of acyl-coenzyme A binding protein (ACBP) predispose to cardiovascular disease: Evidence for a phylogenetically conserved proaging function of ACBP.,2023,"Madeo, Frank","BioTechMed-Graz, Graz, Austria.",None
36484341,Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.,2023,"Dosne, Anne-Gaelle; Li, Xia; Luo, Man Melody; Nnane, Ivo; Perez Ruixo, Juan; Zhou, Honghui; Sun, Yu-Nien; Xu, Yan","Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Beerse, Belgium.; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Beerse, Belgium.; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.; Janssen-Cilag Spain, Part of Janssen Pharmaceutical Companies, Madrid, Spain.; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.",None
36482155,Pharmacological inhibition of SK-channels with AP14145 prevents atrial arrhythmogenic changes in a porcine model for obstructive respiratory events.,2023,"Diness, Jonas G","Acesion Pharma, Copenhagen, Denmark.",None
36481125,"Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.",2023,"Modur, Vijay","Formerly Sanofi, Cambridge, MA, United States; Currently Eloxx Pharmaceuticals, Watertown, MA, United States.",patrick.deegan@addenbrookes.nhs.uk.
36479888,A retrospective study: efficacy of an originator versus a generic formulation of simvastatin in patients who suffer from hyperlipidaemia.,,"Snyman, J R; Snyman, K R","Clinical pharmacologist, Pretoria, South Africa. Email: jacques@dermav.co.za.; Pharmaceutics, Cape Town, South Africa.",jacques@dermav.co.za.
36469127,SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum.,2023,"Nakamura, Takahiro; Isobe, Satoko; Hosono, Kumiko; Ohtakaki, Yukie; Yasuda, Naoto; Mitsuta, Soh; Hosono, Tatsunori; Fukushima, Hideaki; Kinoshita, Masao; Umeda, Atsushi; Kinoshita, Yuichi; Fukami, Kana","Medicine Division, Nippon Boehringer Ingelheim Co., Ltd., 2-1-1, Osaki, Shinagawa-Ku, Tokyo, 141-6017, Japan.; FibroScan Division, Integral Corporation, 2-25-2, Kamiosaki, Shinagawa-Ku, Tokyo, 141-0021, Japan.; Immunology, Hepatology & Dermatology Medical Franchise Dept., Medical Division, Novartis Pharma K.K., 1-23-1, Toranomon, Minato-Ku, Tokyo, 105-6333, Japan.; Product Development 1St Group, Product Development Dept., Fujirebio Inc., 2-1-1, Nishishinjuku, Shinjuku-Ku, Tokyo, 163-0410, Japan.; Ultrasound Business Area, Siemens Healthcare KK, 1-11-1, Osaki, Shinagawa-Ku, Tokyo, 141-8644, Japan.; FibroScan Division, Integral Corporation, 2-25-2, Kamiosaki, Shinagawa-Ku, Tokyo, 141-0021, Japan.; Clinical Development & Operations Japan, Nippon Boehringer Ingelheim Co., Ltd., 2-1-1, Osaki, Shinagawa-Ku, Tokyo, 141-6017, Japan.; Diagnostics Business Area, Siemens Healthcare Diagnostics KK, 1-11-1, Osaki, Shinagawa-Ku, Tokyo, 141-8673, Japan.; Marketing Dep. H.U. Frontier, Inc., Shinjuku Mitsui Building, 2-1-1, Nishishinjuku, Shinjuku-Ku, Tokyo, 163-0408, Japan.; Clinical Development Dept, EA Pharma Co., Ltd., 2-1-1, Irifune, Chuo-Ku, Tokyo, 104-0042, Japan.; Global Drug Development Division, Novartis Pharma KK, 1-23-1, Toranomon, Minato-Ku, Tokyo, 105-6333, Japan.; 2Nd Product Planning Dept, 2Nd Product Planning Division, Fujirebio Inc, 2-1-1, Nishishinjuku, Shinjuku-Ku, Tokyo, 163-0410, Japan.",sumida19701106@yahoo.co.jp.
36462135,Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review.,2023,"Freedman, Daniel","Covis Pharma Group, Waltham, MA, USA.",ansellje@gmail.com.
36458420,Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System.,2023,"DuMontier, Clark; Driver, Jane A","New England Geriatrics Research, Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts, USA.; New England Geriatrics Research, Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts, USA.",None
36456851,CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis.,2023,"Wang, Jingjun; Chandra, Rajat","Sumitovant Biopharma, Inc, New York, NY, USA.; Sumitovant Biopharma, Inc, New York, NY, USA.",adam.carrera@urovant.com.
36449257,Preferences for Anaemia Treatment Attributes among Patients with Non-Dialysis-Dependent Chronic Kidney Disease.,2023,"Alexandre, Ana Filipa; Morga, Antonia; Jiletcovici, Alina","Health Economics Outcomes Research, Medical Affairs, Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE, Leiden, The Netherlands. anafalexandre@gmail.com.; Astellas Pharma Europe Ltd, Bourne Business Park, 300 Dashwood Lang Rd, Addlestone, KT15 2NX, UK.; Astellas Pharma Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.",anafalexandre@gmail.com.
36436417,Discovery of novel danshensu derivatives bearing pyrazolone moiety as potential anti-ischemic stroke agents with antioxidant activity.,2023,"Wang, Yan","Baoshan Zhaohui New Drug R & D and Transformation Functional Platform, Zhaohui Pharmaceutical, Shanghai 201908, China.",wangtf66@shu.edu.cn.
36428281,Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.,2023,"Masuda, Esteban S","Rigel Pharmaceuticals, South San Francisco, California.",None
36418094,A Missense Mutation of the Plasminogen Gene in a Japanese Family with Hereditary Angioedema with Normal C1 Inhibitor: Third Family Survey in Asia.,2023/Jul/01,"Horiuchi, Takahiko","Center for Research, Education, and Treatment of Angioedema, a Specified Non-profit Corporation, Japan.",None
36417955,Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trial.,2023,"White, Harvey; Alsweiler, Caroline","Green Lane Clinical Coordinating Centre Ltd, Auckland, New Zealand.; Green Lane Clinical Coordinating Centre Ltd, Auckland, New Zealand.",jeffrey.carson@rutgers.edu.
36411210,Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.,2023,"Pacaud, Lida","Legend Biotech, 10 Knightsbridge Road, Piscataway, NJ, 08554, US. Electronic address: Lida.Pacaud@legendbiotech.com.",sundar.jagannath@mountsinai.org.
36404264,"Smoking history and pulmonary arterial hypertension: Demographics, onset, and outcomes.",2023,"Zhao, Carol; Yen, Joseph; Selej, Mona","Actelion Pharmaceuticals US, Inc., South San Francisco, California.; Janssen Pharmaceuticals US, Inc., Titusville, New Jersey.; Actelion Pharmaceuticals US, Inc., South San Francisco, California.",afrost@houstonmethodist.org.
36401881,Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study.,2023/Nov/01,"Jo, Joo-Young; Jeon, Ja-Young; Yoo, Hyun-Jeong","Pfizer Pharmaceuticals Korea Ltd, Seoul, Korea.; Pfizer Pharmaceuticals Korea Ltd, Seoul, Korea.; Pfizer Pharmaceuticals Korea Ltd, Seoul, Korea.",None
36384356,A simple core dataset for triglyceride-induced acute pancreatitis.,2023,"Jones, Richard; Jandhyala, Ravi","Akcea Therapeutics Ireland Ltd., Dublin, Ireland.; Medialis Ltd., England, UK.",None
36383059,The Future for Inotropes in Heart Failure. Do Not Throw the Baby Out With the Bathwater!,2023/Jan/01,"Pollesello, Piero","Critical Care Unit, Orion Pharma, Espoo, Finland; and.",None
36379315,A comparative study of different doses of bone marrow-derived mesenchymal stem cells improve post-stroke neurological outcomes via intravenous transplantation.,2023/Jan/01,"Chen, Yuan; Peng, Dingguo; Li, Jingyi; Zhang, Lingling; Chen, Jiacheng; Wang, Lin; Gao, Yansong","Jiuzhitang Maker (Beijing) Cell Technology Limited Company, Beijing 102600, China.; Suzhou Xishan Zhongke Pharmaceutical Research and Development Limited Company, Suzhou 215000, China.; Jiuzhitang Maker (Beijing) Cell Technology Limited Company, Beijing 102600, China.; Jiuzhitang Maker (Beijing) Cell Technology Limited Company, Beijing 102600, China.; Suzhou Xishan Zhongke Pharmaceutical Research and Development Limited Company, Suzhou 215000, China.; Jiuzhitang Maker (Beijing) Cell Technology Limited Company, Beijing 102600, China. Electronic address: lwang@jztmaker.com.; Jiuzhitang Maker (Beijing) Cell Technology Limited Company, Beijing 102600, China. Electronic address: ysgao@jztmaker.com.",ysgao@jztmaker.com.
36375047,Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition.,2023/Apr/11,"Lebozec, Kristell; Toledano, Elie; François, Déborah","Acticor-Biotech, Hôpital Bichat, Paris, France.; Acticor-Biotech, Hôpital Bichat, Paris, France.; Acticor-Biotech, Hôpital Bichat, Paris, France.",None
36371664,Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019).,2023/Jan/11,"Heiss, Christian; Pollock, Kevin G; Sandler, Belinda; Arora, Jasleen","Diabetes & Vascular Medicine, Surrey and Sussex Healthcare NHS Trust, Redhill, UK.; Innovative Medicines, Bristol-Myers Squibb Pharmaceuticals Ltd, London, UK.; Innovative Medicines, Bristol-Myers Squibb Pharmaceuticals Ltd, London, UK.; Innovative Medicines, Bristol-Myers Squibb Pharmaceuticals Ltd, London, UK.",simon.delusignan@phc.ox.ac.uk.
36368677,"A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult Subjects.",2023,"Brager, Jenna; Chapman, Chris; Kaplin, Adam","MyMD Pharmaceuticals, Inc. Baltimore, MD, USA.; MyMD Pharmaceuticals, Inc. Baltimore, MD, USA.; MyMD Pharmaceuticals, Inc. Baltimore, MD, USA.",None
36368459,Shunaoxin dropping pill improves cognitive functions of rats with chronic cerebral hypoperfusion via the microbiota-gut-brain axis.,2023/Jan/01,"Sun, Peinan; Zhang, Tong; Gao, Peng; Zhang, Shuang","No. 6 Traditional Chinese Medicine Factory, Tianjin Zhongxin Pharmaceutical Group Corporation Ltd, Tianjin, China.; No. 6 Traditional Chinese Medicine Factory, Tianjin Zhongxin Pharmaceutical Group Corporation Ltd, Tianjin, China.; No. 6 Traditional Chinese Medicine Factory, Tianjin Zhongxin Pharmaceutical Group Corporation Ltd, Tianjin, China.; Tianjin Zhongxin Pharmaceutical Group Corporation Ltd, Sales Company, Tianjin, China. Electronic address: yiren_shuang@163.com.",youcai.zhang@tju.edu.cn.
36367466,A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.,2023,"Lawatscheck, Robert","Medical Affairs and Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany.",gbakris@uchicago.edu.
36357295,Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.,2023,"Akram, Muhammad","Legend Biotech USA, Piscataway, NJ.",sundar.jagannath@mountsinai.com.
36355313,Different Perspectives of Patients and Physicians on LDL-C Target Achievement in the Treatment of Hypercholesterolemia: Results on Secondary Prevention from the German PROCYON Survey.,2023,"Willfeld, Kathy; Beier, Lea","Novartis Pharma GmbH, Nuremberg, Germany.; Novartis Pharma GmbH, Nuremberg, Germany.",Oliver.Weingaertner@med.uni-jena.de.
36351465,"Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.",2023/Jan/03,"Hutchinson, Howard G","AstraZeneca BioPharmaceuticals, Wilmington, Delaware, USA.",nissens@ccf.org.
36347049,Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studies.,2023/Jan/01,"Kelepouris, Nicky","US Medical Affairs-Rare Endocrine Disorders, Novo Nordisk, Inc, Plainsboro, New Jersey, USA.",None
36342827,Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.,2023/Jan/03,"Pfarr, Egon","Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany (E.P.).",None
36342789,"Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.",2023/Feb/21,"Langkilde, Anna Maria","Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (A.M.L.).",None
36334386,The International Natural Product Sciences Taskforce (INPST) and the power of Twitter networking exemplified through #INPST hashtag analysis.,2023,"Shine, V J","Cancer Research Program, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, Kerala 695014, India.",bairong.shen@scu.edu.cn.
36332897,Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency.,2023,"Roubert, Bernard; Goehring, Udo-Michael; Dorigotti, Fabio","Vifor Pharma, Glattbrugg, Switzerland.; Vifor Pharma, Glattbrugg, Switzerland.; Vifor Pharma, Glattbrugg, Switzerland.",Javed.Butler@bswhealth.org.
36331326,Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.,2023/Jan/07,"Kallend, David G; Lawrence, David; Garcia Conde, Lorena","DalCor Pharmaceuticals, Montreal, Quebec, Canada.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",None
36331249,"Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.",2023,"Markovtsov, Vadim","Translational Biology, Rigel Pharmaceuticals, South San Francisco, CA, USA.",None
36329372,Real-World Safety and Clinical Outcomes of Macitentan in Asian Patients with Pulmonary Arterial Hypertension: A Prospective Multicenter Study.,2023,"Jung, Su Young; Park, Minseok; Kim, SuYoun","Medical Affairs, Janssen Korea Ltd., Seoul, Korea.; Medical Affairs, Janssen Korea Ltd., Seoul, Korea.; Medical Affairs, Janssen Korea Ltd., Seoul, Korea.",hjchang@yuhs.ac.
36326604,Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.,2023/Jan/01,"Langkilde, Anna Maria; Petersson, Magnus","Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.",None
36325584,Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.,2023,"Peil, Barbara; Pfarr, Egon","Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.",None
36321924,Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: A nationwide cohort study.,2023,"Steurbaut, Stephane","Centre for Pharmaceutical Research, Research group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Jette, Belgium.",None
36317407,Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.,2023,"Sawada, Sono; Kajiyama, Kazuhiro; Shida, Haruka; Kimura, Ryota; Nakazato, Yuki; Iguchi, Toyotaka; Oniyama, Yukio; Ishiguro, Chieko; Uyama, Yoshiaki","Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.; Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.; Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.; Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.; Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.; Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.; Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.; Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.",None
36316612,Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.,2023,"Louie, Michael J; Sasiela, William J; Gillard, Kristin K","Esperion Therapeutics, Inc., Ann Arbor, MI, USA.; Esperion Therapeutics, Inc., Ann Arbor, MI, USA.; Esperion Therapeutics, Inc., Ann Arbor, MI, USA.",robert.mcqueen@cuanschutz.edu.
36316102,Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.,2023/Jan/27,"Wheeler, Alistair; Zou, Liangxing; Paolini, John F","Clinical Development, Kiniksa Pharmaceuticals Corp, Lexington, Massachusetts, USA.; Clinical Development, Kiniksa Pharmaceuticals Corp, Lexington, Massachusetts, USA.; Clinical Development, Kiniksa Pharmaceuticals Corp, Lexington, Massachusetts, USA jpaolini@kiniksa.com.",jpaolini@kiniksa.com.
36314141,Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.,2023,"Shen, Xian; Stampehl, Mark","Novartis Pharmaceuticals Corporation, East Hanover, NJ (X.S., M.S.).; Novartis Pharmaceuticals Corporation, East Hanover, NJ (X.S., M.S.).",None
36310329,Risks of Myocarditis and Pericarditis Following Vaccination with SARS-CoV-2 mRNA Vaccines in Japan: An Analysis of Spontaneous Reports of Suspected Adverse Events.,2023,"Kobayashi, Hidetaka; Fukuda, Sayoko; Matsukawa, Rina; Asakura, Yumi; Kanno, Yuri; Hatta, Tomohiro; Saito, Yurina; Shimizu, Yuki; Kawarasaki, Shuichi; Kihara, Mari; Kinoshita, Natsumi; Umeda, Hikari; Iguchi, Toyotaka","Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan. kobayashi-hidetaka@pmda.go.jp.; Office of OTC/Quasi-Drugs, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.; Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency (PMDA), Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan.",kobayashi-hidetaka@pmda.go.jp.
36307922,Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition.,2023/Feb/02,"Ditmarsch, Marc; Simmons, Mark; Alp, Nicholas; Turner, Traci; Davidson, Michael H; Kastelein, John J P","NewAmsterdam Pharma B.V., Naarden, 1411 DC, The Netherlands.; Medpace and Medpace Reference Laboratories, Cincinnati, OH 45227, USA.; Medpace and Medpace Reference Laboratories, Cincinnati, OH 45227, USA.; Medpace and Medpace Reference Laboratories, Cincinnati, OH 45227, USA.; NewAmsterdam Pharma B.V., Naarden, 1411 DC, The Netherlands.; NewAmsterdam Pharma B.V., Naarden, 1411 DC, The Netherlands.",None
36306151,"Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.",2023,"Koethe, John R; Silver, Heidi","Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee.; Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee.",None
36305696,Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.,2023/Mar/15,"Stein, Evan; Graham, Christine; DiPetrillo, Lauren; Akerman, Sarah; Stanford, Arielle D; Jiang, Ying; Yagoda, Sergey; McDonnell, David; Hopkinson, Craig","Metabolic & Atherosclerosis Research Center, Cincinnati, OH, USA.; Alkermes, Inc., Waltham, MA, USA.; Alkermes, Inc., Waltham, MA, USA.; Alkermes, Inc., Waltham, MA, USA.; Alkermes, Inc., Waltham, MA, USA.; Alkermes, Inc., Waltham, MA, USA.; Alkermes, Inc., Waltham, MA, USA.; Alkermes Pharma Ireland Ltd., Dublin, Ireland.; Alkermes, Inc., Waltham, MA, USA.",None
36301617,Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.,2023/May/04,"McEwan, Phil; Boyce, Rebecca; Sanchez, Juan Jose Garcia; Sjöström, C David; Stefansson, Bergur; Nolan, Stephen","Health Economics and Outcomes Research Ltd, Cardiff, UK.; Health Economics and Outcomes Research Ltd, Cardiff, UK.; Global Market Access and Pricing, BioPharmaceuticals, AstraZeneca, Cambridge, UK.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.",None
36279931,Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design.,2023,"Braceras, Rogelio; Gaynor, Tanya; Pak, Jonathan; Senyucel, Cagri","Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT.; Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT.; Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT.; Eli Lilly and Company, Indiannapolis, IN.",christopher.granger@duke.edu.
36278846,"Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence-Based Data Analyses of a National Multicenter Prospective Registry.",2023,"Valls, Raquel; Artigas, Laura; Mas, José Manuel; Coma, Mireia","Anaxomics Biotech, Barcelona, Spain.; Anaxomics Biotech, Barcelona, Spain.; Anaxomics Biotech, Barcelona, Spain.; Anaxomics Biotech, Barcelona, Spain.",None
36272688,"Biopharmaceutical, preclinical pharmacokinetic and pharmaco-dynamic investigations of an orally administered novel 3-nbutylphthalide prodrug for ischemic stroke treatment.",2023/Jan/01,"Liu, Qiang; Zhang, Yan","YaoPharma Co., Ltd., Chongqing 401121, PR China.; YaoPharma Co., Ltd., Chongqing 401121, PR China.",zhangling83@scu.edu.cn.
36271807,Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.,2023,"Pacaud, Lida; Garrett, Ashraf","Legend Biotech USA, Inc, Piscataway, NJ, USA.; Legend Biotech USA, Inc, Piscataway, NJ, USA.",None
36269898,"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).",2023/Feb/20,"Zhang, Yiwen; Fan, Xiaohu","Legend Biotech China, Nanjing, Jiangsu, China.; Legend Biotech China, Nanjing, Jiangsu, China.",None
36265461,Responses in Blood Pressure and Kidney Function to Soluble Guanylyl Cyclase Stimulation or Activation in Normal and Diabetic Rats.,2023,"Benardeau, Agnes M","Bayer Pharma AG, Wuppertal, Germany.",None
36265076,INCIDENCE OF NEW DIABETIC MACULAR EDEMA IN FELLOW EYES OF PATIENTS IN THE VISTA AND VIVID STUDIES.,2023/Feb/01,"Moini, Hadi; Reed, Kimberly; Silva, Fabiana Q; Berliner, Alyson; Du, Weiming","Regeneron Pharmaceuticals, Inc., Tarrytown, New York; and.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York; and.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York; and.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York; and.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York; and.",None
36260313,Signal and Noise: Proton Pump Inhibitors and the Risk of Dementia?,2023,"Kuo, I Fan","Optimal Use and Evaluation, Clinical Services and Evaluation Branch, Pharmaceutical, Laboratory & Blood Services, British Columbia Ministry of Health, Victoria, British Columbia, Canada.",None
36256500,Heart rate control with landiolol hydrochloride in infants with ventricular dysfunction and pulmonary hypertension.,2023,"Unger, Martin; Ackerl, Jakob; Shatilova, Olga","AOP Orphan Pharmaceuticals GmbH, Vienna, Austria.; AOP Orphan Pharmaceuticals GmbH, Vienna, Austria.; AOP Orphan Pharmaceuticals GmbH, Vienna, Austria.",None
36254693,Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.,2023/Jan/01,"Salsali, Afshin","Novo Nordisk pharmaceutical company, Vandtårnsvej 110, 2860 Søborg, Copenhagen, Denmark.",None
36244653,Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial.,2023,"Connelly, M A","Laboratory Corporation of America Holdings (Labcorp), Morrisville, North Carolina; and the.",b.d.westenbrink@umcg.nl.
36240297,Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation.,2023/Apr/25,"Monia, Brett P; Revenko, Alexey","Ionis Pharmaceuticals, Inc, Carlsbad, CA.; Ionis Pharmaceuticals, Inc, Carlsbad, CA.",None
36228891,"Crataegus pinnatifida: A botanical, ethnopharmacological, phytochemical, and pharmacological overview.",2023/Jan/30,"Zhang, Chi","Sichuan Engineering Technology Research Centre for Injection of Traditional Chinese Medicines, China Resources Sanjiu (Yaan) Pharmaceutical Co., Ltd., Yaan, Sichuan, 625000, PR China. Electronic address: zhangchi46@999.com.cn.",wanli@cdutcm.edu.cn.
36223849,The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema.,2023,"Kasper, Jonathan","Alimera Sciences, Inc, Alpharetta, Georgia (J.K.).",pauline.merrill@gmail.com.
36216094,Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.,2023/Jan/01,"Ferber, Philippe C; Koch, Cornelia","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",lars.lund@alumni.duke.edu.
36202739,"Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF).",2023,"Adamsson Eryd, Samuel; Bodegård, Johan","CVRM Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.; CVRM Evidence, BioPharmaceuticals Medical, AstraZeneca, Oslo, Norway.",gianluigi.savarese@ki.se.
36196060,Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF.,2023,"Schweizer, Anja; Obergfell, Achim","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",None
36181769,Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.,2023,"Lefkowitz, Martin","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",None
36179890,Health Care Resource Utilization by Patients with Alagille Syndrome.,2023,"Goldstein, Andrea; Howard, Robin; Mogul, Douglas B; Marden, Jessica R; Anderson, Annika; Gaburo, Katherine; Kirson, Noam","Mirum Pharmaceuticals, Inc., Foster City, CA.; Mirum Pharmaceuticals, Inc., Foster City, CA.; Mirum Pharmaceuticals, Inc., Foster City, CA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.",nebel@stanford.edu.
36177609,Adverse drug reaction related to drug shortage: A retrospective study on the French National Pharmacovigilance Database.,2023,"Grandvuillemin, Aurélie; Fresse, Audrey; Pietri, Tessa","Centre Régional de Pharmacovigilance de Dijon, CHU Dijon Bourgogne, Dijon, France.; CHRU de Nancy - Hôpitaux de Brabois, Centre Régional de Pharmacovigilance, Vandœuvre-lès-Nancy, France.; Aix-Marseille Université, Inserm, UMR 1106, Assistance publique - Hôpitaux de Marseille, Service de pharmacologie clinique, Centre régional de pharmacovigilance, Marseille, France.",None
36166754,Asebogenin suppresses thrombus formation via inhibition of Syk phosphorylation.,2023,"Liu, Yi; Zhang, Yadong","DeepKinase Biotechnologies Ltd., Beijing, China.; DeepKinase Biotechnologies Ltd., Beijing, China.",None
36151787,Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant.,2023,"Cherepanov, Dasha; Romanus, Dorothy","Takeda Development Center Americas, Inc (TDCA), Lexington, Massachusetts, United States.; Takeda Development Center Americas, Inc (TDCA), Lexington, Massachusetts, United States.",None
36137735,Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.,2023,"Vranic, Ivana; Wu, Joseph; Wang, Cunshan; Kwok, Kenneth; Menon, Sujatha; Yndestad, Arne; Connell, Carol A","Pfizer Ltd, Tadworth, UK.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, New York, New York, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Oslo, Norway.; Pfizer Inc, Groton, Connecticut, USA.",ccharles@mednet.ucla.edu.
36127823,Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.,2023,"Martínez, Sara; Kahatt, Carmen; Fudio, Salvador; Corral, Gema; Zeaiter, Ali; Montilla, Lola","PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.",None
36126301,A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.,2023/Jan/26,"Gryaznov, Sergei","Maia Biotechnology lnc, Chicago, IL.",None
36124702,Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.,2023/Apr/03,"Modesto, Irene; Mundayat, Rajiv; Vranic, Ivana","Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Ltd, Tadworth, Surrey, UK.",None
36124445,SARS-CoV-2 infection and multi-organ system damage: A review.,2023/Feb/01,"Rabaan, Ali A; Alhumaid, Saad","Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Saudi Arabia.; Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Saudi Arabia.",None
36117281,Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.,2023,"Karcher, Helene; Becher, Anja; Balez, Sébastien; Clemens, Andreas","Novartis Pharma AG, Basel, Switzerland.; Oxford PharmaGenesis, Oxford, UK.; Novartis Pharma S.A.S., Rueil Malmaison, France.; Novartis Pharma AG, Basel, Switzerland.",None
36115814,Ischemia With Nonobstructive Coronary Arteries: Insights From the ISCHEMIA Trial.,2023,"Min, James K","Cleerly, Inc, New York, New York, USA.",harmony.reynolds@nyulangone.org.
36114655,Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction.,2023,"Gimpelewicz, Claudio; Davison, Beth A; Severin, Thomas; Cotter, Gad","Novartis Pharma, Basel, Switzerland.; Momentum Research Inc., Chapel Hill, NC, USA.; Novartis Pharma, Basel, Switzerland.; Momentum Research Inc., Chapel Hill, NC, USA.",None
36106615,Blood pressure-independent renoprotective effects of small interference RNA targeting liver angiotensinogen in experimental diabetes.,2023,"Zlatev, Ivan; Rooney, Timothy; Kasper, Anne; Nioi, Paul; Foster, Don","Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.",None
36096275,Patient preferences for newer oral therapies in type 2 diabetes.,2023/Jan/15,"Pang, Christianne; Wood, Richard; Soleymanlou, Nima","dQ&A - The Diabetes Research Company, San Francisco, CA, USA.; dQ&A - The Diabetes Research Company, San Francisco, CA, USA.; Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA.",abhinav.sharma@mcgill.ca.
36096175,Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life.,2023,"Goldstein, Andrea; Howard, Robin; Garner, Will; Vig, Pamela; Marden, Jessica R; Billmyer, Emma; Anderson, Annika; Kirson, Noam","Mirum Pharmaceuticals, Inc., Foster City, CA.; Mirum Pharmaceuticals, Inc., Foster City, CA.; Mirum Pharmaceuticals, Inc., Foster City, CA.; Mirum Pharmaceuticals, Inc., Foster City, CA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.",binita.kamath@sickkids.ca.
36095849,Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.,2023/Jan/19,"Akram, Muhammad; Nesheiwat, Tonia; Pacaud, Lida","Legend Biotech USA Inc., Piscataway, NJ.; Legend Biotech USA Inc., Piscataway, NJ.; Legend Biotech USA Inc., Piscataway, NJ.",None
36089068,Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE).,2023,"Pfister, Thomas; Hsu Schmitz, Shu-Fang","Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.",l.howard@imperial.ac.uk.
36082907,Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality.,2023/May/22,"Baker, Hana","Diabetes and Complications Research, Lilly Research Laboratories, Eli Lilly and Company, 307 E Merrill St, Indianapolis, IN 46225, USA.",None
36057089,"A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: The ACTEMRA® (ACT)-Bridge study.",2023/Aug/25,"Hashimoto, Hideyuki; Yoshida, Amika; Yamashita, Katsuhisa","Drug Safety Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; Drug Safety Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.; Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.",None
36002313,Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.,2023/Jan/25,"Suzuki, Manabu; Deguchi, Hisato; Fernandez, Jovelle","Japan Medical Office, Takeda Pharmaceutical Company Limited.; Japan Medical Office, Takeda Pharmaceutical Company Limited.; Japan Medical Office, Takeda Pharmaceutical Company Limited.",None
35960908,Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.,2023/Jan/20,"Popa McKiver, Mihaela; Jou, Ying-Ming; Yao, David; Das, Prianka","Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",None
35953437,Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking.,2023/Feb/02,"Jiao, Lixia","Amarin Pharma, Inc., Bridgewater, NJ, USA.",None
35938912,Demonstration of ultrasound-mediated therapeutic delivery of fibrin-targeted pioglitazone-loaded echogenic liposomes into the arterial bed for attenuation of peri-stent restenosis.,2023,"Genstler, Curtis","Boston Scientific Inc, Minneapolis, MN, USA.",None
35894657,A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's.,2023/Feb/01,"Batta, Rohit; Overbeck, Kamilla; Raud, Johan","Vicore Pharma AB, Gothenburg.; Vicore Pharma AB, Gothenburg.; Vicore Pharma AB, Gothenburg.",None
35882498,"Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15.",2023/Jan/10,"Primo, Daniel; Miyazaki, Takahiro; Overwijk, Willem W","Vivia Biotech, Madrid, Spain.; Nektar Therapeutics, San Francisco, CA.; Nektar Therapeutics, San Francisco, CA.",None
35843487,Time to Resolution of Diabetic Macular Edema after Treatment with Intravitreal Aflibercept Injection or Laser in VISTA and VIVID.,2023,"Du, Weiming; Moini, Hadi","Regeneron Pharmaceuticals, Inc, Tarrytown, New York.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.",TALCOTK@ccf.org.
35840087,"A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.",2023,"Scott, Emma","Clinical Research Hematology/Oncology, The Janssen Pharmaceutical Companies of Johnson & Johnson, United States.",qbashir@mdanderson.org.
35816231,Profiling target engagement and cellular uptake of cRGD-decorated clinical-stage core-crosslinked polymeric micelles.,2023,"Hu, Qizhi; Thewissen, Marielle; Rijcken, Cristianne J F","Cristal Therapeutics, Maastricht, The Netherlands.; Cristal Therapeutics, Maastricht, The Netherlands.; Cristal Therapeutics, Maastricht, The Netherlands.",tlammers@ukaachen.de.
35796854,Outcome of Stroke Patients with Unknown Onset and Unknown Time Last Known Well Undergoing Endovascular Therapy.,2023,"Riegler, Christoph; Nolte, Christian H","Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.",sebastian.stoesser@ukbonn.de.
35790595,Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review.,2023,"Proudfoot, Clare; Gautam, Raju; Cristino, Joaquim; Agrawal, Rumjhum; Thakur, Lalit; Tolley, Keith","Novartis Pharma AG, Basel, Switzerland.; Novartis Healthcare Pvt. Ltd., Hyderabad, India.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Healthcare Pvt. Ltd., Hyderabad, India.; Novartis Healthcare Pvt. Ltd., Hyderabad, India.; Tolley Health Economics Ltd., Unit 5, 11-13 Eagle Parade, Buxton, SK17 6EQ, Derbyshire, UK. keith@tolleyhealtheconomics.com.",keith@tolleyhealtheconomics.com.
35787344,Therapeutic monoclonal antibodies with a focus on hereditary angioedema.,2023,"Sexton, Daniel J","Takeda Pharmaceutical Company Limited, Lexington, MA, USA.",bzuraw@health.ucsd.edu.
35777957,"The relationship between interstitial lung abnormalities, mortality, and multimorbidity: a cohort study.",2023,"Sanders, Jason Leigh; Wang, Shuai","Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.; Pfizer Inc, New York, New York, USA.",ghunninghake@bwh.harvard.edu.
35776266,The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?,2023,"Schoonen, Marieke","Center for Observational Research, Amgen Ltd, Uxbridge, UK.",vmaher@gmail.com.
35728628,[Prescriptions of statins in the elderly according to the type of healthcare establishment: An example of the usefulness of territorial hospital groups].,2023,"Amsallem, A; Berthou-Contreras, J; Joret, N; Limat, S; Clairet, A-L","Pôle pharmaceutique, CHRU Jean-Minjoz, 3, boulevard Alexander-Fleming, 25030 Besançon cedex, France.; Pôle pharmaceutique, CHRU Jean-Minjoz, 3, boulevard Alexander-Fleming, 25030 Besançon cedex, France.; Pôle pharmaceutique, CHRU Jean-Minjoz, 3, boulevard Alexander-Fleming, 25030 Besançon cedex, France.; Pôle pharmaceutique, CHRU Jean-Minjoz, 3, boulevard Alexander-Fleming, 25030 Besançon cedex, France; Inserm, EFS BFC, UMR 1098, université de Bourgogne Franche-Comté, Besançon, France.; Pôle pharmaceutique, CHRU Jean-Minjoz, 3, boulevard Alexander-Fleming, 25030 Besançon cedex, France; Inserm, EFS BFC, UMR 1098, université de Bourgogne Franche-Comté, Besançon, France. Electronic address: alclairet@chu-besancon.fr.",alclairet@chu-besancon.fr.
35700142,Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).,2023/Mar/31,"Gay, Alain","Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany.",None
35658469,"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.",2023/Feb/20,"Zhou, Changwei; Pacaud, Lida","Legend Biotech, Inc, Piscataway, NJ.; Legend Biotech, Inc, Piscataway, NJ.",None
35642121,A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.,2023,"Amoodi, Abdulla Al","Ambulatory Healthcare Services, Academic Affairs, Abu Dhabi Health Services (SEHA), UAE.",None
35597816,Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.,2023,"Gedif, Kinfemichael; Best, Catherine; Patel, Hersh","Novartis Pharmaceuticals Corporation, Fort Worth, TX, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hannover, NJ, USA.",david.lally@neretina.com.
35576489,Adenylate cyclase type 9 antagonizes cAMP accumulation and regulates endothelial signalling involved in atheroprotection.,2023/Mar/31,"Dubé, Marie-Pierre","Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada.",None
35567726,Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.,2023,"Bray, Sarah","Global Biostatistical Science, Amgen Ltd, Cambridge, UK.",k.ray@imperial.ac.uk.
35567698,Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database.,2023,"Kong, Sheldon X","Bayer Pharmaceuticals, Whippany, NJ, USA.",tatsiana.vaitsiakhovich@bayer.com.
35534618,"Prevalence, phenotypic characteristics and prognostic role of apparent treatment resistant hypertension in the German Chronic Kidney Disease (GCKD) study.",2023,"Mielke, Johanna; Trucks-Jansen, Holger; Schurmann, Claudia; Freitag, Daniel F; Eitner, Frank; Becker, Michael S","Bayer AG, Research & Early Development, Disease Understanding and Precision Biomarkers, Division Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Research & Early Development, Disease Understanding and Precision Biomarkers, Division Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Research & Early Development, Disease Understanding and Precision Biomarkers, Division Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Research & Early Development, Disease Understanding and Precision Biomarkers, Division Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Research & Early Development, Precision Nephrology, Division Pharmaceuticals, Wuppertal, Germany.; Bayer AG, Research & Early Development, Precision Nephrology, Division Pharmaceuticals, Wuppertal, Germany. michael.becker@h-da.de.",michael.becker@h-da.de.
35524660,Fungal Metabolites: A Potential Source of Antidiabetic Agents with Particular Reference to PTP1B Inhibitors.,2023,"Deshmukh, Sunil Kumar","Research and Development Division, Greenvention Biotech Pvt. Ltd., Uruli-Kanchan, Pune, 412202, Maharashtra, India.",None
35468618,Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.,2023/Mar/14,"Griffin, Faith; Cornwell, Christine; Shen, Angela; Heery, Christopher","Arcellx, Inc., Gaithersburg, MD.; Arcellx, Inc., Gaithersburg, MD.; Arcellx, Inc., Gaithersburg, MD.; Arcellx, Inc., Gaithersburg, MD.",None
35467312,"Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.",2023,"Jia, Yu; Sanchez, Santiago Zuluaga; Martinez, Laura","Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.",zhaoquanming1@sina.com.
35451488,Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.,2023/Feb/13,"Scheerer, Markus F","Global Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany.",None
35440699,Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.,2023,"Moini, Hadi; Reed, Kimberly; Du, Weiming; Vitti, Robert; Berliner, Alyson J","Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",drrishisingh@gmail.com.
35220445,Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia.,2023,"Kintscher, Ulrich","Institut für Pharmakologie, Charité - Universitätsmedizin Berlin, Hessische Str. 3-4, 10115, Berlin, Germany.",felix.mahfoud@uks.eu.
35039401,Predicting flow diverter sizing using the AneuGuide,2023,"Shan, Yejie; Leng, Xiaochang; Xiang, Jianping","ArteryFlow Technology Co., Ltd, Hangzhou, China.; ArteryFlow Technology Co., Ltd, Hangzhou, China.; ArteryFlow Technology Co., Ltd, Hangzhou, China liuaihuadoctor@163.com jianping.xiang@arteryflow.com.",liuaihuadoctor@163.com
35022767,Overcoming barriers in the design and implementation of clinical trials for acute kidney injury: a report from the 2020 Kidney Disease Clinical Trialists meeting.,2023/Mar/31,"Bernholz, Juliane; Sharma, Amit; Ali, Omar","AM-Pharma, Utrecht, The Netherlands.; Bayer Pharmaceuticals, Cambridge, MA, USA.; Verpora Ltd, Nottingham, UK.",None
34637052,Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis.,2023,"Steurbaut, Stephane","Centre for Pharmaceutical Research, Research Group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Jette, Belgium.",Maxim.grymonprez@ugent.be.
34433549,"Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study.",2023,"Tainton, Jodi; Simonyi, Susan","Allergan Australia Pty Ltd, Gordon, New South Wales, Australia.; Allergan Singapore Pte Ltd, Singapore.",samantha.fraser-bell@sydney.edu.au.
